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3It gives me great pleasure to introduce the EMCDDA’s
annual report for 1999. This is the fourth annual report
that the Centre has produced. It has undergone some
minor changes in form and content since the last report.
These have been made so that the report can reflect more
clearly the rapidly evolving trends and patterns in drug
use in Europe, as well as make it more accessible to its
varied readership. Our aim is to provide up-to-date,
quality information as a basis for sound decision-making.
The collection and collation of comparable, reliable and
useful information takes a great deal of time and effort, as
does the creation of the local, national and European
networks through which such information is gathered.
Action on drugs and problems related to drugs has been
high on the agenda, both in Europe and elsewhere.
Significant progress was made during 1998. At the special
session on drugs of the United Nations General Assembly
(8-10 June 1998), the world community strengthened its
commitment to confronting the world drug problem in a
collaborative, balanced way. The adoption of a political
declaration on the guiding principles of drug demand
reduction by 185 participating countries constituted a
considerable advance in the international ‘drugs debate’.
It was the first time at this level that demand reduction
was recognised as an indispensable component of any
global approach to the world drug problem. The General
Assembly requested the Commission on Narcotic Drugs
to explore a proposed action plan based on this declara-
tion. The United Nations International Drug Control
Programme (UNDCP) prepared a preliminary draft that
was discussed and amended by an intergovernmental
working group with specialised agencies, that included
the EMCDDA, in December 1998.
The 42nd session of the Commission on Narcotic Drugs (1)
ended with the adoption of a resolution on the first
United Nations action plan on drug demand reduction.
The plan focused on identifying, assessing and communi-
cating information on the causes and consequences of
substance use; coordination mechanisms and the partici-
pation of all relevant authorities and sectors of society;
the implementation of research and the dissemination of
results; the development of customised programmes
ranging from the discouragement of initial use to reduc-
tion of the negative health and social consequences of
drug use; the enhancement of information and services
offered to the public and to drug users in particular; and
the development of evaluation strategies.
Action against drug trafficking and drug misuse was also a
major priority at European Union level. The Europol
Convention entered into force on 1 October, following its
ratification in June 1998 by all Member States, providing
the EU with a complementary tool to prevent and combat
unlawful drug trafficking. The coordination and imple-
mentation of a third European Drug Prevention Week
during the Austrian Presidency was an important step in
the implementation of the first Community action
programme for the prevention of drug dependence.
The United Kingdom and Austrian Presidencies played a
central role in developing a wide range of initiatives. In
early 1998 the United Kingdom Presidency invited
Horizontal Drug Group (HDG) members to outline their
likely priorities for inclusion in a post-1999 European
drugs strategy. The HDG (2) coordinated the European
Union input for the UN General Assembly session on
drugs. The Cardiff European Council (3) endorsed a set of
key elements for a European Union strategy to tackle all
aspects of the problem in 2000–04 (4). The Austrian
Presidency pursued the task and the Vienna European
Council (5), having examined the report on drugs and
drug-related issues of the Presidency period, invited
European institutions to develop an integrated and
balanced post-1999 drugs strategy further, in line with the
new opportunities offered by the Amsterdam Treaty. The
Council specified that full use should be made of the
expertise of the European Monitoring Centre for Drugs
and Drug Addiction.
Preface
(1) Vienna, 16 to 25 March 1999. 
(2) This Horizontal Drugs Group was created by the Permanent Representatives Committee (Coreper) in February 1997 as a forum to
coordinate the drugs activities of the Union, especially when they are of a trans-pillar nature. The HDG met 11 times in 1998. 
(3) 15 and 16 June 1998 — Presidency conclusions. 
(4) Based on the Council report to the European Council on activities on drugs and drug-related issues under the UK Presidency, includ-
ing key elements of a post-1999 EU drugs strategy (7930/2/98 REV 2). 
(5) 11 and 12 December 1998. 
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The European Parliament examined and commented on
the Council report (6). It especially emphasised the need
to ensure maximum synergy between all Community
efforts, and called upon the Commission and the Council
to record all initiatives on drugs in one single document.
The requirement for reliable and comparable information
on drugs was stressed through the adoption by the
European Parliament, of the document on the EMCDDA’s
annual report (7).
The post-1999 EU drug strategy is envisaged as multidis-
ciplinary, balanced and integrated, covering a range of
actions on demand and supply reduction involving inter-
national cooperation across the three pillars of the EU.
Both the European Parliament and Council stated the
importance of focusing upon the improvement of cooper-
ation with EU accession countries, and in assistance for
facilitating the taking of the Community drug acquis.
The Commission took advantage of the work already
completed by the Centre between 1995 and 1999 and the
inputs of both the European Parliament and Council in
the preparation of its proposal for an EU action plan to
combat drugs (2000–04). The action plan foresees an
important role for the EMCDDA in providing the
European institutions and Member States with relevant
information, observing that ‘the extent and magnitude of
the drugs phenomenon is now better known thanks to the
valuable work carried out by the European Monitoring
Centre for Drugs and Drug Addiction’.
The launching in 1998 of the fifth framework programme
for research for 1998–2002 should also be noted. It
includes support for research activities into the psycho-
logical and socioeconomic factors involved in drug use in
order to develop a better understanding of long-term
health and social consequences and the pursuit of more
effective treatment strategies.
Efforts have been made with the Phare programme to
develop information systems for collecting, processing
and distributing data on drug use, and to achieve conver-
gence between the central and east European countries
(CEECs) and the tasks and data currently being pursued by
the EMCDDA Reitox national focal point network. Much
remains to be done and the Centre and its partners are
aware that they are standing at the threshold of a major,
new venture.
The EMCDDA, in close collaboration with the Reitox
national focal points, will continue to concentrate its
efforts on the regular collection, analysis and dissemina-
tion of data at European level; the improvement of data
comparison methods; the implementation of key
harmonised epidemiological indicators; the systematic
and scientific evaluation of demand reduction initiatives;
and cooperation with European and international bodies 
and organisations.
The Centre’s core tasks include, in epidemiology, the
implementation of five harmonised key indicators
(demand for treatment by drug users; drug-related deaths,
mortality and causes of death among drug users; the
incidence of drug-related infectious diseases; the compa-
rability of surveys of drug use, behaviour and attitudes in
the general population; and the comparability of preva-
lence estimates of problem drug use). Enhancement of the
European database on demand reduction activities
(EDDRA) is the leading project in the identification,
assessment and promotion of routine, scientific evalua-
tion in the demand reduction field. Scientific investiga-
tion and collaboration with institutional partners
continue in the implementation of the joint action on
new synthetic drugs, as does the annual preparation and
publication of this report and a series of research
monographs and other studies.
I believe that this report demonstrates the real progress
made by the Centre since its foundation. This has been
achieved through the commitment and hard work of
those involved in the process at all levels throughout the
European Union. I am confident that the EMCDDA is now
well placed to respond to the challenges that the next
millennium is bound to present.
Georges Estievenart 
Executive Director 
EMCDDA
(6) EP resolution on the report, including key elements of a post-1999 EU drugs strategy, from the Council to the European Council on
activities on drugs and drug-related issues under the UK Presidency (7930/2/98 – C4-0409/98).
(7) Report on the 1997 annual report of the European Monitoring Centre for Drugs and Drug Addiction on the state of the drugs
problem in the European Union (C4-0552/97).
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Developments in drug use,
problems and responses
1C h a p t e r
Throughout the European Union (EU), national, regional and local
policies for the prevention of drug use and addiction, as well as 
assistance to and treatment of drug users, are changing. More efforts are
being made at all levels and by all sectors to ensure that cooperation
and coordination between the educational, health, social and criminal
justice systems become more effective and efficient.
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Despite the considerable differences between EU
countries, and between drug users and patterns of use,
some clear trends in, and consequences of drug use are
emerging throughout the Union. More details about
patterns and consequences of drug use are provided in
Chapter 2.
Prevalence and patterns of
problem drug use
In most Member States, the main substance recorded by
indicators of problem drug use has been heroin. In some
northern States, amphetamines are significant in admissions
to treatment, although overdoses and drug-related 
infectious diseases often also involve heroin. Estimates of
the prevalence of the overall number of problem drug users
thus largely refer to problem opiate use.
Out of a total EU population of about 375 million, an
estimated 1 to 1.5 million are problem users (mainly of
heroin). This estimate is based on a 12-month period
prevalence rate of 2.7 to 4.0 per 1 000. The range reflects
the margin of uncertainty around any estimate and the
fundamental issue of definition. The lower figure can be
taken as indicating the extent of dependence — ‘addic-
tion’ in common parlance — while the higher figure
represents a somewhat broader population which, while
not dependent in the strict sense, are nonetheless using
opiates or other drugs in a sufficiently intense or risky
fashion (for example, by injection) to be at significant risk
of experiencing serious consequences such as depend-
ence, overdose, and infectious diseases. 
This estimate also excludes occasional use of opiates.
Surveys, although usually unreliable regarding the assess-
ment of problem drug use, suggest that up to 1 % of the
Defining problem drug use
‘Problem drug use’ is defined as the use of drugs in a way
that significantly increases the risk of serious, adverse
physical, psychological or social consequences for the
user. This definition includes dependence (addiction), 
but also covers patterns of non-dependent use that may
lead the user to seek help or that are associated with
increased mortality or morbidity, such as overdoses or
infectious diseases.
The operational definition used by the EMCDDA to
compare estimates of the prevalence of problem drug use
is limited to intravenous drug use or long duration/regular
use of opiates, cocaine or amphetamines. For practical
reasons, ecstasy and cannabis are not included when
comparing estimates for different countries, even though,
as shown elsewhere in this report, the use of these 
drugs may sometimes be associated with personal or
social problems.
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general population and 1 to 2 % of the school or youth
population have tried heroin or other illicit opiates. This
implies that the total number of people with some experi-
ence of these drugs could be in the order of a few million.
It is unclear to what extent this figure includes users who
smoke heroin on a more than experimental basis.
Since most indicators used to generate prevalence
estimates are more likely to detect injecting drug users
(IDUs), heroin smokers may be under-represented. It is
also not clear to what extent estimates of problem drug
use cover heavy users of drugs such as cocaine, ampheta-
mines or combinations of legal and illegal drugs (such as
medicines and alcohol) if they are not using heroin.
The overall prevalence of problem drug use as defined in
this context, and in particular of heroin, appears to have
been largely stable in most EU States in recent years.
However, there is a continuing incidence of new cases
balanced by others who become abstinent or die. The
estimate for the EU as a whole is a little higher than in
previous reports, due to new or improved estimates from
a larger number of countries. 
The known/treated population is predominantly male
with an average age between 24 and 33. This figure is
slowly increasing in most Member States, perhaps partly
as a result of increased substitution treatment which tends
to be offered or taken up by older clients. This population
is also associated with serious health and social problems
linked to multiple drug use, psychiatric co-morbidity,
infectious diseases, crime, imprisonment and social
exclusion (see also Chapter 2).
Social distribution and diffusion
Problem drug use is unequally distributed between and
within countries, with large differences between cities
and within specific areas. The more socially deprived
areas tend to have higher prevalence, although the
relationship between prevalence and socioeconomic
factors is complex. Not all socially deprived areas have
high levels of problem drug use, and high-prevalence
pockets are also found in some of the richest cities or
regions. 
This picture of heroin and urban deprivation should not
be oversimplified. Although, in general, heroin is more
prevalent in urban areas, diffusion to smaller towns and
rural areas is increasingly apparent.
Furthermore, there have been repeated reports over
recent years of heroin use, mostly smoking by new
groups. For example, young people from socially
integrated backgrounds, heavy recreational users of
ecstasy, amphetamines and other drugs, individuals from
some minority groups and older people with problematic
heavy consumption of alcohol and/or medicines are also
smoking heroin. Initiation into heroin use, including
injecting, also continues in areas of established heroin use.
Insight into diffusion processes, both geographical and
social, is a valuable field for further study (see Chapter 2
for examples). The steady rise in the availability and use of
amphetamines and cocaine, plus the wide variety of
combinations of legal substances such as medicines and
alcohol used with illegal drugs, need to be taken into
account in the future development of treatment
responses.
Treatment responses to 
problem drug use
Challenges for treatment services
Poly-drug use, co-morbidity (both psychiatric and
organic) and an ageing population challenge treatment
services in many countries. This development is crucial
when determining the best approach to delivering high-
quality treatment and ensuring its provision in all settings. 
One response to this trend, evident in some countries, is
that as patterns of drug use change the number of multi-
ple patterns increases. Treatment centres, which generally
define themselves by the substances used by their clients,
are also changing. There are signs that care centres for
drug addicts are merging with those for alcoholics,
addicts of prescribed drugs and illegal drug users.
Greece offers new service
The non-residential, drug-free unit Diavasi in Greece
meets the needs of adults who, despite their drug habit,
are nevertheless able to lead a relatively stable life and to
maintain fairly good relationships with their families who
support their efforts to become abstinent.
Diavasi offers both day and evening treatment
programmes, as well as services targeted at the user’s
family to help strengthen family relations and consolidate
a new attitude.
Treatment is also supplemented by many other activities
and the Diavasi cultural centre hosts exhibitions, 
films, concerts and plays in cooperation with the local
community.
Developments in drug use, problems and responses
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Primary healthcare involvement
In parallel with the developments observed in specialised
treatment centres, the primary healthcare system through-
out the EU is increasing its involvement in the care of
drug users, probably due to the expansion of substitution
treatment and financial cutbacks in the social sector in
many countries. At the same time, there has been a move
away from residential treatment towards out-patient treat-
ment.
For example, general practitioners (GPs) in the UK are
increasingly involved in seeing drug users and are
currently the main providers of generic healthcare
services to them. As a result, a new edition of clinical
guidelines on treating drug users has been revised and is
being distributed to all GPs in England in 1999.
In France, the proportion of GPs (39 %) who see at least
one drug user has not increased since 1995. However,
GPs are seeing more users, usually as regular patients.
This indicates, as in other countries, a move towards
long-term, ongoing care relationships, although many
GPs are reluctant to see drug users who are considered
troublesome. Doctors may also feel incompetent in treat-
ing such cases or believe only specialised people can
help drug users.
Substitution treatment
Substitution treatment for opiate dependence is rapidly
expanding in Europe and GPs are largely involved in this.
Since many countries do not have national registration
formalities (which in some cases they had before, as in
the UK), it is not possible to give an exact number of
patients undergoing substitution treatment. An educated
guess is that about 300 000 persons in the EU are receiv-
ing substitution treatment. There are also great variations
between Member States. It is estimated that per 100 000
population aged 16 to 60, about 200 receive substitution
treatment in Spain compared with six or less in Greece or
Finland. 
Setting the estimate of patients in substitution treatment
against the total prevalence estimate implies that within
the EU 20 % of all problem opiate users and perhaps 
30 % of dependent opiate users receive substitution treat-
ment. In 1999, the EMCDDA is publishing an in-depth
study on substitution treatment in the EU.
Questions and assessment
This issue raises a series of questions:
• What is the impact of the growth of substitution 
treatment on public health consequences such as 
drug-related deaths and infectious diseases, as well as 
on social consequences such as drug-related crime and
the illicit market? 
• Are substitute drugs such as methadone involved 
in overdoses? 
• What is the long-term outcome of substitution 
treatment? 
• What are the expansion limits of substitution 
treatment (in terms of capturing a higher proportion 
of the dependent population)? 
• What is the relationship between substitution 
treatment and other services such as psychosocial 
support or drug-free treatment?
• What are the consequences of different modalities 
for delivering substitution treatment (the increasing role
of GPs, the involvement of pharmacists, the impact of
‘take-home’ drugs)?
• What are the needs of target groups who are not
reached by existing substitution programmes?
• To what extent can other substitution programmes, 
such as heroin prescription, meet needs that cannot be
achieved through extending and improving methadone
and associated services?
• How can the broader social, economic and environ-
mental correlates of problematic opiate use be
addressed? 
• What responses are needed for younger users, those
who are not yet dependent or who are smoking heroin?
Some possible answers?
Given the scale of substitution services across Europe,
there are only limited data on research and evaluation of
treatment processes, its benefits and the factors associ-
ated with good treatment. These include the quality of the
management and organisation of services, and of the
staff, and the level of multidisciplinary and interagency
work to ensure good relations and links across a range of
community institutions. Alongside drug-free treatment,
there is now a substantial consensus on the benefits of
methadone maintenance. Systematic reviews of this area
indicate that treatment can improve psychological and
social well-being, and reduce illicit heroin use, criminal-
ity and HIV transmission. However, further research is
needed to determine the role of such treatment in reduc-
ing hepatitis C transmission. 
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Training for both generalists and specialists and good
models for working together are necessary if services are
to continue expanding and high standards maintained.
Models of delivery range from the purely specialist to
predominantly primary care, but better integration
between these approaches is needed. Pharmacists are
also taking an increasingly active role in substitution
treatment.
Diversion- and methadone-related deaths continue to be
substantial problems in some countries. Countries with
lower levels of supervision are more likely to report
higher rates of diversion. Overall, countries with high
levels of control tend to reduce them in order to improve
access while countries with low levels of supervision tend
to increase control. 
Methadone is by far the most common opiate substitute
in the EU, although in France the prescription of
buprenorphine by GPs has risen steadily since 1996. In
Portugal, treatment with LAAM, a substitution medication
with a longer effect than methadone, has been estab-
lished over the last six years, while Denmark and Spain
have recently begun experiments with this medicine.
Over the past five years, there has been a substantial
growth in the evaluation of treatment. The science and
treatment evaluation culture continues to expand and has
been promoted through research and training networks
across the EU. Large-scale national treatment evaluation
projects, such as the ‘National treatment outcome
research study’ (NTORS — www.ntors.org.uk) in the UK,
and several smaller-scale outcome evaluation studies
have been carried out. 
Heroin prescription 
In 1998, an experiment to supply heroin on strictly
medical grounds began in the Netherlands, following an
earlier study carried out in Switzerland. The selection
criteria the addicts have to meet before entering the
programme are strict and only problematic addicts with a
long history of unsuccessful treatment are admitted.
Although first reports describe the challenges faced in the
first six months, results show that it is possible to organise
and carry out this complex experiment. 
Medical heroin prescription was also under discussion in
1998 in Denmark, Germany and Spain, and continues at
a low level in the UK. In 1999, the German federal
government plans rapidly to implement former initiatives
of the Bundesrat (the federal chamber of the German
Länder), in particular to carry out a scientific trial on
heroin maintenance treatment with long-term addicts
who failed with other treatments.
In Luxembourg, the Prime Minister has confirmed the
government’s will to implement a small-scale heroin
distribution programme. The pertinent bill still has to be
voted on in Parliament.
Community responses to
problem drug use
A broad, although ill-defined, range of drug-use patterns
in the EU involves more than experimental or intermittent
recreational use but is not usually reflected in problem
indicators such as treatment demand and not covered by
the prevalence estimates of problem drug use. These
French alternative
In France, the prescription of buprenorphine has
increased rapidly since its introduction in 1996. French
GPs prescribe buprenorphine to about one third of heroin
users who consult them. According to the 1998 Inserm
evaluation study, ‘Evaluer la mise à disposition du
Subutex pour la prise en charge des usagers de drogue’,
(‘Evalution of the use Subutex for the treatment of drug
users’) the social background of such clients is usually
poor and clients are generally older users (45 % are over
30 years of age).
After one year, the progress of around 69 % of these
clients is still monitored by their GP. Of this group, 9 out
of 10 are still taking buprenorphine. Although overall
heroin consumption has fallen by 43 %, just over one fifth
of users are still injecting, but in many cases buprenor-
phine is also injected. It is thought that users continue to
inject because they are dependent on the ritual itself and
its social context (injecting with others), and because the
effect of the drug is insufficient if taken orally.
Deaths seem to have occurred from mixing buprenor-
phine and benzodiazepines, particularly in countries
with a high level of substitution medication where
combining it with benzodiazepines is also frequent.
Developments in drug use, problems and responses
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patterns include the use of amphetamines, ecstasy and
other drugs by young people, multiple use of medicines,
alcohol and illicit drugs by various age groups, and
increased heroin smoking by different groups in different
populations.
Responses to drug use by younger people mainly focus
on synthetic drug use (see Chapter 3). However, some
initiatives for experimental users of different drugs have
been reported from Belgium, Denmark, Greece, Spain,
France and Austria. Often, these try to involve the young
people in alternative activities within and outside the
educational system, increase the awareness of drug
behaviour and other life choices, and involve peers,
parents and teachers in activities. 
Such initiatives frequently focus on general social and
health issues, as well as on illegal drug use. For example,
the committees on social environment in France are
active in 20 % of secondary schools. These committees
are instrumental in changing the relationship between
pupils and adults and promote participation and the
assumption of responsibility by all players.
Problem drug use, and in particular chronic drug depend-
ence, is linked not only to individual difficulties requiring
specific interventions such as treatment, but also to 
more structural, social factors requiring responses at
community level.
Social exclusion 
Social exclusion and drug problems are closely related to
marginalised communities and individuals. Many drug
services report that the health and social conditions of
their (often ageing) clients are deteriorating. This suggests
that both structural responses and more specific interven-
tions are needed. Some community development
programmes, together with outreach work and low-
threshold services, take this into account.
Although some publicity has been given to the increasing
use of drugs by relatively affluent ‘rich kids’, drug services
are aware that problems mainly arise in socially margin-
alised groups and areas. There is a growing focus on the
need for community work in disadvantaged areas, involv-
ing cooperation between the education, health, social
and criminal justice systems, employers and non-govern-
mental organisations (NGOs). Activities related to these
groups centre on raising awareness and training. 
In the Netherlands, the fundamental premise underlying
most policies is that drug use should be contained and
curbed, but not at the expense of stigmatising and isolat-
ing drug users socially. This approach is also seen in
demand reduction strategies where the emphasis is on
informing and convincing people of the hazards of drug
use rather than on moral premises. Another goal of
prevention strategies is to protect society itself from what
the general public perceives as the danger and social
nuisance caused by drug use.
In Sweden, drug policy is closely linked to alcohol
measures. These two areas are in turn part of the total
social policy. For the Swedes, drug schemes should be
based on the fact that all citizens have the right to live
their lives in dignity and no group no matter what their
actions or lifestyle should be excluded from the commu-
nity. An ongoing government investigation is focusing on
drug use and social exclusion, and aims to explore drug
use in marginalised groups as well as studying how
marginalisation may lead to drug use. 
Danish help for the young
The Danish project Tjek-Punkt (‘Checkpoint’) aims to
(re)establish a constructive relationship among teenagers
from the most deprived backgrounds. These young people
can go to the Tjek-Punkt without an appointment and can
receive a meal, use the telephone or simply talk to the
staff. The Tjek-Punkt works because visitors come of their
own free will and are guaranteed anonymity. The help
offered can extend to both fieldwork and case work. The
project aims to motivate these youngsters to ask for and
receive treatment — even to be rehoused — to seek other
kinds of help and to encourage them to become involved
in their own future.
North-West London Drug Prevention Team
A project was developed by the North-West London Drug
Prevention Team to target young people expelled from
their schools. The project developed an assessment
process which helps teachers to work with these young-
sters as well as a drug education programme relevant to
their specific needs, including helping drug users to
modify their behaviour. The scheme helps young people
to address their drug-using behaviour, and at the same
time ties them into a process through which they can win
a youth achievement award. This is important for regain-
ing self-respect and for pursuing further education and
gainful employment in the future. 
The connection between social exclusion and drugs is a
main feature of the UK programme ‘Tackling drugs to
build a better Britain’. This scheme targets six high-risk
groups on which services and activities should focus:
those expelled from school; truants; children in care;
young offenders; young homeless; and children of drug-
using parents.
Ethnic minorities are sometimes particularly vulnerable to
drug use, partly because of social exclusion. Some
countries deal with drug problems in an ethnic group
through specific prevention or treatment interventions.
For example, following a comparative study on
Luxembourgish and Portuguese drug addicts living in
Luxembourg, actions targeted specifically at the
Portuguese community are about to be implemented.
Drug use has also been reported particularly to affect the
Roma population in Spain, Portugal and Sweden.
Outreach work and early intervention
A pilot study undertaken for the EMCDDA analyses how
long heroin users who undergo treatment had used the
drug before first entering treatment (see Chapter 2). The
study found that the younger the age of first heroin use,
the longer the time lag before treatment. Heroin users
undergoing treatment for the first time did so, on
average, five years after first use. Younger users, however,
took seven to eight years or even longer to seek treat-
ment. 
This means that treatment-demand indicators miss new
epidemics among younger people and that treatment
services have little contact with them. This factor raises
issues of the availability, accessibility and attractiveness
of treatment, and the need to investigate obstacles to
obtaining treatment, especially for younger users.
However, the results also suggest that latency is more
importantly a function of the natural history of addiction
once a certain level of treatment availability exists. If so,
then treatment services do not appear to provide an
appropriate basis for early interventions, especially
among younger users, and alternative strategies should be
considered. 
The grey zone between prevention and treatment gener-
ally widens and becomes more prominent as a result of
both budget cuts and the reluctance of drug users
themselves to recognise the need to seek treatment. Drug
services thus need to go out onto the streets where young
people meet in order to make contact and offer help,
including referrals to treatment centres.
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Roma and drugs
In Spain, drug addiction affects specific groups of Roma,
leading to increased social, family and cultural fragmen-
tation and alienation in a community already vulnerable.
The sale of drugs by some members of the community
reinforces the stereotype of Roma as drug dealers. 
Generally Roma addicts do not benefit adequately from
treatment and harm-reduction services. This leads to a
higher rate of HIV infection among the community,
although methadone-maintenance programmes have
been accepted and may be a solution to this problem.
Children at risk
Drug-using children are perhaps the most vulnerable of
all risk groups. Specific projects aim to protect these
children and help them find a way out of the drug trap,
but one of the major problems they face is getting the
children to seek treatment.
In Rome, children under the age of 16 when they first use
heroin usually take an average of eight to nine years to
enter treatment. This compares unfavourably with over-
21-year-olds who generally seek treatment within three to
four years of first use. Similar patterns are found in other
Italian cities. 
In Lisbon, a pilot project has been introduced to respond
to the specific needs of children and groups of high-risk
young people such as school drop-outs, children of drug
users and children from broken homes or criminal
backgrounds.
The project team identified areas where such youths
congregated and then began promoting various activities
designed to draw the children into a wider social setting.
Artistic and socio-educational pastimes designed to
stimulate acceptable social behaviour and to gain trust
helped workers to approach the target group and in some
cases allowed them to refer children to other services. 
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Outreach work may have different objectives. Street
workers may be seen as local resources who pick up
signals and encourage young people to integrate into the
community. Such workers may give advice on safer sex
and drug use to help prevent infectious diseases, as well
as counsel and help drug users to contact support
services. Some outreach initiatives also provide help
within drug-user groups. 
Public nuisance and community safety
Public order and nuisance issues are a high priority in
many Member States. In the Netherlands in 1998, the
public prosecutor introduced guidelines for ‘coffee shops’
stating that those causing a public nuisance can be
closed. In Belgium, a new law passed in November 1998
allows the authorities to close public places where drug
offences are committed.
Challenges for healthcare
systems
Mortality and morbidity
In recent years, 6 000 to 7 000 acute drug-related deaths
(overdoses) have been officially recorded each year in the
EU. This figure has remained relatively stable, although
differences may be observed within individual countries.
The large majority of such deaths involve opiates, mainly
heroin, but other substances such as benzodiazepines
and alcohol are also often present. The actual number of
acute deaths directly attributed to intoxication with
heroin or other opiates is likely to be somewhat higher
due to under-recording, but by how much is hard to
assess. Acute deaths from other illegal drugs are much
less commonly recorded.
If indirect deaths were also included, such as those
arising from drug-related infectious diseases, accidents or
suicides, and if under-reporting of acute deaths were
taken into account, then the total figure would be consid-
erably higher — perhaps by a factor of three or more.
The incidence of new cases of AIDS related to injecting
drugs is decreasing, partly because of improved treat-
ment. However, hepatitis B and especially C prevalence
is high. Despite behavioural changes and a reduction in
the proportion of injectors in most countries, the
incidence of new infections of HIV (and probably of
hepatitis) among the younger-age group and new injec-
tors appears to be continuing. This indicates that transmis-
sion of infectious diseases is not under control and
continued and expanded preventive efforts are needed.
Low-threshold services and harm 
reduction
Low-threshold services have existed for some time in a
few Member States, and have been reluctantly introduced
in others throughout the 1990s. They now exist in all EU
countries, but differ in availability and type of service.
Generally, they provide individual assistance, and
medical, psychological and social care to mainly very
deprived users, mostly older users with a long history of
addiction. They offer basic services such as washing facil-
ities, meals, needle and syringe exchanges and basic
medical attention. 
Needle exchanges
Needle exchanges exist in all countries, although to a
different extent. In some countries, they are less relevant
as pharmacies provide free or cheap needles. Needle
exchanges were introduced early in the Netherlands,
Sweden and the UK, but relatively late in Spain, France
and Italy, the countries most affected by HIV. However, 
in recent years the number of programmes in these
countries has been rising rapidly. Often the rule is 
‘one-for-one’ exchange, but in some countries, such as 
the Netherlands, there are exceptions to this practice at
local level.
In Belgium, the supply, sale and delivery free of charge of
syringes to prevent infectious diseases were made possi-
ble by a law passed in November 1998. This law states
that the distribution or exchange of syringes can no
longer be considered as supporting or facilitating illicit
drug use and those engaging in these activities cannot 
be prosecuted.
Day-centre care in Austria
An Austrian project known as Wald (‘Forest’) provides
low-threshold services through a day centre where clients
may find temporary work. Every day, at least eight people
— drug users or homeless persons — can work for up to
four hours on the basis of a daily employment contract.
The jobs include tending forests, reforestation and other
similar employment. The short-term goals of the project
are psychological and social stabilisation, developing the
ability to work and the capacity to complete tasks. The
long-term aim is to help reintegrate people into the
regular job market. 
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Injecting rooms
The desirability, availability and status of injecting or
‘fixing’ rooms have been raised as issues in many parts of
the EU.
In Germany, ‘fixing’ rooms have existed for several years
in some large cities. The main purpose is to prevent fatal
incidents by providing a hygenic setting and medical
supervision. The new federal government is committed to
providing a legal basis for these rooms which have until
now operated on a precarious basis.
In Luxembourg, a parliamentary bill has been introduced
which proposes setting up injecting rooms which 
will provide addicts with hygienic conditions and
medical control.
The Netherlands has increased the number of gebruik-
sruimten (literally ‘using spaces’) available for opiate
users, the majority of whom are not injecting, in both
major and smaller cities. The rooms are seen as a way of
reducing the nuisance level to the public of drug users. 
Discussions on injecting rooms have also taken place 
in Denmark.
Drug users and the criminal
justice system
Between 15 and 50 % of prisoners in the EU have or
have had problems with substance use. The concentra-
tion of drug users within the penal system is clearly a
challenge, but also presents an opportunity to confront
the problem and to increase efforts where they are most
needed.
Three strategies have been identified regarding demand
and harm reduction in prisons:
• drug-free prison wings;
• methadone treatment; and
• involvement of local community drug services. 
Syringe exchange exists in a few prisons in Germany 
and Spain and in the latter a memorandum to all prisons
from the prison institutions’ directorate recommends 
that syringe exchange be available in all prisons. In the
UK, inmates who inject have recently been allowed 
sterilising tablets.
Several Member States report that overcrowding in
prisons often hinders progress in this area. Lack of train-
ing of prison personnel is another problem. Consistency
of treatment is also often lacking between prisons and
between the prison and the community. This can lead to a
lack of continuity for drug users who pass from the penal
system into the community or for users from the commu-
nity who are committed to prisons.
Alternatives to prison 
An EMCDDA study, ‘Alternatives to prison in cases of
drug addiction’, gives an overview of the various options
available in the Member States studied. The following
alternative measures are used throughout the EU:
• postponement of legal proceedings or of a sentence; 
• parole;
• exemption from prison term;
• suspension of application of the sentence;
• replacement of prison term;
• exemption from criminal responsibility; and
• other special formulas for applying a prison sentence,
such as partial liberty, charging the custody of the
offender to a third party or integrating the jailed 
drug addict into a daytime detoxification programme
(with the obligation to return to prison at night) and 
other variations.
The application of such alternatives, however, is limited
in practice and some existing legal alternatives are not
sufficiently used. 
Treatment in prison yields results
Little evaluation of treatment in prison has been 
carried out with sufficiently representative samples.
Nevertheless, information from evaluations of
methadone-treatment programmes in prisons in Spain
gives some indication of the positive benefits accruing to
prisoners undergoing treatment. The key findings are that:
• subjects under treatment display less aggressive 
behaviour;
• patient participation in treatment activities is 
increasing;
• inmates in treatment exhibit greater self-control;
• treatment programmes are retaining more subjects; and 
• the habit of sharing hypodermic syringes is decreasing.
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Compulsory care
Only the Netherlands and Sweden report compulsory
care, although the choice of terminology might very well
hide the fact that there is more or less compulsory care in
most EU countries when addicts have to or can choose
between imprisonment or treatment alternatives.
In Sweden, the use of compulsory care has declined
sharply. Some form of specialised treatment has been
interchanged with regular treatment and out-patient
contacts in recent years. Although the costs of substance
use treatment may be unaffected, the services are not. 
Policy changes regarding drug offenders
The principle of therapy instead of punishment has been
adopted as extended in the general guidelines of the drug
policies in a growing number of countries. For example,
in Germany the federal strategy affirms priority of treat-
ment and also emphasises the importance of harm reduc-
tion, in Ireland where a project for a drug-court system is
being developed and in Austria under the revised
Narcotic Substance Act (1 January 1998).
Some Member States have consolidated social and
medical support towards drug-addicted offenders using
the first contact with enforcement authorities as a door to
treatment or counselling facilities. Behind the general
principles, insufficient resources are, in practice,
allocated for treatment and care. In some countries, for
example Austria, the principle of legality makes it manda-
tory for police to report and prosecute drug offences such
as possession, thus creating a contradiction between
medical and psychosocial approaches to the problem and
law-enforcement activities.
To reduce this contradiction, the judicial systems in most
EU countries are moving towards legal instruments and
facilities allowing small-scale offenders with drug
problems to avoid prison. This trend, which is more
evident in some countries than in others, is prevalent
enough to be defined as a pan-European phenomenon. 
In addition, prosecution for minor drug-related offences
relating to cannabis (possession of small amounts for
personal use) seems increasingly deferred or social
measures such as counselling preferred to legal recourse. 
Prevention and health 
promotion
Family, parents and schools all have a role to play in
preventing drug use. School is still the main setting for
prevention activities and more countries now believe that
these should start as early as possible. School is possibly
one of the best ways of reaching the majority of children
and as teachers generally take their job seriously,
programmes introduced through the education system
can have a real impact. Substantial evidence shows that
school programmes can at least postpone drug use
among young people. Preventive activities do not stop in
the compulsory educational system and more countries
now extend such work into universities. 
Teacher training and parental involvement are crucial and
are promoted throughout the EU, although the role of the
family, and especially parents, varies. In southern Europe,
the family is seen more as a support, while in northern
Europe the responsibility of the parent is stressed.
Hope offered to convicted addicts
A forensic addiction clinic for drug users resisting regular
care and treatment opened in 1998 in the Netherlands.
This is a new, experimental facility to treat criminal
addicts who are admitted for compulsory care on remand
under a suspended detention order. The clinic’s
programme has three stages: intramural, semi-mural, and
re-socialisation. In the final stage, clients are supported
while learning to live independently again.
Those attending the clinic must complete a long-term
programme whose main elements are work-related
projects. The aim is to offer the most appropriate mix of
treatment, practical and social skills, and labour and
educational projects to each individual.
Long-term addicts who have committed a series of crimi-
nal offences and who require intensive care are eligible to
join the scheme. Admission to a regular clinic would not
be appropriate because of the severity of the addiction
and/or of the criminal activities of the addicts, or because
of repeated failure to complete treatment. 
In its first four years, the clinic will operate as a scientific
experiment. The first evaluation results will be published
in 2000.
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Policy developments
Towards a balanced approach
Striking a balance between demand and supply reduction
is a major political consideration. From a global point of
view, political approaches to the drug problem in Europe
show a gradual progression from the repressive positions
prevalent in the past decade to strategies that focus more
on prevention and treatment and the need to reduce the
risks caused by drug use.
Overall, drug policy in Europe takes the middle way
between repression and tolerance. There exist both
pragmatic policies reflecting the fact that illicit drugs are
available and require a range of responses (including
socio-medical) to limit their use and harmful conse-
quences, and strong law-enforcement approaches to
drug-related crime to protect public order and reduce the
supply and availability of illicit drugs. The evolution of
drug laws and strategies reflecting governmental
concerns to adopt alternative approaches to pure repres-
sion is a barometer of these new trends.
In Austria, a new law, the Narcotic Substance Act, replaced
the Narcotic Drugs Act in January 1998. Under the new
law, alternatives to criminal prosecution and the therapy
instead of punishment model — principle first introduced
in 1980 — now apply to petty offences involving the
acquisition of illegal substances. Rules pertaining to
withdrawal of the police report on first-time consumers of
cannabis have been eased. In health policy, pain therapy,
withdrawal and substitution treatments were given a firmer
legal basis and the range of health-related measures
provided by the law was extended. In addition to medical
treatment and supervision, health-related measures now
also include substitution treatment, psychotherapy,
psycho-medical and socio-therapeutic treatment and care. 
Important practical changes to Germany’s narcotic law
came into effect on 1 February 1998. These include facili-
tating the regulation of prescribing narcotics (BtMVV) for
pain treatment and for methadone maintenance treat-
ment. Current drugs policy strengthens harm reduction
and treatment prior to punishment, clarifying the legal
position of injecting rooms and introducing experimental
projects on medical prescription of heroin. 
In Greece, special treatment can now be provided for
addicted drug users who kick the habit on their own
without entering a detoxification programme.
In Ireland, a pilot project to set up a drug-court
programme is being developed. In addition, a new
regulation lays down rules for prescribing methadone.
Schools lead the way
In 1998, in Belgium, a new tool was designed for use in
secondary schools. It was based on materials previously
developed as part of the national drug policy towards
schools and introduced to allow school drug policies to
be evaluated. 
By providing all pupils with questionnaires and focusing
on their attitudes towards a variety of activities including
smoking, drinking and illegal drugs, actual drug use, as
well as the pupils’ opinion of the drug policy at school,
can be estimated.
The questionnaire results can give the school authorities
an indication of the atmosphere in the school and can
demonstrate what pupils would like to see change. The
school receives the results together with recommenda-
tions for prevention activities, how to work with parents
on the issue and suggestions for adopting and optimising
drug policies.
A school programme, ‘Walk Tall’, was developed in
Ireland in 1996 and introduced into urban primary
schools throughout the country. It forms part of a new
subject — social, personal and health education — being
introduced into the primary school syllabus from
September 1999.
‘Walk Tall’, which adopts a whole-school approach,
focuses on active learning and the development of self-
esteem, assertiveness and decision-making skills to help
children withstand pressures to use drugs. It emphasises
self-respect, emotions, influences, decision-making and
drug awareness and is based on the premise that self-
confidence and its association with substance misuse
have an important role to play in preventing abuse. The
programme will be extended to all primary schools over
the next two years. 
An evaluation (Morgan, 1998) concludes that the
approaches adopted by the programme are most effective
in preventing substance abuse and reports a high rate of
satisfaction among participating teachers. A full evalua-
tion of the programme is expected at a later date.
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In Italy, the suspension of the detention order for drug
addicts has been extended to a four-year penalty from its
normal three years. 
In 1998, in Portugal, a national strategy committee was
created and aimed to establish new orientations and
priorities in the national drug policies. Modifications of
drug laws were recorded in the field of treatment and
rehabilitation.
One of the aims of the UK’s strategy ‘Tackling drugs to
build a better Britain’ is to reduce the number of young
people abusing drugs. The Crime and Disorder Act 1998
created parenting orders that hold parents responsible 
for the behaviour of their children. The Drug Treatment
and Testing Order, a key component of the UK strategy,
aims to strengthen treatment options for drug users 
and offenders.
Harm reduction
After years of semi-marginal status in many countries,
harm reduction is increasingly recognised as an impor-
tant tool in national and local drug policies. Debate now
focuses mostly on the scientific evidence. Projects aim to
give legal, professional or political recognition to a range
of activities described above, such as needle exchange,
injecting rooms or substitution treatment, which attempt
to reduce the health and social damage caused by drug
addiction.
Discussions are still intense on the interpretation of the
precept establishing the use of scheduled drugs only for
medical and scientific purposes as laid down in UN
conventions, and laws prohibiting the delivery of narcotic
substances and instruments for drug use (Article 4 of the
1961 UN Single Convention on Narcotic Drugs, and
Article 5 of the 1971 UN Convention on Psychotropic
Substances). This still leaves some fine-tuning to be
achieved between prohibiting use and possessing
narcotics and the more pragmatic philosophical
approach behind harm reduction measures.
Decriminalisation
Prohibition of possession and/or use of drugs is the
general concept followed by all 15 EU drug control
systems. Legalisation is not considered an option in any
national drug policy. Nevertheless, Member States are
aware that the prosecution and imprisonment of individu-
als with drug problems cause even greater problems. 
At the same time, the thin grey line of the past years
between users and traffickers has widened in Europe
under new drug strategies that focus on issues such as
prevention, help and treatment for drug users even if they
are convicted offenders, and punishment for drug traffick-
ers even if they are users. 
Drug consumption, in general, seems not to be prose-
cuted in most EU countries. However, debate continues
on how to deal with consumers in possession of small
quantities of drugs for personal use, or who commit petty
crimes because of their drug dependence.
Developments in European drug policies and new legal
approaches towards illicit drugs show a shift towards
decriminalising some behaviour linked to consuming and
possessing drugs for personal use, notably when this is
related to drug dependence. Most Member States reject
extreme solutions — such as full legalisation or harsh
repression — but continue to prohibit drug consumption
while modifying the penalties and measures applied to it. 
In Belgium, a directive issued in 1998 harmonises the
action of judicial authorities. For the first time, a distinc-
tion has been established between possession of cannabis
for personal use and other illegal drugs with non-accept-
able risks for health. The possession of cannabis for
personal use remains an offence, but attracts the lowest
prosecution priority if pursued. In the case of a one-time
or occasional user of cannabis, a simplified police report 
is filed and, as with all other drug offences, the drug 
is seized.
In Luxembourg, a new law proposes decriminalising
reduced-risk substances (like cannabis) and re-scaling
penalties. 
Decriminalisation of illicit consumption and possession
for personal use in Portugal is being considered. This,
together with other measures, forms the government’s
strategy and represents an overall modification of the
country’s drug law.
Theory and practice
Although the trend in many Member States, as seen in
policy statements, is to reduce the emphasis on prosecut-
ing and imprisoning drug users, the other side of the coin
reveals increased enforcement activity. For example,
police arrests and indicators of drug use in prison suggest
some need for fine-tuning theory and practice within
some areas of the criminal justice system. The number of
police arrests, apparently more for use-related offences
than trafficking (see Chapter 2), is increasing in most
Member States with cannabis being the main drug
involved.
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Portugal: Modification of law
to decriminalise possession of
drugs for personal use
proposed by a committee
appointed by the government.
Italy: Administrative
sanctions for activities
related to personal
use of drugs.
UK: Proceedings can be
dropped for possession of
small quantities, occasional
or personal use.
Ireland: Fines
levied for the first
two offences of
possession of
cannabis.
Luxembourg: Usually
no prosecution for
personal use.
Sweden: Use or possession
of small amounts are
usually sentenced with a
fine, or on a voluntary
basis, exchanged with
counselling. In special
cases, the proceedings may
be suspended.
Austria: Proceedings
discontinued for possession
of small quantities of any
drug for personal use.
Denmark: No proceedings for possession or supply of small quantities
of cannabis. Fines for trafficking small quantities of cannabis. Warning
for drugs other than cannabis and first-time offences. Fine usual for
subsequent offences. Imprisonment for offences involving supply for
commercial reasons or organised trafficking.
Note: Where a Member
State is not mentioned,
data are unavailable.
Summary of EU responses to minor drug-related offences
Netherlands: Regulations for investigating and prosecuting
Opium Act offences assign lowest priority to the possession of
‘hard’ (up to 0.5 g) and ‘soft’ drugs (up to 5 g) for personal use. In
‘coffee shops’, the sale of a maximum of 5 g of hashish and
marijuana per transaction is generally not investigated. Up to one
month’s imprisonment and/or a fine of NLG 5 000 is incurred for
possessing, selling or producing up to 30 g of soft drugs; posses-
sion of hard drugs for personal use is sentenced with a maximum
of one year imprisonment and/or a fine of NLG 10 000.
Germany: No proceed-
ings for small-scale
possession, import or
export for personal use of
‘insignificant quantities’ of
drugs.
France: The Ministry of
Justice recommends not
prosecuting occasional
users of illicit drugs.
Instead, offenders receive
warnings or referral to
health or social care
services.
Spain: Administrative sanctions for
use of drugs and possession for use
in public places. Therefore, use and
possession for use of illicit drugs is
decriminalised.
Belgium: Lowest prosecution
measures applied for one-
time or occasional possession
for personal use of cannabis.
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At the same time, the number of drug users and problem
drug users in prison is high in most Member States for
which data are available. While some are imprisoned for
dealing or trafficking, many appear to be users impris-
oned for other offences.
The blurred line between licit 
and illicit drugs 
A growing issue in drug policy concerns the extent to
which it is useful to maintain the traditional distinctions
between illicit drugs such as cannabis and cocaine, licit
recreational substances such as alcohol and tobacco, and
licit psychoactive medicines such as tranquillisers and
analgesics. The status of other substances such as solvents
and steroids adds a further dimension to this debate.
It is clear from a variety of epidemiological indicators that
illicit drug-use patterns frequently also involve licit
substances, notably alcohol, tobacco and tranquillisers
(taken for non-medical purposes). The more problematic
patterns of drug use, in particular, are characterised by
multiple use of licit and illicit substances, while treatment
centres are reporting more poly-drug use. It is not clear if
this represents a change in perception or a real change.
Experts suggest it is probably both.
This reality has long been recognised in the prevention
field and prevention initiatives are generally geared to
preventing the use of any drug, whether illicit or licit.
Increasingly, this trend is also being recognised in the
treatment field and, as noted earlier, there is a tendency
towards merging care for those experiencing problems
with illegal drugs, alcohol or prescription drugs.
The trend towards a more unified approach to licit and
illicit drug use is also reflected in developments in some
Member States.
The French Government recently decided that the 
authority formerly dealing with illegal drugs only, the
Interministerial Mission for the Fight against Drugs and
Drug Addiction (MILDT), and the French National Focal
Point, the French Observatory for Drugs and Drug
Addiction (OFDT), would in future be responsible for
issues involving legal drugs, including alcohol and
tobacco. In Germany, the Netherlands and Austria, this
policy has been followed for some time. 
In the German language, the term ‘addiction prevention’
rather than ‘drug prevention’ is used. 
These developments have important implications not
only in the fields of prevention, harm reduction and treat-
ment, but also for the legal bases of an integrated
approach. It is not clear how this will evolve in the future.
Cooperation between sectors 
In an area where so many factors are interrelated and so
many authorities and organisations participate, positive
results will only be achieved if all parties cooperate.
Across Europe, cooperation between the health, social,
education and criminal justice systems appears to be
improving, and there is less rivalry than before.
Cooperation occurs both at national level between
ministries and at local level where the police work with
social workers and teachers. The primary health sector is
also becoming more involved.
At the same time, the borders between prevention and
treatment are blurring. Drug users at different stages
depend on varying structures for help. The nature of drug
use is characterised by ups and downs and this affects the
way prevention and treatment are implemented and used.
In most countries, outreach work and low-threshold facil-
ities are developing quickly. More traditional structures
do not cater for all needs while these newer facilities are
seen as providing a valuable service. Cooperation
between the criminal justice system and the health and
social sectors is also developing with diversion schemes
for drug-using offenders and projects for imprisoned drug
users, although much remains to be done in these areas.
Developments in national coordination
A clear trend in recent years has been the development of
horizontal drug coordination bodies within national
administrations. These groups coordinate national drug
strategies and reinforce local authorities which imple-
ment national political and legal guidelines. In 1998,
coordination between these two levels strengthened,
underlining the importance and effectiveness of national
coordination mechanisms.
In Austria, competence in the field of drugs is held at
federal level by the Labour, Health and Social Affairs
Ministry (FMLHSA), with two departments primarily
responsible for drug-related issues. One department deals
with treatment and addiction prevention, the drug casual-
ties register and, since summer 1998, legal matters
connected with drugs and drug addiction. Also in summer
1998, responsibility for the coordination of drug-related
issues was transferred to the head of the pharmaceuticals
group. This group includes the Austrian Narcotic Drugs
Monitoring Agency (ANDMA), which is responsible for
maintaining the register of personal drug-related data and
for monitoring activities concerning substitution treatment.
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In Germany, the office of the commissioner for drug
issues of the federal government transferred in 1998 from
the Interior Ministry to the Health Ministry, illustrating the
growing emphasis on the social and health aspects of
drug dependency. The national advisory board on drug
issues will be chaired by the Health Ministry’s drug
commissioner. Drug-related regulations require the
approval of the Bundesrat (federal chamber of Länder)
and the Bundestag (federal parliament). Drug and addic-
tion representatives of health ministers in the 16
Bundesländer have regular meetings in the Committee for
Addiction Services. A third coordination body is the
Standing Working Group of Drug Commissioners, tradi-
tionally chaired by the Federal Health Ministry.
In Ireland, coordination has been allocated a high priority
with the institution of a Cabinet Committee on Social
Inclusion and Drugs which is chaired by the Taoiseach
(Prime Minister). This committee is serviced by a high-
level interdepartmental group. A Minister of State at the
Department for Tourism, Sport and Recreation is responsi-
ble for coordinating the national drug strategy through,
inter alia, the National Drug Strategy Team. This team
includes representatives from relevant government
departments and agencies, along with representatives
from the voluntary and community sectors. Integration is
also a feature of the integrated services process and the
work of the local drug task forces.
In 1999, the post of national drug monitor (NDM) was
created in the Netherlands.
In 1998, the Portuguese Government restructured the
coordinating structure known as ‘Projecto vida’. The
national coordinator was given the tasks of promoting
interdepartmental coordination in developing the activi-
ties of the various services involved in drug addiction
prevention, representing Portugal at international level in
drug-addiction prevention matters, and setting up the
Technical Monitoring Commission composed of
delegates from the competent ministries to support and
assist him in his work. 
In Spain, an order of 24 November 1998 issued by the
Ministry of the Interior establishes the functions, compo-
sition and structure of the advisory council of the Spanish
Observatory on Drugs and Drug Addiction. The observa-
tory is the official body providing support and advice to
the government members of the national plan on drugs
(PNSD).
In the UK, the first anti-drugs coordinator has been
appointed, along with a deputy — both acting as govern-
mental expert advisers on action against drugs, and on
ways to increase the profile of drug policies and improve
coordination of local and national strategies. The anti-
drugs coordinator chairs a new body, the Anti-drugs
Strategic Steering Group, which meets regularly to help
assess overall progress in implementing the strategy. The
deputy coordinator addresses the four main areas of the
strategy — young people, communities, treatment and
availability — through four newly formed strategy support
groups which report to the steering group. Under the
strategy, drug action teams (DATs) operate as strategic
planners at local level and are the main mechanism for
pooling resources. They also work together on a regional
basis to ensure county-wide coherence in strategic plans.
Similar organisational changes to improve coordination
have also been introduced in Ireland and Portugal.
Developments in European cooperation
European Drug Prevention Week (see Chapter 3) was the
main action funded by the programme of Community
action on the prevention of drug dependence in the year
1998. The three other priorities for this programme for
1998 were ‘Young people and synthetic drugs’,
‘Particularly vulnerable groups and preventive and health
actions linked to drug tourism’ and ‘Support for exchange
of information and experiences’ through ‘Improving
practices in Europe’. The budget allocated to these four
actions in 1998 was ECU 5 million. Community funding
was also provided for projects focusing on the reintegra-
tion  of marginalised groups, including addicts, into the
workplace. The estimated annual budget for these
projects within the Employment-Integra initiative was
ECU 15 to ECU 20 million. A further ECU 11 million was
provided for candidate countries in central and eastern
Europe within the Phare multi-country programme for the
fight against drugs. 
These are just a few examples of European cooperation.
But Europe is also improving its cooperation in other
Finnish initiative
Since 1996, Finland has had an ombudsman for
substance abusers. Working throughout the country, the
ombudsman gives counselling in legal matters relating to
services and safeguards the clients’ legal rights in issues
concerning municipal financial obligations, sickness pay
and other financial matters, as well as data protection.
The first report on the ombudsman’s activities was
published in 1998. 
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areas. For example, the Euregio cross-border partnership
between Belgium, Germany and the Netherlands uses
outreach workers from all three countries. Similarly, the
treatment of drug addicts at the Centro Italiano di
Solidarietá in Rome was an essential source of inspiration
for the Danish project ‘Human being’. By the end of a
three-year trial period, an external evaluation found that
the project had succeeded in obtaining and adapting the
treatment model, but that it had also become very much
like treatment in other Danish socio-educational treat-
ment centres. 
Nordic cooperation and exchange of experiences have a
long history. A common research centre, the Nordic
Council for Alcohol and Drug Research, is financed by
the Nordic Council of Ministers. 
The Mondorf Group coordinates activities in Luxembourg
and the border regions of Belgium, Germany and France.
Information, evaluation and
research 
Progressive harmonisation of 
epidemiological indicators
Improving comparability is a central task for the EMCDDA.
The Centre has been working with scientific experts and
partners from various national focal points (NFPs) to
develop five key epidemiological indicators on the preva-
lence and health consequences of drug use. At an October
1998 meeting, the Centre’s Management Board adopted a
key paper on the role and financing of the NFPs. From
1999, the focal points are committed to ensuring that use
of these indicators is implemented to a set timetable.
The five indicators concern: 
• surveys of drug use, behaviour and attitudes in the
general population;
• prevalence estimates of problematic drug use;
• demand for treatment by drug users;
• drug-related deaths, mortality and causes of death 
in drug users; and
• drug-related infectious diseases (HIV, AIDS, hepatitis B
and C). 
Although the nature of the standards to be implemented
varies according to the indicator, each will include a core
data set, definitions and methodological guidelines for
data collection, analysis and reporting. 
Since structures for collecting data on each indicator
differ between Member States, and the NFPs themselves
vary considerably in terms of their expertise and potential
to influence the implementation of standards, the first task
will be for each focal point to identify realistic targets and
implement concrete work plans for progressively achiev-
ing these targets. It is important that the NFPs establish
national reference groups made up of key partners and
experts to carry out work on each indicator. They must
also ensure that national authorities are committed to this
task and offer both political and institutional support. 
Although the EMCDDA is optimistic about progress,
comparability across the EU will not be achieved quickly
or without difficulties. Improved comparability of statis-
tics must be accompanied by measures ensuring the
quality (including training), interpretation and under-
standing of data in a national and local context. 
Improving evaluation 
Evaluation practice has improved in the EU, although
many gaps still remain in terms of scientific and financial
support and in the awareness of relevant professionals of
the necessity and benefits of evaluation. This can result in
assessments that are not scientifically sound or in total
resistance to evaluation. The EMCDDA’s ‘Guidelines for
the evaluation of drug prevention’ and the promotion of
its exchange on drug demand reduction action (EDDRA)
information system by the NFPs put evaluation on the
agenda of national administrations and professionals
alike. Several countries, such as France and Italy, have
developed their own evaluation guidelines on the basis of
the EMCDDA’s guidelines. Other countries, such as
Luxembourg and Portugal, are developing evaluation
systems based on EDDRA.
Research
For the first time, drugs are specifically included in the
EU’s research programme. European Commission
Directorate-General XII (Science, Research and
Development) has implemented its fifth framework
programme (1998–2002) which refers to drugs in the
context of public health research. This provides an excel-
lent opportunity to strengthen the scientific knowledge
base needed to improve the understanding of drug-
related problems and to develop evidence of the impact
and effectiveness of public health responses.
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Trends in drug use
Cannabis
• Considerable differences remain between countries in
the extent of cannabis use. However, there are indica-
tions of a convergence in prevalence levels (higher-
prevalence countries: stable or some decrease after
increases over the 1990s; lower-prevalence countries:
increase in recent years).
• A tentative, conservative extrapolation from recent
surveys suggest that over 40 million people in the EU
have used cannabis (about 16 % of the population aged
15 to 64) and that at least 12 million have used it in the
last 12 months (about 5 % of people aged 15 to 64).
• These proportions are higher among young people. On
average, about one in five adolescents aged 15 to 16
report that they have used cannabis, and by the time they
reach their mid-20s, the proportion approaches one in
three.
• Some increase in treatment demand for cannabis is
noted in several countries especially in younger clients.
• In most countries, cannabis is the main drug involved in
arrests for drug offences, mostly related to use rather than
trafficking. 
• The quantities of cannabis seized per year are stable,
although the number of seizures is steadily increasing.
Availability remains high across most of the EU and the
cannabis market appears entrenched with mostly stable
prices.
• In much of the EU, cannabis use is not associated with
any specific social or recreational context nor with any
particular group. 
Amphetamines, ecstasy, LSD
• Public concern about ‘synthetic drugs’ rose in the
1990s in response to the adoption of ecstasy and related
drugs within a mass recreational and music culture
known as ‘rave’, ‘techno’ or ‘dance’ that mostly involved
mainstream youth. The most recent development is one of
diversification regarding the drugs that are used and the
contexts and manner in which they are used.
• The dominant trend, confirming last year’s annual
report, is a long-term, and continuing, rise in the 
availability and use of amphetamines. Within the broader
recreational youth culture, amphetamines are mostly
taken by sniffing (powder) or orally (as pills or added to
drinks).
• Ecstasy continues to be available and used not only
within recreational dance and party settings, but also in
more private situations, although there are considerable
differences between countries. Recent evidence from
several countries suggests a stabilisation or decline in the
level of use (seizures also show an overall decrease) and
some disenchantment with pills sold as ecstasy. Analyses
of ecstasy pills show wide variations and, periodically,
high levels of amphetamine content.
• The patterns of diversification in use are hard to define
precisely. Various reports point to increased interest in
stimulant-type drugs such as amphetamines and/or
cocaine in some situations and in hallucinogens such as
LSD or mushrooms in others. The use of drugs with
sedative effects, such as heroin or benzodiazepines, is
also reported, especially in heavy consumers of ecstasy or
amphetamines. 
• Other patterns reported in this context, and in 
particular reflected on the Internet, include the use of, or
experimentation with, different substances, including for
enhancing sexuality, developing physical or mental
capacities, or self-medication of psychological states. 
• In more northern countries, amphetamines have been,
and continue to be, used (often injected) by chronic,
problematic drug users in more socially marginalised
situations that are not usually linked to the mainstream
youth drug scene.
• Apart from this more traditional, problematic pattern of
amphetamine use, the increases in amphetamines and
ecstasy are barely reflected in indicators such as 
treatment demand.
Overall trends
Developments in drug use, problems and responses
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Trends in drug use
Opiates
• The level of heavy opiate use or dependence (mainly
heroin) appears relatively stable across the EU. The
average age of known users continues to rise slowly,
although this may also reflect the expansion of 
substitution treatments.
• The total number of problematic opiate users is
estimated to be up to 1.5 million people (4.0 per 1 000
population) in the EU, of whom about 1 million (2.7 per 
1 000 population) probably meet the criteria for 
dependence (addiction).
• Although there are differences in prevalence between
countries, differences within countries are greater and
appear associated with a range of factors including social
exclusion. Geographical spread outside major cities is
also reported. 
• There continue to be reports from several countries of
increased heroin use, especially by smoking, amongst
different groups. Recent studies suggest that young users
take longer than average to enter treatment, so most 
existing indicators would not confirm this trend.
Cocaine
• The prevalence of cocaine use is lower than for 
amphetamines or ecstasy but higher than for heroin.
• Increased seizures and supply indicators suggest
continuing steady growth in the cocaine market across
the EU.
• Increases in treatment demand involving cocaine are
reported from some countries and cocaine is commonly
recorded as a secondary drug by heroin addicts.
• The situation regarding crack is not clear, although
some growth beyond the previously limited number of 
localities is reported from some countries.
Multiple drug use
• The use of various medicines and/or alcohol is increas-
ingly reported, both among problematic drug users and in
recreational drug scenes.
Health consequences
• Trends in reported drug-related deaths (mainly
overdoses) are stable overall, although a few countries
note increases or decreases.
• AIDS incidence is decreasing in almost every country,
partly reflecting improved treatment. 
• HIV prevalence is stable or decreasing in general,
although increases are reported in a few local studies and
the continued reporting of new cases in younger age
groups indicates that transmission continues.
• Prevalence of hepatitis B and C is still high (especially
C) and not decreasing.
• There are reports of increasing co-morbidity (other
psychiatric or organic diseases in combination with drug
dependence) amongst injecting and other problematic
drug users.
Law-enforcement indicators
• Police arrest mostly for use, and the proportion of
arrests for trafficking is not generally increasing.
• Fairly high proportions of prison population are drug
users, although they are not necessarily imprisoned for
drug offences.
1999 Extended annual report on the state of the drugs problem in the European Union
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Trends in demand reduction responses to drug use
• Both in treatment and prevention, the borders between
licit and illicit drugs are blurring.
• Between prevention and treatment, the classical 
interventions, many initiatives are emerging that might 
be termed ‘outreach work’, but which may have very
different objectives and approaches.
• Problematic drug use is clearly linked to social 
exclusion and prevention and treatment options must 
be more comprehensive and not only deal with drugs.
• Community work is considered more and more 
important in preventing and managing drug use.
• Especially in southern Europe, the family as a source 
of support is a major factor in prevention and treatment.
In northern Europe, the responsibility of parents as 
educators is increasingly stressed.
• Substitution treatment is expanding fast. However,
psychosocial treatment, accompanying substitution 
treatment, is not always given the same priority.
• Primary healthcare is becoming more and more
involved in treating drug users.
• Drug use is a major problem within the criminal justice
system. Different options of alternatives to prison, care
within prisons and compulsory treatment are developing.
• Evaluation of demand reduction activities is improving,
but most activities are still not evaluated. The impact 
of the EMCDDA in enhancing evaluation practice is
considered important.
Trends in drug policies
• Drug strategies show the still growing importance of
prevention and treatment over punishment in cases of
drug use.
• The aim of reducing the risks caused by drug use is
emphasised by some Member States, providing a legal
basis for ‘harm reduction activities’. 
• Political responses to minor drug-related offences aim
to reduce the emphasis on prosecuting and imprisoning
drug users. However, data shows that use-related offences
are not decreasing in relation to overall drug-related
offences. 
• Some countries put new emphasis on the danger of
addictive substances regardless of their legal status.
• The need to coordinate the multilateral efforts in
tackling the drug phenomenon, meant that some 
Member States developed national horizontal bodies 
to oversee the design and implementation of the national
drug policy.
2C h a p t e r
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Prevalence, patterns and
consequences of drug use
This chapter presents updated information on a range of indicators of
different aspects of the drug phenomenon in the EU. This will help to
ensure that information may be compared, where possible, between the
Member States, to highlight broad similarities and differences and to
comment on methodological limitations and developments.
The information is largely based on national reports
provided by the national focal points, supplemented by
results of published research or scientific studies carried
out by the EMCDDA.
The broad areas covered are:
• the prevalence of drug use;
• health consequences;
• law-enforcement indicators; and
• illicit drug market indicators.
Although the emphasis is on national data, local or
regional information is included to illustrate some of the
richness and variation within countries. (See Chapter 1
for details of the five key epidemiological indicators in
the EU Member States.)
Prevalence of drug use
Drug use in the general population
The extent and pattern of consumption of different illegal
drugs in the mainstream population can be estimated
through general population surveys. These surveys also
highlight characteristics and behaviour of users, and
attitudes towards drugs of different sections of the popula-
tion. Information is based on self-reporting by partici-
pants and data are collected by personal or telephone
interviews or by posted questionnaires.
Generally, surveys provide information on whether a
person has ever tried a drug (lifetime prevalence) or has
taken one recently (last 12 months or last 30 days preva-
lence, sometimes called ‘current use’), along with socio-
demographic characteristics and attitudes towards drugs.
This methodology is useful for substances whose use is
relatively common and not socially stigmatised. It has
more limited use for studying more marginalised forms of
drug use. Such a study would require large samples, and
surveys may exclude those in institutions or without a
permanent address or telephone contact. New emerging
trends appearing among local or closed, trend-setting
groups are also difficult to identify.
National population surveys
National population surveys on drug use have been
conducted in 11 Member States over recent years (the
Flemish Community in Belgium, Denmark, Germany,
Greece, Spain, France, Ireland, the Netherlands, Finland,
Sweden and the UK). Information on Greece and the
Netherlands has not been included in previous EMCDDA
annual reports because only cities were surveyed or
because national information was too outdated. Results
from Ireland are not yet available.
Cross-national comparative analysis of survey results can
help to identify and understand drug-use patterns, show
international similarities and differences, and help in
formulating drug policies. Differences in prevalence of
1999 Extended annual report on the state of the drugs problem in the European Union
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use between countries do exist, but direct comparisons
should be made with caution. Such differences may result
from methodological factors, such as data-collection
methods, the sampling frame used or the age ranges
chosen in reporting results. Social and cultural differ-
ences regarding drug use between countries may also
influence the willingness to report drug use. Illegal drug
use appears to be concentrated in urban areas, and the
relative proportion of a country’s rural and urban popula-
tions may influence its overall prevalence figures.
The EMCDDA has been working to develop common
European guidelines for population surveys on drugs.
These guidelines will include a set of basic common core
items, which may be incorporated into broader surveys,
common reporting formats and methodological guide-
lines. A preliminary joint analysis of several recent
national surveys is also being done. This will allow ex-
ploration of the actual compliance of existing national
questionnaires with the set of common core items, and
will explore the possibilities of conducting research at
European level on such issues as patterns of drug use or
drug-using careers with existing survey databases.
Similarities and differences
Despite the differences between countries regarding the
level of drug use, there are also similarities across the EU.
Cannabis is the illegal substance most frequently used in
all countries, whereas other drugs have much lower preva-
lence rates. In all cases, recent use (last 12 months) is
much less common than lifetime experience. This seems
to indicate that for most people drug use is an occasional
experience or is discontinued after a time. Only a limited
proportion of cases evolve into continuous use.
Lifetime experience with drugs
Recent surveys show that in the EU lifetime experience 
of cannabis in the general adult population ranges from
10 % in Finland to 20 to 30 % in Denmark, Spain and the
UK. Young adults report consistently higher rates of
lifetime experience with cannabis, ranging from 16 to 
17 % in Finland and Sweden to 35 to 40 % in Denmark,
Spain and the UK. Figures from the former East Germany
and the Flemish Community in Belgium are lower, but the
figures are taken from a particular social situation or from
relatively outdated surveys.
Amphetamines are generally the second most prevalent
substance, with about 1 to 4 % of the general EU adult
population and about 1 to 5 % of young adults in Europe
having experimented with them. Ecstasy has been tried by
0.5 to 3 % of the general adult population in Europe and
between 1 and 5 % of young adults. Experience with
ecstasy seems to be relatively more concentrated among
young adults in the EU than other substances, with preva-
lence higher among people in their 20s. Experience with
amphetamines and ecstasy among the general population
seems to be significantly higher in the UK than in other
countries.
Cocaine has been tried by 1 to 3 % of the whole adult
population in Europe, and by 1 to 5 % of young adults. In
Spain and France, cocaine has been tried by a higher
proportion of the population than amphetamines.
Recent drug use
People who admit to having used drugs may include
those who experimented with them long ago and never
used them again. Data on recent drug use would thus
give additional insight into the present situation. In this
report, last 12 months prevalence is used as an indicator
of recent drug use as last 30 days’ prevalence figures are
in many cases too low to be able to draw meaningful
conclusions.
Recent cannabis use is reported by 1 to 9 % of the adult
population in Europe, depending on the country: Sweden
presents the lowest rates, and Spain and the UK the
highest. As with lifetime experience, recent use is higher
among young adults, ranging from 2 to 20 %, although in
most countries figures are between 6 and 10 %.
Recent use of substances other than cannabis in the EU is
generally very low, rarely exceeding 1 % among the
general adult population and generally below 2 % among
young adults. Higher levels are reported for cocaine in
Spain, and for amphetamines and ecstasy in the UK.
Trends
Consistent information on trends is limited at present as
few EU countries have undertaken series of surveys using
the same methods. With information presented in this
report and other data contained in national reports
(including local surveys or older surveys), it can be
concluded that cannabis use (in terms of cannabis experi-
ence) has increased during the 1990s in most EU
countries. The level of drug use in EU countries also
appears to have converged, at least for cannabis experi-
ence. According with information presented in the
national reports, in countries with high- or medium-level
prevalence figures (Denmark, Germany and the UK), the
increase seems to have levelled off over recent years.
Countries with low initial prevalence figures (Greece,
Finland and Sweden) show an increasing trend.
Prevalence, patterns and consequences of drug use
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Information on trends for substances other than cannabis
is more limited and difficult to interpret. Figures are much
lower and more easily affected by random changes (wider
confidence intervals) and by methodological problems.
No major changes in prevalence figures have been
observed over recent years among the general population.
Cocaine seems to produce divergent trends in different
countries, and amphetamine use, especially ecstasy, has
increased moderately in several countries, especially
among young adults.
Identifying trends in use of these substances would be
facilitated if the analysis concentrated on more selected
subgroups of the population surveyed, such as people in
their 20s living in urban areas. A good case in point is the
1994 British crime survey which reported 3 % last 12
months prevalence of ecstasy use among 20- to 24-year-
olds (4 % in males and 3 % in females). The figure in the
1996 British crime survey for the same group was 6 % 
(11 % for males and 3 % for females).
Drug use among schoolchildren
Information on drug use among schoolchildren may be
useful for assessing future trends among the general
population and for planning and evaluating prevention
strategies. School surveys are relatively less expensive
than general population surveys because information is
usually collected with anonymous self-administered
questionnaires answered in the classroom.
Notes: Lifetime experience = lifetime prevalence (LTP); recent use = last 12 months 
            prevalence (LYP). Results of the most recent surveys were used here. 
Lifetime experience and recent use of cannabis among adults 
in some EU countries (measured by population surveys)
Figure 1
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For more detailed information on each survey, see Tables 1 and 2. 
Some Member States were unable to supply data. 
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Notes: Results of the most recent surveys were used. For more detailed information on each survey, see Table 1.
            Some Member States were unable to supply data.
Lifetime experience of cannabis, amphetamine and cocaine use in some EU countries
(measured by population surveys)    
Figure 2 
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School surveys generally focus on 12- to 18-year-olds,
especially the 15 to 16 age range. Some new trends in
drug use may not be well represented in this age group,
however, and use among trendy club-goers may be better
represented by adults in their early 20s.
Most EU countries have conducted national school
surveys over recent years, some as part of the ‘European
school survey project on alcohol and other drugs’
(ESPAD). This project coordinates school surveys in both
EU and non-EU countries using similar questionnaires and
methodology. It is coordinated by the Swedish Council for
Information on Alcohol and other Drugs (CAN) with
support from the Pompidou Group of the Council of
Europe, an intergovernmental structure which aims to
promote and support the establishment of national
policies and programmes and strengthen international
cooperation on drugs. In 1995, 25 European countries
participated in the project. The study is being repeated in
1999 using the same questionnaire and methodology.
Methodological factors must be taken into account when
comparing prevalence figures of drug use among school-
children between countries. Factors such as the type of
schools selected and the context in which the question-
naire is administered may influence reported prevalence.
The exact age of the students is important because given
the limited range, one or two years’ difference may
double prevalence rates. The social context, such as
living in an urban or rural area, may also significantly
influence the onset of drug use in this age range. For
example, in Finland the 1995 national school survey
reported a lifetime prevalence of 5.5 % for cannabis
among 15- to 16-year-olds, but in the same year, 17- to
18-year-olds in Helsinki reported a 30 % lifetime preva-
lence rate for cannabis.
Experimentation with drugs among schoolchildren is
generally a recent experience and lifetime prevalence
and last 12 months prevalence figures are far more similar
than they are among adults. In this report, the age group
15 to 16 has been selected to present the results because
the ESPAD project concentrates on this group. Almost 
all other national surveys include this age group in 
their studies.
Cannabis use by schoolchildren
In most EU countries, cannabis is the most widely used
illegal substance. The proportion of 15- to 16-year-olds
who report cannabis use ranges from about 5 to 40 %,
depending on the country. The lowest rates are reported
in Finland and Portugal, and the highest in Ireland and
the UK. Some countries that report a low prevalence of
cannabis experience report higher levels of solvent use.
Solvent use by schoolchildren
Figures on solvent use should be interpreted with caution
because different questionnaires may ask for them in
different ways, making comparisons difficult.
In general, solvents are the second most commonly used
substance among 15- to 16-year-olds, ranging from about
3 to 4 % in the Flemish Community in Belgium, Spain
and Luxembourg to 20 % in the 1995 survey in the UK. In
some countries (Greece and Sweden), experience with
solvents is reported more frequently than experience with
cannabis, although methodological problems may influ-
ence the figures.
Other drugs used by schoolchildren
Use of amphetamines is reported by 1 to 13 % of 15- to
16-year-olds, although in most cases figures are between
2 and 8 %. Ecstasy experience is reported by 1 to 9 % of
schoolchildren, and use of LSD and hallucinogens by 1 %
to over 10 %, although in most cases the figures are
between 2 and 5 %. Ireland, the Netherlands and the UK
report comparatively higher figures for amphetamines,
hallucinogens and ecstasy experience than other countries.
Cocaine and heroin present the lowest lifetime preva-
lence figures. Cocaine has been tried by an average of 
1 to 3 % of schoolchildren. Heroin has been experienced
by less than 1 % of those surveyed, although this rises to 
2 % in Denmark, Ireland, Italy and the UK.
Trends among schoolchildren and young people
Several countries report information on trends in drug use
among young people or schoolchildren from different
sources including national school, local school, youth and
conscript surveys. Most countries that have access to this
information report that cannabis use has increased clearly
during the 1990s, in some cases to a remarkable extent.
In general, the upward trend has continued in recent
years. However, Finland and the UK reported in their
1998 national reports that after several years of increases,
cannabis use among young people has stabilised or even
decreased in recent years. Information on trends about
other substances is more limited.
Amphetamine and ecstasy use seem to have increased in
the 1990s among schoolchildren, although at lower
levels than cannabis.
Prevalence, patterns and consequences of drug use
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Estimating problem drug use
Problem drug use, such as addiction to opiates or stimu-
lants, injecting or drug use associated with criminal be-
haviour, poses the highest risks to the individual drug user
and to society. Consequences of problematic use include:
• extreme mortality (injectors may be at 20 times higher
risk than non-drug-using peers);
• risk of infectious diseases (rates of HIV or hepatitis
infection may be 10 to 100 times higher); and
• loss of educational opportunities, employment, social
support, partner, family and friends.
For society, besides health, social care and law-enforce-
ment costs, problem drug use often incurs costs related to
property damage as well as, more subjectively, nuisance
and feelings of insecurity.
Despite the large impact on society made by problematic
drug users, their numbers are relatively small. Opiate
addiction or injecting drug use is generally low in the
adult population and almost absent at school age. Use of
hard drugs such as opiates is usually hidden and users are
unwilling to admit to it for fear of stigmatisation. It is thus
not possible to obtain reliable prevalence figures through
general population or school surveys.
Estimating prevalence requires indirect methods, such as
multiplier techniques or advanced statistical models, such
as three-sample capture—recapture. These methods
extrapolate prevalence from known numbers in drug
registries (treatment, arrests, deaths). However, statistical
uncertainty is always present in estimations which are
therefore expressed as a confidence interval (which, with
95 % certainty, contains the real prevalence rate) or, if this
is not possible, as a ‘plausibility range’. In addition, preva-
lence estimates at national level are difficult to obtain
because of within-country heterogeneity and lack of data.
All this means that prevalence figures should be inter-
preted as only a crude indication of prevalence, or as a
‘best estimate’ of the number of problem drug users in a
given area.
National estimates of problem drug use
Updated national estimates are presented for the
countries that participated in an EMCDDA study to
improve prevalence estimates at national level (see Figure
4 and Tables 4 and 5). Until recently, methods and defini-
tions varied significantly — the terms ‘opiate addicts’ or
‘heroin addicts’ were used in some countries, while a
wider definition of ‘heavy/severe drug abusers’ or ‘high-
risk drug consumers’ was used in others. For example, in
Sweden, frequent users of cannabis and ecstasy were
included, although over 90 % of the total estimate are
amphetamine injectors.
In the EMCDDA study, all participating countries
provided figures using the same definition of problem
drug use: ‘intravenous drug use (IDU) or long-
duration/regular use of opiates, cocaine and/or ampheta-
mines’. This definition excludes ecstasy and cannabis
users and those who do not use, or at least not regularly,
opiates, cocaine or amphetamines. The study applied
methods already used in some countries to all participat-
ing countries.
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Figure 3 Lifetime experience of cannabis, solvent and cocaine use among 15- to 16-year-old schoolchildren 
in some EU countries (measured by school surveys)    
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Notes: The estimate for Belgium only includes IDUs and thus underestimates problem drug use. 
            For more detailed information, see Tables 4 and 5. Some Member States were unable to provide data.
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Six basic methods were used, mainly based on statistical
models incorporating drug indicators (see Table 4):
• multivariate indicator or synthetic estimation;
• capture—recapture;
• three multiplier methods based on contact rates with
treatment or police, or on mortality rates; and
• a multiplier method using back-calculated numbers of
IDUs with HIV/AIDS in combination with HIV/AIDS rates
among IDUs.
In general, prevalence of problem drug use seems lowest
in Germany, Austria, Finland and Sweden and highest in
Italy, Luxembourg and the UK. In the countries with inter-
mediate prevalence, the estimates typically range
between three and five problem drug users per 1 000
population aged 15 to 54.
Given the methodological caveats already mentioned,
estimates based on multiple methods giving comparable
results should be regarded as more reliable. The
EMCDDA study is now investigating social indicators to
estimate prevalence of problem drug use using statistical
modelling techniques. Possible social indicators include
unemployment, property crimes, migration, housing
density and socioeconomic status. As these data are more
widely available than drug-specific data, estimates might
be easier to obtain even at regional level or where there
are few reliable drug data. The Netherlands based its
study on social indicators and confirmed previous
estimates obtained using other methods.
Incidence
Another EMCDDA study recently examined ways of using
observed incidence — defined as the rate of new cases a
year — of new drug users in treatment to estimate real
incidence of problem drug use and, more importantly, the
direction of trends in incidence which could be used for
future projections. This was done using a back-calcula-
tion model and estimates of the latency time between
onset of drug use and first treatment (Box 1 shows the
results for Italy using different models). The results
indicate a generally stable incidence of problem drug use
with two peaks in 1986 and 1991 (the initial zero value is
an artefact of the method and should be disregarded).
As incidence is directly related to prevalence (the rate of
all existing cases in a certain year), this work will lead to
improved prevalence estimates. It may also give more
insight into the changes in prevalence over time and
determining factors. The long-term aim is to be able to
relate changes in drug policies and interventions to
changes in incidence and prevalence of problem drug
use.
Geographical spread of drug use
A third EMCDDA project evaluated the possible use of
geographic information systems (GIS) to map drug-use
data and estimates and to develop models of geographic
spread between cities and towns. The example for
Glasgow shows how peak incidence gradually moved
from the city centre (1984) to the outskirts (1988) and
then on to neighbouring towns (1990). This pattern of
spread from larger cities to surrounding towns has been
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Incidence of new cases of problem drug use in Italy
Here, estimates have been back-calculated from the
observed incidence of new cases in treatment. The
incidence curves of new problem drug users provided by
the back-calculation model depend greatly on the latency
period model chosen (two models were used, both with
and without adjustment for ‘age at first use’). However,
the location of the peaks of the epidemic and the 
qualitative trends seem to have been estimated robustly.
The initial low incidence (1982–84) is a spurious result of
the method and should be disregarded.
Source: ‘Pilot project to estimate time trends and incidence of
problem drug use in the European Union’, EMCDDA, 1999.
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This map illustrates the estimated peak
incidence of new cases of problem drug
use in the west of Scotland from 1984–91.
Each ‘isoline’ represents the location of
the highest incidence of new drug users in
a given year, thus showing where and
when drug use spread most rapidly.
For example, these isolines show drug
misuse starting in the centre of Glasgow
in 1984, before spreading more rapidly
to the suburbs in 1988.
By combining this type of information
with other data such as social indicators
(trends in unemployment, socioeco-
nomic status) or drug trafficking routes, 
it may be possible to make predictions
about the spread of drug use within and
between countries.
Note: Incidence was estimated using an ‘infectiousness’ model of macro-
geographic spread.
Source: ‘Pilot project to develop a model of geographic spread of drug use in the
European Union’, EMCDDA, 1999.
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observed previously. It may, therefore, be possible to
predict the future spread of problem drug use at macro
level using this type of model. A follow-up to these
projects is expected gradually to improve knowledge on
prevalence and the dynamics of the spread of problem
drug use in Europe.
Local prevalence estimates
Prevalence estimates of problem drug use were first
developed, and are more easily applied, at local level. An
overview of local prevalence estimates since 1993
suggests that even when techniques vary and definitions
are not always compatible, important differences may
exist between cities and towns in Europe (see Figure 5).
For example, estimates in the age range 15 to 54 vary
from 3.2 to 3.9 per 1 000 for Berlin to 16.1 to 25.2 for
Aberdeen, and possibly even 44 to 124 per 1 000 in the
region of Setúbal, Portugal (not shown). Less dramatic,
but still important, differences in prevalence are observed
between major cities. However, variability within a
country may be just as pronounced, as illustrated by the
Netherlands (from 6.3 to 12.6 – 13.3 per 1 000 aged 15 to
54) and the UK (from 5.3 to 16.1 – 25.2 per 1 000 aged
15 to 54).
In 1997, a study commissioned by the EMCDDA
produced estimates for opiate use in six cities using
comparable methods and definitions. Estimated preva-
lence for ages 15 to 54 ranged from 4.2 to 8.1 per 1 000
in Helsinki (not shown) to 12.7 to 29 per 1 000 in the city
of Setúbal. This suggests that the wide range of prevalence
found in other studies cannot be attributed only to
methodological issues, but partly reflects real differences.
Figure 5 Local prevalence estimates of problem drug use in the EU 
(rate per 1 000 population aged 15 to 54)
Notes:
1. The surface of the symbol is proportional to the
estimated prevalence rate.
2. This map shows available local estimates of the preva-
lence of problem drug use, not the prevalence of problem
drug use throughout the EU. Countries and cities not
indicated have not provided an estimate, but may also
have high rates of problem drug use. For national-level
estimates, see Table 4.
3. Prevalence estimates of problem drug use are not
directly comparable because of differing methods and 
definitions. However, despite these differences a global
impression can be given. Estimates of problem drug use in
Stockholm and Helsinki include amphetamine injectors.
Estimates of use in Copenhagen and studies in the UK
used a wider definition than opiate use. The Berlin
estimate is limited to injecting drug users. Most other
estimates refer to opiate addicts or problematic opiate
users.
4. For estimates prior to 1993, see the EMCDDA’s 1997
and 1998 annual reports.
5. For sources, see end of chapter.
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Indicators of health 
consequences
Demand for treatment
The number of admissions to drug treatment is a useful
indirect indicator of trends in prevalence of problematic
drug use, although changes in service availability, treat-
ment modalities or reporting procedures must be taken
into account. Treatment information may be especially
useful in describing characteristics and patterns of drug
use (injection, multiple drug use) among problematic
users, and in identifying patterns of service uptake, so
helping to assess service needs.
The EMCDDA is also working to improve quality and
comparability of treatment demand information at
European level. Building on previous work undertaken by
the Pompidou Group, a new common European protocol
on a treatment demand indicator has been drawn up by
the EMCDDA. This protocol will be adopted and
promoted by both organisations.
At present, almost all EU countries provide information
on drug treatment. Methods of data collection and cover-
age of various types of treatment centres (in-patient, out-
patient and others) vary. This may explain some of the
cross-national differences in substances reported by
treated clients and other characteristics. New services
(such as substitution, low-threshold) may attract new
users, increase the number of treatment admissions or
change profiles like age, sex and route of administration.
Characteristics of clients entering treatment
With these limits in mind, some common features can be
identified consistently among clients entering treatment
in EU countries. These are, for example, the predomi-
nance of opiate clients and of young males. Other
characteristics, especially the proportion of injectors
among treated clients, differ from country to country.
These differences may give important insight into the
extent and nature of public health problems related to
drug abuse.
The majority of clients (70 to 95 %) required treatment for
opiate (mainly heroin) use (see Figure 6 and Table 6). The
Flemish Community in Belgium, Finland and Sweden
were the exceptions, with under 40 % of opiate cases.
However, in these countries, treatment information was
based only on hospital discharges or specialised in-
patient treatment centres, which may bias the type of
population covered. In some countries, methadone is
increasingly mentioned as the primary drug. This may
result from clients in methadone-maintenance
programmes willing to switch to drug-free programmes,
or to data-collection methods where clients already
enrolled in a methadone programme are signed up in
another clinic as new methadone cases.
In most countries, cocaine is reported as the main drug by
less than 10 % of treatment admissions. In Luxembourg
(15 %) and the Netherlands (18 %) the proportion is
higher. Heroin users frequently report cocaine as a
second drug.
Cannabis is generally reported as a main drug by about
10 % or less of treatment admissions in the EU. In some
countries, this proportion is higher: Belgium (22 % in the
Flemish Community and 13.2 % in the French
Community), Germany (16.2 %) and Finland (17.9 %).
Amphetamines, amphetamine derivatives (such as
ecstasy) and hallucinogens are primary drugs for gener-
ally less than 1 or 2 % of treatment cases. However, the
proportion is higher in Finland (48 %), Sweden (20 %),
the Flemish Community in Belgium (19 %), and Great
Britain (9 %). However, as mentioned before, data from
the Flemish Community in Belgium, Finland and Sweden
come from different types of treatment centres than in
most other countries.
Prevalence of injecting among drug users in treatment
varies widely between countries, although important
differences also exist within countries. Opiates are the
substances most commonly injected, ranging from about
14 % (the Netherlands) to over 80 % (Greece and
Luxembourg), although in most countries that provide
this information, 30 to 60 % of opiate clients admitted to
treatment inject their drug.
Injection of amphetamines is reported frequently in the
Scandinavian countries and the UK, although this is not a
common pattern in most countries. In some, a significant
proportion of clients admitted to treatment for cocaine
use injected the substance. This pattern of use does not
seem to be common among cocaine users in general in
the EU.
In all EU countries, young males make up the largest
group admitted to treatment for drug use. Depending on
the country, males represent 70 to 85 % of clients admit-
ted to treatment. This high proportion has remained
relatively stable in recent years.
The mean age of clients admitted to treatment ranges
from 24.3 (Ireland) to 33 (Sweden). In most cases, it is 
25 to 35. In Ireland, the general population is much
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younger than in any other EU country which could
explain the younger age of drug users entering treatment.
Some countries report an increase in the mean age,
which can be interpreted as the possible existence of an
ageing cohort of drug users, with fewer new cases.
However, the ageing of the treated population is difficult
to interpret because the expansion of substitution
programmes has attracted older clients, some of whom
were not previously in contact with treatment services.
Trends in the treated population
Some interesting trends in the characteristics of the
treated population have been identified in recent years,
and these changes may highlight variations among the
whole population of problem drug users. New trends can
be identified by monitoring all treatment admissions, but
also by comparing the characteristics of clients seeking
treatment for the first time with those of old clients.
Available treatment information indicates that in general
the proportion of treatment admissions for opiates is
decreasing, while cases of treatment for cocaine and
cannabis are increasing, although they remain at lower
levels than for opiates. Recently, some countries reported
the increase in cannabis cases, especially among clients
treated for the first time.
This result requires more detailed examination, as other
factors should also be considered. These include the type
of reporting centres, the sources of referral and other
characteristics of the client such as simultaneous use of
other drugs as well as whether treatment is an alternative
to administrative sanctions. Attention should also be paid
Notes: For more detailed information on the characteristics of clients admitted to drug 
            treatment, see Table 6. Some Member States were unable to provide data.
Proportion of clients admitted to drug treatment whose main drugs were opiates in some EU countries 
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Notes:  For more detailed information, see Table 6 which presents information on 'all clients' but on 'new clients' admitted to treatment
             for the first time. Some Member States were unable to provide data.
Proportion of clients admitted to treatment for opiate use who injected the drug in some EU countries    Figure 7 
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Analysis of treatment data using statistical and mathematical models
An EMCDDA project analysed the ‘latency time’ between
first use of opiates (mainly heroin) and first demand for
treatment in Amsterdam, Lisbon, London and Rome. 
The graph shows a similar pattern in Amsterdam, London
and Rome. The main factor determining latency time in
all three sites was age at first use. Other influential 
determinants were route of administration, gender,
ethnicity and year of first treatment. Lisbon also partici-
pated in the study, but latency time was not plotted as the
treatment services had existed for only a short time,
resulting in a biased (longer) latency period. A different
(shorter) latency time has more recently been found in
Dublin, possibly because the heroin epidemic is much
newer there.
However, in cities with long-established and stable treat-
ment capacity, and not too recent heroin epidemics,
latency time before treatment, as well as its determinants
(mainly age at first use), appear similar.
The table above, giving the results for Rome, shows that
the mean latency time differs greatly according to age,
being much longer in those who started using drugs at a
young age. There is also much variability within each age
group — of those who started using drugs under 16 years
of age, 25 % enter treatment within six years, 50 %
(including the first group) within eight years and 75 %
(including both previous groups) within 13 years. This
information is important for treatment services as it may
partly reflect ‘treatment attraction’.
It is now clear that treatment services do not attract young
drug users. This may be either because these users do not
feel the need for treatment, or because the services are
less well suited to treat them. This should be studied
further at local level, for example by interviewing users
on the streets and in treatment about their reasons for
attending or not.
The statistical analysis of treatment data can generate
hypotheses that lead to further research and potentially
important information for treatment services.
Latency time between first use of opiates and first demand for treatment in Rome (years)
Age at first use Sample size Mean 25 % Median (50 %) 75 %
Under 16 555 9.2 6 8 13
16–21 2 675 7.0 3 6 10
Over 21 1 426 4.7 1 3 7
Source: ‘Pilot project to estimate time trends and incidence of problem drug use in the European Union’, EMCDDA, 1999.
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to the increase in clients admitted to treatment for cocaine
use in some countries (Spain and the Netherlands).
Most EU countries report a decrease in the proportion of
injectors among treated opiate users. This shift is detected
among all clients, and more clearly with new clients,
with some countries having experienced this trend for
several years. Changes in the route of administration of
drugs may have a major impact on public health conse-
quences of problem drug use (fatal and non-fatal
overdoses and infectious diseases), and close monitoring
of this pattern of use is important.
Drug-related deaths and mortality 
of drug users
Drug-related deaths
Death is a possible consequence of some forms of drug
use, although the risk varies depending on the substance
and the pattern of use. Drug-related deaths are a cause of
grave social concern, especially acute forms (‘overdoses’)
among young people. Their number is often simplistically
used as a marker of a country’s drug situation.
In the EU, statistics on drug-related deaths generally refer
to deaths occurring shortly after drug use (sometimes
known as acute intoxication, overdose, poisoning or
drug-induced deaths). Other types of deaths (from infec-
tious diseases, accidents or suicides) should be taken into
account when assessing the overall impact of drug use in
society. However, their causal relationship to drug use
and the methods of recording such cases are less clear.
Direct comparisons between national statistics cannot be
made because these depend not only on the prevalence
of drug use, but also on the methods and definitions used
to record cases. Some countries use rather restrictive
definitions, while others use broader criteria. The detec-
tion rates of reporting systems also vary substantially
between countries. Bearing in mind these limits, if
recording methods are maintained consistently within a
country, drug-related deaths can be a useful indicator of
trends for severe forms of drug use.
Improving the quality and comparability of death stat-
istics is difficult, however, because countries rely on
different types of registries (general mortality or
forensic/police) which use different recording and report-
ing procedures. The EMCDDA has been working in
collaboration with Eurostat and the World Health
Organisation to produce standard guidelines for reporting
results from both types of registries. The feasibility of
implementing these standards is being tested in all EU
countries during 1999.
Trends in drug-related deaths
Trends in drug-related deaths differ from country to
country, perhaps as a result of changes in recording pro-
cedures. Despite these limitations, some general trends in
drug-related deaths can be outlined (see Figure 8 and
Table 7). In most EU countries, acute drug-related deaths
increased markedly during the late 1980s and early
1990s. Since then, the number of drug-related deaths in
many countries has stabilised or even decreased,
although in some it has continued to increase until
recently. In a few Member States, the trend is still
upwards, specially in those where opiate use appears to
have spread more recently as in Greece, Ireland and
Portugal, although in the last the number decreased in
1997 partly due to under-notification.
The reasons for this changing trend are not clear.
Variations in recording practices may play a role, but it
may also be related to a stabilisation in problematic drug-
use prevalence, to changes in the patterns of use (such as
a decrease in injecting) or to the effects of interventions
(like the spread of opiate substitution programmes).
Although other substances are often present, opiates are
found in most cases of deaths by acute intoxication
recorded in the national statistics. Alcohol and benzo-
diazepines are frequently found and may be risk factors
for fatality in cases of opiate intoxication. Acute deaths
relating solely to cocaine or amphetamines are unusual.
Deaths related to ecstasy or similar substances, although
widely publicised, are few in number. For instance, in
England and Wales the number of deaths where positive
toxicology to ecstasy was recorded in the death certificate
peaked in 1994 with 23 cases falling to 10 in 1995 and
rising to 12 in 1996. These figures may underestimate the
number of deaths where ecstasy is present but, on the
other hand, the presence of a substance in the toxicologi-
cal examination does not necessarily imply a causal
relationship with the death. This may change if chronic
use develops, or if use in combination with other
substances increases.
Mortality of drug users
In addition to national statistics on drug-related deaths,
mortality risk associated with some forms of drug use may
be assessed by following groups of drug users and
monitoring their mortality (known as longitudinal or
cohort studies). Problematic drug users have a much
higher risk of death than the general population, from a
wide range of causes and not just acute intoxication.
Longitudinal studies indicate that opiate injectors have a 20
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to 30 times higher risk of death by overdose, HIV infection,
accident or suicide than non-drug users of the same age.
Mortality among injectors has increased with the spread of
HIV infection, while non-injectors or users of other
psychoactive substances have a much lower risk of death,
especially from acute intoxication. The EMCDDA has
developed a standard protocol to conduct mortality cohort
studies among drug users recruited in treatment centres.
This protocol will improve comparability between the
results of mortality studies conducted in different localities
in the EU.
Drug-related infectious diseases
Infectious diseases, such as HIV and hepatitis B and C,
have reached high prevalence among IDUs in most
countries. By their very nature, infectious diseases pose a
threat to others, to partners and children of IDUs, and to
clients of prostitutes. The rise of heterosexually acquired
AIDS in Spain is largely driven by the large epidemic
among IDUs.
There is still no cure for HIV, which requires lifelong use
of strong medication with many side effects. In many
countries, HIV/AIDS is still the major health threat to
IDUs, but in others hepatitis B and, especially, hepatitis C
— both of which are difficult to treat — may pose a
heavier burden to IDUs and public health resources.
Other infection-related problems in IDUs are tuberculo-
sis, sexually transmitted diseases (STDs), abscesses and
endocarditis.
The spread of infectious diseases is difficult to measure.
Antibody levels in blood or saliva reflect the prevalence of
those who have ever been infected and recent infections
cannot be distinguished. In some cases, such as for HIV or
hepatitis C, most of these people have a chronic infection,
sometimes with severe long-term implications such as
AIDS (in the case of HIV) or severe liver problems (hepa-
titis B and C), and long-term transmissibility to others.
Prevalence can vary greatly between areas and
subgroups, so that a national average prevalence rate may
be difficult to derive or interpret. Trends in prevalence are
also hard to interpret, often because of a lack of repeated
data and because the total number of prevalent infections
reacts only slowly to changes in the rate of new infec-
tions. In order to assess the effects of interventions and
factors related to infection, it is important to know the
incidence rates of new infections.
These data can only be obtained in settings that permit
repeated testing of the same individual, such as cohort
studies or surveillance of person-based test results in
reference laboratories. Cohort studies can give data of
good quality, which allow clear scientific conclusions to
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             For more details, see Table 7. 
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be drawn about changes over time or interventions. But
these studies are expensive, often only local and over
time they become no longer representative of the popula-
tion of IDUs in general. Laboratory surveillance can cover
large areas, but it depends on the strongly biased sample
of IDUs who are being tested for different reasons, while
background information on risk behaviour is poor. A
possible ‘surrogate’ incidence might be derived from
prevalence data in young IDUs or from IDUs with a short
injecting history, as this necessarily reflects more recent
infections.
The EMCDDA has been collecting data from the different
available data sources, such as screening of IDUs in treat-
ment, needle exchanges, notification of self-reported or
‘known’ test results (the quality of which may be
unknown) by services, results of studies or rates of infec-
tion in opiate overdose deaths. Although these data are
difficult to compare, many sources have a large coverage
and the data do provide a rough impression of the spread
of these diseases in IDUs in the EU.
A current EMCDDA project is investigating how to
improve these data and to develop a valid and compar-
able European surveillance system of infectious diseases
in IDUs. The aim is to give public health authorities a
rapid insight into increases in transmission among IDUs,
at present the largest risk group for HIV and hepatitis C
infection. Another EMCDDA project is studying the
public health costs of infectious diseases in IDUs and the
cost-effectiveness of interventions.
HIV
There are major differences between countries in preva-
lence rates for HIV infection among IDUs, ranging from 
1 % in England, Wales and Ireland to 32 % in Spain (see
Figure 9 and Table 8). Similar differences in prevalence
also exist within countries, between regions and cities.
Prevalence is declining slowly in some countries (France
and Italy), but apparently not in other countries (Spain
and Portugal). In Finland, an increase (statistically not
significant) from 0 % to 3 % has been reported this year,
possibly indicating an increase in transmission. Even in
countries where prevalence remains stable, transmission
most probably continues among IDUs. This stable state is
called an endemic situation, meaning that the new infec-
tions balance the numbers of deaths and migrations of
infected IDUs. The HIV epidemic has now entered the
stable endemic phase in most west European countries.
Modelling studies, based on estimates of HIV incidence
from reported AIDS cases, have shown that new genera-
tions of users have continued to become infected in the
1990s. This ongoing transmission in young IDUs,
however, has been hidden by the general decline in
incidence after the first epidemic phase (see the
EMCDDA’s 1998 annual report).
HIV prevalence rates often differ between subgroups of
IDUs. Female IDUs sometimes have higher infection rates,
possibly because they more often have a sexual partner
with whom they share injecting materials. IDUs who have
been imprisoned also have higher rates of infection.
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Differences in prevalence are often found between ethnic
groups. Prevalence rates differ strongly by age or length of
injecting career, as the risk of infection cumulates with
use. However, incidence studies show that young and
new IDUs often take the highest risks, presumably
because they have not yet learned how to protect
themselves. Therefore, it is important that prevention
measures target these young and new IDUs, or, if pos-
sible, prevent them from starting to inject.
The data given currently provide the best available infor-
mation on HIV among IDUs in the EU (Table 8). Where
possible, data are presented from sources with national
coverage. In some cases, these are not available and local
prevalence is presented instead.
The Netherlands illustrates geographical variation in
prevalence within a country, with prevalence ranging
between 2 % in Arnhem and 26 % in Amsterdam. As only
local studies exist, a national average cannot be given. In
other countries, data collection is so extensive that a 
national average becomes meaningful. For example, in
Italy 16 % of 73 784 tested drug users (mostly IDUs) were
HIV positive, while prevalence differed markedly by
region (1 to 28 %). In France, the national average is
estimated to be between 16 and 18 % according to a
national survey of treatment centres. As this figure is
based on self-reported or ‘known’ test results notified by
the drug services, it may be less reliable than data based
on other sources such as screening.
AIDS
Incidence rates for AIDS also vary greatly between
countries and in general continue to decline (see Figure
10 and Table 9). This is probably the effect of a steady
increase in uptake of new combination treatments among
IDUs which delay the onset of AIDS. The only country
that has still not shown a decrease is Portugal. This may
be because the rate of new infections has been increasing
until recently or possibly because pre-AIDS treatment is
not being offered to IDUs to a significant extent. The
HIV incidence in injecting drug users (cases per million total population, 
back-calculation by country)
Back-calculation estimates of HIV incidence show large
differences between countries. Countries with low
incidence are shown in the right-hand figure while those
with high incidence are shown in the left-hand figure
(note the different scales). In the above figures, the
estimated peak incidence of HIV occurred between 1986
and 1988 in most countries. The shape of the HIV
incidence curves is also different from that of the AIDS
incidence curves, illustrating delayed and less peaked
incidence because of the long and variable incubation
time between HIV infection and AIDS. The curve for
Portugal began to rise later than in other countries and
continued rising until 1994, possibly because the heroin
epidemic also started later.
Source: Jager and Ruitenberg (1997), unpublished results.
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proportion of IDUs among all cumulative AIDS cases
differs significantly between countries, illustrating varia-
tions in the relative importance of IDUs in the AIDS
epidemic.
AIDS monitoring is becoming less useful as an indicator
of the extent of HIV infection. Instead, AIDS is becoming
more an indicator of treatment uptake. New, highly effec-
tive treatments are further increasing the time lag
between HIV infection and AIDS, which was already
about 10 years. Centralised reporting of known HIV cases
is now being considered in Europe to complement exist-
ing AIDS reporting.
Hepatitis B
The prevalence of antibodies against hepatitis B infection
(anti-HBc, indicating past infection) differs markedly
among EU countries — from 19 % in the UK to 68 % in
Greece and a high, but local, prevalence of 80 % in
Germany (see Figure 11 and Table 10). Some lower rates
may be less reliable, such as those based on self-reports.
Although the hepatitis B virus (HBV) is probably more
transmissible than the hepatitis C virus (HCV), prevalence
levels of anti-HBc are lower. This is because only about 
10 % of those infected with HBV become chronically
infected (carriers) and thus remain infective for others.
Hepatitis B is less of a public health problem for IDUs
than hepatitis C. As HBV is much more sexually transmis-
sible, it poses a potentially greater problem for the sexual
partners of IDUs and for the general population.
Vaccination for hepatitis B
Since 1996, hepatitis B vaccinations have increasingly
been offered to IDUs. This makes antibody levels for
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
87
19
98
0
1
2
3
4
5
6
7
8
9
AIDS incidence in injecting drug users in the EU (1987–98)        Figure 10 
0
20
40
60
80
100
120
Luxembourg
France
Austria
Belgium
Netherlands 
Germany
Sweden
UK
Denmark
Ireland
Greece
Finland
19
88
Notes:   Figures for 1996–98 are adjusted for reporting delays. 
              In some countries, there may be small differences between the incidence 
              rates provided by the European Centre and national figures.
              For more details, see Table 9.
Source:  European Centre for the Epidemiological Monitoring of AIDS.
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
87
19
98
Incidence rates 
per million
10
Spain
Portugal
Italy
Luxembourg
France
Prevalence, patterns and consequences of drug use
43
hepatitis B less reliable as an indicator for past infection.
Surveillance might need to focus more on those testing
positive for hepatitis B antigen (HBsAg), which is a marker
of current or chronic infection. The proportion with no
antibodies remains important as an indicator of the
population of IDUs still at risk of infection, and to show
the potential for vaccination.
As those infected by both hepatitis B and C may be most
at risk of developing long-term liver problems, the hepa-
titis B vaccine may be a cost-effective method of prevent-
ing liver disease in those infected with HCV. Improving
coverage of hepatitis B vaccination among injecting drug
users is, therefore, important. One problem in offering
vaccinations to IDUs is the need for three injections over
a period of six months or more. Shorter time periods that
might be more appropriate for vaccination of IDUs in
prison are currently being evaluated.
Efforts to develop vaccines for HIV and hepatitis C have
so far been largely unsuccessful, although clinical trials
are evaluating some experimental HIV vaccines that
might give partial protection.
Hepatitis C
Hepatitis C infection shows higher and more similar
prevalence rates across the EU than hepatitis B, generally
between about 50 and just over 90 %, even in countries
with low rates of HIV infection like Greece (see Figure 11
and Table 10). For years, HCV prevalence seemed not to
follow the decline observed in HIV infections. More
recently, HCV prevalence may be declining in the UK
and Switzerland, suggesting that harm reduction
measures might have affected HCV transmission. On the
other hand, a local rise from 89 % to 95 % is reported by
the drugs emergency service in Frankfurt, Germany.
About 80 % of HCV infections in IDUs become chronic.
This implies continuous risk of infection for others, as with
HIV, and risk of severe liver damage in the long term. A
French study by Nalpas et al. (1998) estimated that around
500 000 injecting drug users are infected with hepatitis C
in the EU. Taking infections among ex-IDUs in the general
population into account, the number is probably much
higher. These infections may lead to significant disease
and healthcare costs, possibly comparable to those of HIV.
It is thus important to increase measures that reduce trans-
mission (for example needle exchanges) and disease
progression in those infected (such as treatment and infor-
mation regarding alcohol use).
Saliva tests for HCV are now becoming available thus
making it easier to test IDUs in epidemiological studies.
These tests may underestimate the percentage of IDUs
that ever become infected, but they do give a positive test
result in almost all cases of chronic infection. Using saliva
implies higher safety for the drug user as well as the inter-
viewer or service provider.
Risk behaviour
The high rates of hepatitis infection suggest that risky
injecting practices are still prevalent. Because of the
higher transmissibility of HCV, these levels of risk behav-
iour might be sufficient to transmit HCV, but not HIV. The
transmission of hepatitis B and C may continue in inject-
ing materials, such as cotton, spoons and water, in
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quantities which are insufficient to transmit HIV. HCV
and HBV may also be transmissible by ‘environmental
contamination’ — through fingertips and contaminated
surfaces. IDUs should thus be made aware of the dangers
of sharing materials other than needles and syringes, and
of the importance of washing hands and general hygiene.
Risk behaviour is also difficult to measure because it is
based on self-reports of socially undesirable behaviour.
Such reports can be affected by recall bias and intentional
under-reporting. Other factors, such as ‘mixing patterns’
— who shares with whom — may have become more
important than risk behaviour. For instance, an epidemic
among IDUs is less likely when most share injecting
materials with a steady sexual partner rather than with
strangers. The decline in levels of HCV in the UK may not
be attributable to low levels of sharing, but could possibly
be due to sharing shifting to within close relationships so
reducing transmission of the virus.
Harm reduction measures
In recent years, more countries are introducing syringe-
exchange programmes and pharmacies often actively
distribute clean needles and syringes to IDUs. Syringe-
exchange programmes were set up in Spain, France and
Italy mainly after 1992, but syringes were sold through
pharmacies before then (see Box 5). Although syringe-
exchange programmes in these countries were intro-
duced too late to prevent massive transmission of HIV, the
increase in such projects has been extensive and the
effects on HIV transmission should become visible in the
coming years.
Although harm reduction measures are now being imple-
mented in almost all EU Member States, the fact that
transmission of HIV and hepatitis B and C continues in
many countries (for example, among the young and new
IDUs and in prisons), suggests that harm reduction
measures such as syringe-exchange programmes should
be intensified. It is clear that in practice harm reduction
has become the standard in most EU countries (see Table
11). This is interesting in itself, given the different impres-
sions arising from some recent political controversies
over national drug policies.
Syringes are available in all countries, and condoms and
HIV counselling and testing also seem to be widely avail-
able. Substitution treatment exists in all countries as well,
Growth in syringe-exchange programmes in Spain, France and Italy
(number of new programmes each year)
The graph shows that syringe-exchange programmes
were mainly established after 1992 in Spain, France and
Italy. In France, however, syringes have been readily
available from pharmacies since 1987. The number of
programmes has increased in recent years.
Source: Programas Échange Seringues Europa Sud (Pesesud)
(1998).
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mostly in the form of oral methadone, and heroin trials
have now started in the Netherlands, following
Switzerland’s example (see Chapter 1).
However, the coverage and intensity of harm reduction
measures vary considerably. From the national reports, it
appears that syringe availability is not always nationwide
and may depend greatly on local or regional initiatives
which may be more frequent in high-risk areas. Finland
and Sweden have only limited syringe-exchange
programmes and the former recently restricted the sale of
syringes by pharmacies.
In France, substitution treatment, although increasing,
mostly involves buprenorphine, which is sometimes
injected. Methadone programmes are also developing. In
Germany, wide differences appear to exist between
regions and cities in their implementation of harm reduc-
tion measures.
Prisons
Awareness of the role of prisons in the HIV and hepatitis
epidemics has increased rapidly in recent years. Many
studies among IDUs show higher prevalence rates among
those who had been imprisoned. This may be the result of
selecting more problematic and risk-taking IDUs, as well
as of possible transmission of HIV and hepatitis B and C
in prisons. It may also be that infections occur immedi-
ately after release because of the temporary social disrup-
tion leading to a lack of self-protection (no steady dealer,
no own injecting material).
An EU study brought together data on infections among
IDUs in prison in Europe (the Swedish figures from this
study have been used in Tables 8 and 10). However,
prison populations are in general expected to have higher
prevalence rates and the figures are, therefore, an upper
limit of prevalence in IDUs in general.
The study showed that injecting is highly prevalent in
prisons and that an important proportion of imprisoned
IDUs first injected in prison. Even if this is a selected popula-
tion, the results may indicate that sharing injecting material
is still prevalent in subgroups of IDUs in many countries.
Treatment of HIV and hepatitis
Major improvements have recently been made in treating
both HIV and hepatitis infections, although treatment of
these viral infections is still far from perfect. In the case of
HIV, the virus is merely suppressed and AIDS is delayed.
In the case of hepatitis B and C, about 60 to 80 % of
patients are still infected after being treated for one year.
The side effects of HIV and HCV treatment are severe,
and in the case of HIV treatment lifelong. The side effects
of HIV include nausea, diarrhoea, diabetes, bleeding and
body fat changes and those of HCV include fatigue,
malaise, depression, fever, joint and muscle aches and
blood and autoimmune problems. These effects represent
a serious burden to the patient which, in turn, has conse-
quences for treatment compliance.
Discontinued treatment increases the risk of resistant virus
strains, thus posing high risks for the patient and others.
Treatment is expensive. HIV treatment is estimated to cost
around EUR 8 000 to EUR 12 000 per person per year.
Law-enforcement indicators
Police ‘arrests’ for drug offences
The only data systematically available on law-enforcement
interventions refer to offences against drug laws (such as
HIV, hepatitis C and injecting risk behaviour among intravenous drug users 
in prison (%)
Prison IDUs IDUs IDUs who shared materials IDUs who IDUs who
location infected infected during last injection inject in prison began
with HIV with HCV outside prison in injecting in
previous four weeks prison
Belgium (one site) 0.0 38.5 47 35  (10*) 15
Germany (one site) 1.4 14.4 n.a. 36 (18*) 9
Spain (one site) 23.4 n.a. 32 79 10
France (three sites) 13.3 53.2 34 37 (29*) 7
Italy (three sites) 16.1 64.2 32 25 6
Portugal (three sites) 28.1 61.9 49 57 5
Sweden (nine sites) 2.6 57.6 30 64 5
n.a. = not available   
(*) Figures in parentheses refer to the percentage of the total who have injected in the past four weeks.
Source: European network on HIV/AIDS and hepatitis prevention in prison, ‘Annual report to the European Commission’, May 1998.
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trafficking, possession, and use). These reflect Member
State legislation, administrative recording procedures and
police resources and priorities. Data are affected by differ-
ences in definition and statistical units (persons, offences,
and arrests). Given the difficulty in comparing them
directly, emphasis is placed on time trends.
The number of arrests for drug-related offences has been
steadily increasing since the mid-1980s in the EU as a
whole (see Figure 12). It rose up to twofold in Denmark,
Italy, Luxembourg and Sweden and over six times in
Belgium, Greece, Spain, Portugal and Finland. In these
latter countries, and in Italy and the Netherlands, this
rising trend has accelerated in recent years. However, in
Denmark, Ireland and Luxembourg, the number of drug-
related arrests has been stabilising.
In 10 Member States, cannabis is the main drug involved
in arrests, accounting for nearly half of all cases in
Germany, Italy and Finland and of over 70 % of cases in
Greece, France and the UK. In Luxembourg and Portugal,
heroin is the predominant drug involved, in the
'Arrests' for drug offences in the EU  (1991–97) 
Three-year moving averages indexed (1991 = 100)
Figure 12 
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                arrests used to calculate the rate refers to 1998 (1997 data not available). For the Netherlands, the number of arrests used to calculate the rate is a provisional figure.
                The Member States define 'arrests' for drug offences as follows (the definitions are presented as submitted by the country concerned): Belgium: illicit drug activity registered by the 
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                the modified 1973 drug law; Netherlands: offences against the Opium Act; Austria: reported violations of the Narcotic Drugs Act; Portugal: presumed offences against the drug law;
                Finland: suspected drug offenders; Sweden: suspected of offences against the Narcotic Drugs Act or the Goods Smuggling Act; UK: persons found guilty for drug law offences
Sources:  Reitox national focal points; Eurostat.
Figure 13 'Arrests' for drug offences in 1997 (rates per 1 000 inhabitants)
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Netherlands it is ‘hard drugs’, while in Sweden ampheta-
mines are most common.
Nearly all the EU countries provide data that distinguish
use-related from trafficking-related offences. Use-related
offences remain predominant, ranging from 61 % in
Portugal to over 85 % in Austria and Sweden. In all the
countries, except Belgium and Ireland where it is
decreasing, the proportion of use-related drug offences is
increasing or stable.
To take into account the population size to which they
refer, arrests have been reported for the total population
of each country (see Figure 13). In the nine countries that
count persons as the statistical unit, the rates of drug-
related arrests per 1 000 inhabitants range from 0.4 in
Italy and Luxembourg to 2.3 in Belgium. Where the
statistical unit is the offence (one person can be arrested
for more than one offence), the rates vary from 0.7 per 1
000 in the Netherlands to 2.5 per 1 000 in Germany.
However, these rates should not be compared. It is still
‘Arrests’ for drug offences in the EU
For definitions of ‘arrests’ for drug offences, see Figure 13.
= proportion increasing;     = proportion decreasing;       = proportion stable  n.a.  = data not available
(1) Among all drugs mentioned, whether alone or not; Sweden reports convictions not arrests.
(2) In the Netherlands, all illicit drugs except hashish and marijuana are considered ‘hard’ drugs.
Offence most frequently involved Proportion of ‘arrests’ ( %) % trend over previous three years
Use/possession for use Use/possession for use
Sweden (1997) 88
Austria (1) (1997) 85
France (2) (1998) 82
United Kingdom (2) (1997) 80
Finland (1998) 77
Greece (1998) 75 n.a.
Ireland (1997) 74
Belgium (1997) 71
Germany (1997) 64
Portugal (2) (1998) 61
Dealing/trafficking Dealing/trafficking 
Spain (1998) 100 not applicable
Netherlands (1998) 100 not applicable
Use and trafficking Use and trafficking
Luxembourg (1998) 67 n.a.
For definitions of ‘arrests’ for drug offences, see Figure 13.
= proportion increasing;     = proportion decreasing;      = proportion stable  n.a.  = data not available
(1) Also includes small-scale trafficking (the law differentiates between small and large quantities).
(2) Cases of use plus trafficking are excluded here.
(3) Possession for personal use is normally not prosecuted in the Netherlands; drug use and possession
for use are not criminalised in Spain.
Source: Reitox national focal points. 
Drug most frequently involved Proportion of ‘arrests’(%) % trend over previous three years
Cannabis Cannabis
France (1998) 85
United Kingdom (1997) 74
Greece (1998) 73 n.a.
Belgium (1997) 65 n.a.
Ireland (1997) 64
Spain (1998) 61
Austria (1) (1997) 60
Finland (1997) 47
Italy (1998) 46 n.a.
Germany (1997) 46
Heroin Heroin
Luxembourg (1998) 60
Portugal (1997) 48
Stimulants (mainly amphetamines) Stimulants (mainly amphetamines)
Sweden (1) (1997) 55
‘Hard’ drugs (2) ‘Hard’ drugs (2)
Netherlands (1996) 81
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difficult to assess which aspect of the variation in the
figures between Member States is attributable to differ-
ences in the people committing the offences, in law-
enforcement strategies or in law-enforcement information
systems, such as variations in definitions and recording
procedures.
Prison data
Information at national level on drug use in prison
remains very limited and reliable data are rare. The type
of information varies widely, from people imprisoned for
drug offences to drug users identified on entry to prison,
to levels of use revealed by surveys or tests in prison.
Drug offenders in EU prisons range from 15 to 50 % of
the total prison population. Data provided by some
countries show that in over 75 % of these cases the main
drug offence is related to dealing/trafficking. The propor-
tion of drug offenders among prisoners in Belgium and
Finland is increasing, is stable in the Netherlands and is
decreasing in Luxembourg. Figures are not available for
other countries.
Twelve Member States provide information on drug users
among prisoners. However, the data refer in most cases to
different definitions and cannot be directly compared.
Drug use is reported for 30 to 90 % of prisoners, while
problematic drug use appears to concern 10 to 45 % of
prisoners. These figures generally relate to the local level.
Since the local context varies widely, it cannot be taken
as representative of each country.
Drug market indicators
Seizures, price and purity of illicit drugs
The quantities of drugs seized by law-enforcement
agencies are indirect indicators of the supply and avail-
ability of drugs. Seizures reflect a range of factors other
than the quantities of drugs imported and distributed,
including law-enforcement resources, priorities, strategies
and the vulnerability of traffickers to enforcement efforts.
Although only a proportion of the supply is seized, there is
no factual basis for the common assumption that seizures
represent 10 % of the total supply. This figure varies over
time, between countries and between drugs, and one
exceptionally large seizure can seriously distort the figures
for a given year or country. In general, consistent changes
are a surer guide to trends than year-on-year fluctuations.
Variations in seizures among the Member States do not
always reflect differences in availability or consumption in
these countries. This applies particularly to those that, for
geographical or historical reasons, are first destinations for
imported cannabis, heroin and cocaine, or that produce
synthetic drugs. The number of seizures of different drugs,
which in many countries includes an important proportion
of small seizures from the retail and consumer levels of the
market, should be taken into account. This may be a better
indirect indicator of availability than total quantities,
which are skewed by small numbers of large seizures.
In any event, seizure data should be treated with caution
and interpreted together with other indicators, such 
as price and purity, availability at consumer level, 
information on the structure of drug markets and the
actors involved.
Price and purity are usually considered as indicators of
drug availability at user level. Drug prices vary between
and within Member States according to factors such as
purity of substances, level of drug availability, trafficking
routes, law-enforcement interventions, time and place
where the price and purity are measured and other drug
market indicators.
Some countries provide data on price and purity, but as it
is difficult to analyse these without any additional infor-
mation on contextual factors, it is impossible to compare
them directly.
For this annual report, all Member States provided details
of the quantities seized up to 1997 (1998 data were not
available for Ireland and the UK) and all except Greece and
the Netherlands gave the number of seizures made (see
European survey of drug users 
in prison
A survey was carried out at local level in seven European
countries in 1997 using a common methodology. It
showed proportions of ‘active intravenous drug users’ —
defined as intravenous drug users who have taken drugs
within the 12 months prior to imprisonment — among
prisoners in 21 prisons ranging from 9 % in France to 59 %
in Sweden, and 16 to 46 % in Belgium, Germany, Spain,
Italy and Portugal. However, the prisons examined are not
representative of the whole prison system, which makes it
impossible to extrapolate results to the whole country.
Source: European network on HIV/AIDS and hepatitis prevention
in prison, ‘Annual report to the European Commission’,
May 1998.
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Figures 14 and 15 and Tables 14 and 15). Data on price
and purity were available for some countries, although
they were of uncertain quality and comparability.
Cannabis
The total quantity of cannabis seized increased rapidly in
the early 1990s from 236 tonnes in 1989 to a peak of 758
tonnes in 1995. This indicator has been relatively stable
for three years at about five times the level recorded in the
mid-1980s. The largest quantities of cannabis were seized
in Spain in 1998.
In all Member States that provided data, except Portugal,
cannabis accounted for the greatest number of seizures.
Like data on quantities, the number of seizures showed
an increase from the mid-1980s, but at a steadier rate.
Between 1985 and 1997, the number of cannabis
seizures was multiplied by a factor of eight. In all
countries where 1998 data were available except Austria,
a rising trend was observed.
Generally, cannabis prices appear to be stable, although
Germany and Sweden report a decreasing trend. The
cannabis market is entrenched in most of the EU and,
depending on the country, availability is high and stable
or is increasing.
Heroin
The quantities of heroin seized increased threefold in the
late 1980s and early 1990s, from under 2 tonnes in 1985
to over 6 tonnes in 1991. Since then, the quantities have
fluctuated at a slightly lower level within a range of 5 to 6
tonnes. Fluctuating patterns can be observed in most
Member States. Until 1994, the largest amounts of heroin
were seized in Germany and Italy. Since 1995, the UK
has been in first place, with nearly half of the total
amount seized in the EU in 1997. In 1998, Germany,
Spain, France and Italy, the main seizing countries after
the UK (the UK did not provide data for 1998), show a
decrease in the quantities of heroin seized.
The number of seizures illustrates a clearer pattern.
Overall, the numbers rose steadily from 1985 to 1992
and have since stabilised. There are clear decreases over
the past three years in Denmark, France, Italy,
Luxembourg and Austria and marked increases in Ireland,
Finland, Sweden and the UK. In most Member States,
heroin is the second most commonly seized drug after
cannabis, while in Portugal it is the most common.
The average quantity of heroin per seizure at EU level has
remained stable since the mid-1980s at about 60 to 80 g.
France and the UK are currently seizing a higher quantity
of heroin on average. These results should, however, be
taken with some degree of caution since this measure is
global and only a rough indicator of the average quantity
of a substance seized.
Following a decrease in previous years, the street price of
heroin seems to be stable in most EU countries, although
the trend in Belgium and Germany is falling while Italy
reported an increase in 1997. Heroin purity is reported to
range from 10 to 25 % in Germany, Greece and
Luxembourg and from 30 to 50 % in Spain, Finland and
the UK.
Overall, there are no major indications of change in the
heroin market. While heroin is less widely available than
Notes: Data are not available for Greece and the Netherlands.
            The number of seizures for 1996 and 1997 is underestimated as data for Belgium are missing.
            For more details, see Table 14.
Number of cannabis, heroin and cocaine 
seizures in the EU (1985–97)        
Figure 14 
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cannabis, there appear to be few difficulties in obtaining
supplies for users in most Member States, especially in
large cities. There are reports of increased availability in
smaller cities and towns, too.
Cocaine
The quantities of cocaine seized increased from 1 tonne
in 1985 to over 16 tonnes in 1990. Following four years
of stability, the amounts seized rose sharply to 29 tonnes
in 1994, and 38 tonnes in 1997. Spain remained the
country where the largest quantities of cocaine were
seized in 1998. Although data are missing for some
Member States, the amount of cocaine seized in 1998 in
the EU appears to have decreased, especially in Spain
which reported a fall of over one third.
The number of seizures shows a steadier increase from
1985–97, without any of the sharp peaks and troughs
seen in the data on quantities. This increase is reflected in
almost every Member State, but has been especially
marked in recent years in Spain, Ireland and Austria.
The quantities of cocaine seized have increasingly
exceeded those for heroin since 1987. In recent years,
they have been six to seven times higher. In contrast, the
number of seizures is half that for heroin.
The average quantity of drugs seized at EU level is much
lower for heroin than for cocaine, which has been
increasing slightly since 1985 from about 250 g per
seizure to over 1 kg in 1997. This contrast between heroin
and cocaine seizures may reflect a tendency for cocaine
to be trafficked in larger quantities than heroin, as well as
a lower vulnerability of cocaine retail suppliers and
consumers to law-enforcement interventions compared
with heroin.
After decreases in previous years, the street price of
cocaine is relatively stable in most reporting countries,
although a downward trend is reported in Belgium and
Germany. Limited data suggest that retail purity ranges
between 50 and 70 %, except in Greece which reports 
5 to 10 % purity at user level.
The overall picture is of an expanding market with
increased availability in recent years, especially in metro-
politan areas. Although the situation is unclear, there are
anecdotal reports of increased availability of crack in EU
countries, apart from those established locally in areas of
France, the Netherlands and the UK.
Synthetic drugs: amphetamines, ecstasy and LSD
The quantities of amphetamines seized in the EU
increased slowly in the late 1980s from a relatively low
level in 1985 to over 1 tonne in 1992. Since then, the
upward trend has accelerated and the total amount rose
to over 4 tonnes in 1997. More than 75 % of this is
accounted for by seizures in the UK, although there have
been significant seizures in Germany, France, the
Netherlands and Sweden.
The number of amphetamine seizures in the EU has
increased steadily sevenfold since 1985, but has acceler-
ated in recent years in Germany, France, Ireland, Austria
and Finland. In Sweden and the UK, amphetamines are
the second most common drug seized.
Notes: Data are not available for Greece and the Netherlands. 
            The number of seizures for 1996 and 1997 is underestimated as data for Belgium are missing.      
            The number of ecstasy seizures for 1985–94 is overestimated as LSD seizures are also 
            included for Spain. For more details, see Table 14.      
Number of amphetamine, ecstasy and LSD 
seizures in the EU (1985 –97)        
Figure 16 
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The quantities of ecstasy seized have increased sharply
from 1 000 pills in 1987 to 2.5 million in 1993. Following
stabilisation, they rose to a peak of 9 million in 1996
before decreasing to 4.5 million in 1997. Larger amounts
were seized in Germany, the Netherlands and the UK.
Following a steady upward trend, the number of ecstasy
seizures declined or stabilised in most countries in 1997
and 1998. Only in Denmark has the number of seizures
continued to increase over the last three years.
The quantities of LSD rose from low levels in the 1980s to
over one million units in 1993. They have fallen substan-
tially since and remain relatively stable at around less
than half a million.
As for amphetamines and ecstasy, LSD seizures increased
in the late 1980s and early 1990s, but since 1993–94
have levelled or fallen in all the Member States except
Austria which saw a continuous rise up to 1997.
Apart from trends over time, there are differences
between Member States. In most countries, ampheta-
mines predominate, but in Belgium, France, Italy and
Luxembourg ecstasy is more frequently seized. Seizures
of LSD are less common.
As with other drugs, the data available make comparisons
of price and purity difficult. The recent general trend has
been a decrease in the price of both amphetamines and
ecstasy, although some countries report price stability.
Reported purity ranges for amphetamines are between 
10 and 100 %.
The purity and composition of pills sold as ecstasy vary
considerably and are unknown. In contrast with the 1997
trend, in 1998 the Netherlands (thanks to its surveillance
system on drugs) reported an increase in the presence of
MDMA and a decrease in that of amphetamines in pill
contents. Other synthetic drugs have been reported from
Member States in recent years, including analogues of
MDMA sold as ecstasy (such as MDA, MDEA, MBDB) as
well as ketamine, DOB, 2-CB and, more rarely, 4-MTA.
This may reflect market testing by illicit manufacturers,
but so far there has been no indication that any of these
alternatives is achieving a significant market share.
Data on 1998 seizures appear to confirm that, despite
rising concern about ecstasy in recent years, ampheta-
mines are actually increasingly dominating the market in
synthetic drugs.
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Last 12 months prevalence of drug use in recent nationwide surveys 
among the general population in some EU countries
Table 2
Data collection = data-collection method; interview = face-to-face interview; phone = telephone interview; mail = mailed questionnaire; $ = combined sample: mail (n = 2 143) and phone (n = 425); n.a. = data not available
(1) See list of sources. (2) See list of sources. (a) Hard drugs. (b) Cocaine or crack. (c) Ecstasy and other designer drugs. (d) Amphetamines and ecstasy. (e) All illegal drugs.
Notes: 1. In countries with information on more than two national surveys, only the last two are presented 
2. In some countries (e.g. UK), the age range for young adults is more restricted than in other countries, which tends to produce higher prevalence figures. 
3. In Spain, methodological differences in the 1995 and 1997 surveys (questionnaire and sampling method) limit their comparability. 
4. UK figures for ecstasy have been rounded.
Country Method All adults Younger adults
Year Data Sample Age Cannabis Cocaine Amphetamines Ecstasy Age Cannabis Cocaine Amphetamines Ecstasy
collection range (%) (%) (%) (%) range (%) (%) (%) (%)
Belgium (Flemish C.) 1994 Phone 2 259 (18–65) 1.5 0.2 0.3 0.1 (18–35) 3.6 n.a. n.a. n.a.
Denmark (1) 1994 Interview 2 521 n.a. n.a. n.a. n.a. n.a. (16–44) 7.0 n.a. 0.5 (a) n.a.
Denmark (2) 1994 Mail 1 390 (18–69) 3.3 n.a. n.a. n.a. (16–44) 6.0 n.a. n.a. n.a.
Germany (former East) (1) 1995 Mail 1 541 (18–59) 1.9 0.2 0.2 0.6 (18–39) 3.5 0.3 0.4 1.2
Germany (former West) (1) 1995 Mail 6 292 (18–59) 5.0 0.9 0.8 0.9 (18–39) 8.8 1.6 1.5 1.6
Germany (former East) (2) 1997 Mail 1 682 (18–59) 2.3 0.1 0.3 0.4 (18–39) 4.5 0.2 0.6 0.7
Germany (former West) (2) 1997 Mail 6 338 (18–59) 4.5 0.7 0.5 0.9 (18–39) 7.8 1.2 0.9 1.7
Greece 1998 Interview 3 752 (15–64) 4.4 0.5 0.1 0.1 (15–34) 8.8 1.0 0.1 0.3
Spain (1) 1995 Interview 9 984 (15–64) 7.3 1.9 (b) 1.1 1.3 (c) (15–34) 12.8 3.4 (b) 1.9 2.5 (c)
Spain (2) 1997 Interview 12 445 (15–64) 7.6 1.6 (b) 0.9 0.9 (c) (15–34) 14.2 2.7 (b) 1.7 1.7 (c)
France 1995 Phone 1 993 (18–69) 4.7 0.2 0.3 (d) n.a. (18–39) 8.9 0.3 0.6 (d) n.a.
Netherlands 1997–98 Interview 22 000 (15–69) 5.2 0.7 0.4 0.8 (15–34) 9.8 1.4 0.8 1.8
Finland (1) 1996 Mail 3 009 (16–74) 1.9 n.a. n.a. n.a. (16–34) 5.2 n.a. n.a. n.a.
Finland (2) 1998 Mail $ 2 568 (15–69) 2.5 0.2 (b) 0.2 0.2 (15–34) 6.3 0.4 (b) 0.4 0.4
Sweden (1) 1996 Interview 1 500 (15–69) 1(e) n.a. n.a. n.a. (15–34) 1.0 (e) n.a. n.a. n.a.
Sweden (2) 1998 Interview 1 500 (15–69) 1.0 n.a. n.a. n.a. (15–34) 2.0 n.a. n.a. n.a.
UK (England and Wales) (1) 1994 Interview 10 000 (16–59) 8.0 <0.5 2.0 1.0 (16–29) 20.0 1.0 7.0 3
UK (England and Wales) (2) 1996 Interview 10 940 (16–59) 9.0 <0.5 3.0 1.0 (16–29) 21.0 1.0 8.0 4
Lifetime prevalence of drug use in recent nationwide surveys 
among the general population in some EU countries
Table 1
Tables
Data collection  = data-collection method; interview = face-to-face interview; phone = telephone interview; mail = mailed questionnaire; $ = combined sample: mail (n = 2 143) and phone (n = 425); n.a. = data not available
(1) See list of sources.  (2 )See list of sources.  (a) Hard drugs.  (b) Cocaine or crack.  (c) Ecstasy and other designer drugs.  (d) Amphetamines and ecstasy.
Notes: 1. In countries with information on more than two national surveys, only the last two are presented.
2. In some countries (e.g. UK), the age range for young adults is more restricted than in other countries, which tends to produce higher prevalence figures.
3. In Spain, methodological differences in the 1995 and 1997 surveys (questionnaire and sampling method) limit their comparability.
4. UK figures for Ecstasy have been rounded.
Method All adults Younger adults
Year Data Sample Age Cannabis Cocaine Amphetamines Ecstasy Age Cannabis Cocaine Amphetamines Ecstasy
collection range (%) (%) (%) (%) range (%) (%) (%) (%)
Belgium (Flemish C.) 1994 Phone 2 259 (18–65) 5.8 0.5 0.9 0.5 (18–35) 9.2 1.2 2.0 1.3
Denmark (1) 1994 Interview 2 521 n.a. n.a. n.a. n.a. n.a. (16–44) 37.0 n.a. 5.0(a) n.a.
Denmark (2) 1994 Mail 1 390 (18–69) 31.3 2.0 4.0 n.a. (16–44) 43.0 n.a. n.a. n.a.
Germany (former East) (1) 1995 Mail 1 541 (18–59) 3.6 0.2 0.7 0.7 (18–39) 6.4 0.3 1.3 1.4
Germany (former West) (1) 1995 Mail 6 292 (18–59) 13.9 2.2 2.8 1.6 (18–39) 21.0 3.7 4.1 2.8
Germany (former East) (2) 1997 Mail 1 682 (18–59) 4.2 0.2 0.5 0.7 (18–39) 7.8 0.4 1.0 1.3
Germany (former West) (2) 1997 Mail 6 338 (18–59) 13.4 1.5 1.8 1.7 (18–39) 20.1 2.2 2.4 3.2
Greece 1998 Interview 3 752 (15–64) 13.1 1.3 0.6 0.3 (15–34) 19.7 2.2 0.7 0.6
Spain (1) 1995 Interview 9 984 (15–64) 14.2 3.7 (b) 2.5 2.0 (c) (15–34) 22.9 5.9 (b) 4.0 3.5 (c)
Spain (2) 1997 Interview 12 445 (15–64) 22.2 3.3 (b) 2.5 2.5 (c) (15–34) 31.8 5.2 (b) 4.1 4.7 (c)
France 1995 Phone 1 993 (18–69) 16.0 1.2 0.7 (d) n.a. (18–39) 25.7 1.8 1.4 (d) n.a.
Netherlands 1997–98 Interview 22 000 (15–69) 18.1 2.4 2.1 2.2 (15–34) 27.3 3.7 3.0 4.4
Finland (1) 1996 Mail 3 009 (16–74) 7.3 n.a. 0.7 (a) n.a. (16–34) 15.0 n.a. n.a. n.a.
Finland (2) 1998 Mail $ 2 568 (15–69) 9.7 0.6 (b) 1.0 0.5 (15–34) 17.5 1.2 (b) 2.0 1.3
Sweden (1) 1996 Interview 1 500 (15–69) 9.0 1.0 2.0 0.0 (15–34) 12.0 1.0 3.0 1.0
Sweden (2) 1998 Interview 1 500 (15–69) 13.0 1.0 2.0 0.0 (15–34) 16.0 1.0 3.0 1.0
UK (England and Wales) (1) 1994 Interview 9 646 (16–59) 21.0 2.0 8.0 2.0 (16–29) 34.0 3.0 14.0 6
UK (England and Wales) (2) 1996 Interview 10 940 (16–59) 22.0 3.0 9.0 3.0 (16–29) 36.0 4.0 16.0 9
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Lifetime prevalence of use of different illegal drugs among 15- to 16-year-old students 
in recent nationwide school surveys in some EU countries
Table 3
n.a. = data not available 
(1) See list of sources. (2 ) See list of sources.
(a) Ecstasy and other synthetic or designer drugs. (b) Amphetamines, ecstasy and stimulants. (c) LSD and ecstasy. (d) Hard drugs. 
Notes: LSD  = ‘LSD and other hallucinogens’ in Spain, Ireland, Italy and the UK. 1. In countries with information on more than two national surveys, only the last two are presented. 2. In all the surveys, the method
for data collection was written questionnaires. 3. Crack use has been reported independently of cocaine in Ireland (3 %), Italy (2 %) and the UK (survey 1 to 3 %). 4. The 1997 French survey gives informa-
tion on last year’s prevalence of drug use, not lifetime prevalence. 5. In Germany, a youth survey (12- to 25-year-olds) has been conducted every three to four years since 1970 instead of the school survey.
In the 1997 survey, the total sample was 3 010. Lifetime prevalence for any illegal drug among 14- to 17-year-olds was 11 % (former West Germany) and 10 % (former East Germany). 6. In the Greek
surveys, amphetamines are not included in the category ‘all illegal drugs’. 7. In Luxembourg, the age group selected is 15 to 17. The sample size of this survey is very small and results should be interpreted
with caution. 8. Results of the UK surveys of 1995 and 1997 are not comparable due to differences in methodology (sample and questionnaire).
National prevalence estimates of problem drug use in the EU and Norway 
(absolute numbers of problem drug users aged 15 to 54)
Table 4
n.a.  = data not available 
(1) See list of sources.  
(a) Estimate using HIV/AIDS register instead of back calculation; definition includes only IDUs and thus underestimates all problem drug use. (b) Problematic opiate use. Police data include 7 % non-opiate
users; 10 % were identified because of possession (not necessarily users) and 5 % were identified by other means. Three-sample capture–recapture: police data cover 1 September 1995 to 30 August 1996,
other sources the 1996 calendar year. (c) Heroin addicts or hard drug users.  (d) In Austria an estimate of 10 000 to 15 000 opiate addicts exists (rate 2.2 to 3.3 per 1 000 population aged 15 to 54) based on
‘consistency checks’ between data sources. This estimate was not derived within the EMCDDA project. (e) Problematic opiate and amphetamine users (1997). The lower estimate refers mainly to drug users
with medical problems while the higher also includes drug users with potential legal problems such as driving under the influence. (f) 1992: 1 700 to 3 350 heroin addicts; 8 900 to 12 450 other addicts, mostly
amphetamine injectors (excluding cannabis addicts). The official Swedish estimate which was presented last year includes cannabis addicts and is thus higher.
Extrapolation Extrapolation Mortality Capture– Multivariate Back calculation 
from police date from treatment multiplier recapture indicator (BC) – HIV/AIDS 
data multiplier
Belgium n.a. n.a. n.a. n.a. n.a. 20 200 (a)
Denmark n.a. n.a. 12 500 n.a. n.a. 10 200
Germany 140 843–165 424 94 350–140 600 80 000–112 000 n.a. n.a. n.a.
Greece n.a. n.a. n.a. n.a. n.a. n.a.
Spain n.a. n.a. n.a. n.a. n.a. n.a.
France 164 000 156 000–176 000 n.a. n.a. n.a. 124 000–155 000
Ireland n.a. n.a. 4 600–7 726 6 304–13 735 (b) n.a. 8 600
Italy 172 000 240 000–299 000 n.a. 293 814 248 672 326 000
Luxembourg 1 800 1 900 n.a. n.a. n.a. n.a.
Netherlands n.a. 25 145–29 014 n.a. n.a. 26 984 (c) n.a.
Austria (1) (d) n.a. n.a. n.a. n.a. n.a. n.a.
Portugal n.a. n.a. n.a. n.a. n.a. n.a.
Finland n.a. 1 600–2 400 (e) 4 000–8 500 (e) 8 700–14 500 (e) n.a. n.a.
Sweden n.a. n.a. n.a. 10 600–15 800 (f) n.a. n.a.
UK n.a. 262 633–341 423 88 900–177 800 n.a. 273 923–288 675 n.a.
Norway n.a. n.a. 7 200–10 300 n.a. n.a. n.a.
Year Sample All illegal Cannabis Solvents Amphetamines Ecstasy LSD Cocaine Heroin
drugs (%) (%) (%) (%) (%) (%) (%) (%)
Belgium (Flemish C.) (1) 1996 2 391 n.a. 19.6 2.9 3.2 5.6 2.0 0.6 0.6
Belgium (Flemish C.) (2) 1998 9 211 n.a. 23.7 4.4 3.8 6.2 2.1 1.3 0.7
Denmark 1995 2 571 n.a. 18.0 6.0 1.9 0.5 0.4 0.5 2.0
Greece (1) 1993 10 543 4.5 3.0 6.3 4.0 n.a. 1.1 0.9 0.6
Greece (2) 1998 8 557 11.4 10.2 13.7 3.6 1.8 2.6 1.6 0.8
Spain (1) 1994 21 094 22.1 19.4 3.2 3.5 2.9 (a) 4.5 1.7 0.5
Spain (2) 1996 19 191 29.6 24.3 3.5 4.1 4.6 (a) 5.6 2.5 0.8
France (1) 1993 12 391 15.3 11.9 5.5 2.5 (b) n.a. 1.5 1.1 0.8
France (2) 1997 9 919 27.5 23.0 5.5 1.9 2.5 (c) n.a. 1.5 1.4
Ireland 1995 1 849 37.0 37.0 n.a. 3.0 9.0 13.0 2.0 2.0
Italy 1995 1 641 21.0 19.0 8.0 3.0 4.0 5.0 3.0 2.0
Luxembourg 1998 660 n.a. 18.5 2.1 1.0 1.5 0.0 1.0 0.5
Netherlands 1996 10 455 31.7 31.1 n.a. 7.8 8.1 n.a. 4.3 1.3
Austria 1994 2 250 9.9 9.5 n.a. n.a. n.a. n.a. —   2.0 (d) —
Portugal 1995 4 767 4.7 3.8 n.a. n.a. n.a. 0.2 1.0 0.9
Finland 1995 2 300 5.5 5.2 4.4 0.5 0.2 0.3 0.2 0.1
Sweden (1) 1997 5 683 7.6 6.8 8.7 0.9 0.8 0.5 0.5 0.5
Sweden (2) 1998 5 455 7.7 7.2 8.2 1.1 1.0 1.0 0.6 0.6
UK (1) 1995 7 722 42.0 41.0 20.0 13.0 8.0 14.0 3.0 2.0 
UK (2) 1997 28 756 39.8 37.5 4.0 7.3 3.0 3.2 1.5 0.7
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National prevalence estimates of problem drug use in the EU and Norway 
(prevalence rates of problem drug use per 1 000 inhabitants aged 15 to 54)
Table 5
n.a.  = data not available
(1) See list of sources.
(a) Estimate using HIV/AIDS register instead of back calculation; definition includes only IDUs and thus underestimates all problem drug use.  (b) Problematic opiate use. Police data include 7 % non-opiate users;
10 % were identified because of possession (not necessarily users) and 5 % were identified by other means. Three-sample capture—recapture: police data cover 1 September 1995 to 30 August 1996, other
sources the 1996 calendar year. (c) Heroin addicts or hard drug users.  (d) In Austria an estimate of 10 000 to 15 000 opiate addicts exists (rate 2.2 to 3.3 per 1 000 population aged 15 to 54) based on ‘consistency
checks’ between data sources. This estimate was not derived within the EMCDDA project. (e) Problematic opiate and amphetamine users (1997). See Table 4. (f) 1992: 1 700 to 3 350 heroin addicts; 8 900 to 
12 450 other addicts, mostly amphetamine injectors (excluding cannabis addicts). The official Swedish estimate which was presented last year includes cannabis addicts and is thus higher.
Total population Extrapolation Extrapolation Mortality Capture – Multivariate Back calculation
size from police data from treatment multiplier recapture indicator (BC) – HIV/AIDS
(age 15 to 54) (%) data (%) (%) (%) (%) multiplier (%)
Belgium 5 602 499 n.a. n.a. n.a. n.a. n.a. 3.6 (a)
Denmark 3 014 995 n.a. n.a. 4.1 n.a. n.a. 3.4
Germany 45 207 736 3.1–3.7 2.1–3.1 1.8–2.5 n.a. n.a. n.a.
Greece n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Spain n.a. n.a. n.a. n.a. n.a. n.a. n.a.
France 32 431 857 5.1 4.8–5.4 n.a. n.a. n.a. 3.8–4.8
Ireland 2 061 028 n.a. n.a. 2.2–3.7 3.1–6.7 (b) n.a. 4.2
Italy 32 315 499 5.3 7.4–9.3 n.a. 9.1 7.7 10.1
Luxembourg 220 572 8.2 8.6 n.a. n.a. n.a. n.a.
Netherlands 9 117 319 n.a. 2.8–3.2 n.a. n.a. 3.0 (c) n.a.
Austria (1) (d) n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Portugal n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Finland 2 895 000 n.a. 0.6–0.8 (e) 1.4–2.9 (e) 3.0–5.0 (e) n.a. n.a.
Sweden 4 765 656 n.a. n.a. n.a. 2.2–3.3 (f) n.a. n.a.
UK 32 481 100 n.a. 8.1–10.5 2.7–5.5 n.a. 8.4–8.9 n.a.
Norway 2 462 300 n.a. n.a. 2.8–4.2 n.a. n.a. n.a.
Some characteristics of persons treated for drug problems in the EUTable 6
Year Mean Age Gender IV route of % distribution of main drug (% IV route of administration)
age distribution distribution administration 
male/female of main drug
< 25 > 35 (%) Opiates (a) Cocaine Amphetamines (b) Ecstasy Hallucinogens Cannabis Others (c)
Belgium (Brussels) 1997 30 21 17 78/22 n.a. 77.1(n.a.) 7.2(n.a.) (d) n.a. n.a. 0.1 6.6 8.6
Belgium (Flemish C.) 1996 26.6 52 18.5 75/25 n.a. 39.5(n.a.) 7.1(n.a.) 18.7(n.a.) 1.2 4.9 22 5.5
Belgium (French C.) 1997 27.4 37.4 14.1 74/26 24 67.7(34) 3.8(35) 0.7(0) 2.5 0.1 13.2 11.9
Denmark 1997 32.5 20 40 73/27 27 84.6 (53) 0.7(n.a.) 2(n.a.) n.a. n.a. 10.5 0.6
Germany (e) 1998 28.1 41 22 77/23 37.1 64.6(49) 7.1(38) 3.2(13) n.a. 1.2 18 5.9
Greece 1998 31.6 21 35.1 84/16 77.5 91.9(84) 0.7(0) 0(n.a.) 0 0 5.7 1.7
Spain 1997 29.6 24.8 18.9 84/16 27.3 84.9(31) 8.9(6) 0.6(2) 0.5 0.2 4.2 0.7
France (f) 1997 29.8 21 21.5 76/24 63 78.6(73) 3.1(47) 0.5(56) 0.7 0.4 11 5.7
Ireland 1997 24.3 60.5 8.2 69/31 49.2 79.8 (65) 0.9(10) 1(0) 5 0.5 10.6 2.1
Italy 1998 30.5 19.5 25 86/14 n.a. 86.4 (74) 3.2 (23.6) 0.2 (6.8) 0.7 0.2 67.6 1.7
Luxembourg 1997 28.5 27 15 81/19 79 81(88) 15(80) 1(n.a.) 1 n.a. 4 n.a.
Netherlands (g) 1998 30.8 23.2 30.4 81/19 9.8 65.1(13.6) 17.5(2.6) 3(8.7) 1.1 0.2 10.9 2.0
Austria n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Portugal (h) 1997 28.2 29.1 16 80/20 41.9 96.9 (n.a.) 1.2(n.a.) n.a. n.a. n.a. 1.9 1.5
Finland 1997 n.a. 37.2 22.7 72/28 n.a. 27.2(n.a.) 0.6(n.a.) 47.9(n.a.) n.a. 6.4 17.9 n.a.
Sweden 1996 33 17 42 72/28 n.a. 39(n.a.) < 1(n.a.) 20(n.a.) n.a. <1 7 33
UK (Great Britain) (i) 1997 n.a. 42 15 74/26 40 71(58) 4(5) 9(44) n.a. 0 8 7
IV  = intravenous; n.a.  = data not available
(a) In some countries (Germany, Italy and Luxembourg), information about IV route of admission of opiates refers to heroin. (b) In some countries, ‘amphetamines’ include ecstasy. (c) ‘Others’ include: Belgium
(Brussels – hypnotics, sedatives, others); Belgium (Flemish Community – hypnotics, sedatives); Belgium (French Community – hypnotics, sedatives, solvents, others); France (solvents, hypnotics, sedatives);
Sweden (multiple abuse); UK (hypnotics, sedatives, solvents, others). (d) Cocaine  = stimulants including cocaine and amphetamines. (e) IV  = currently injecting the drug. (f)Data refer to specialised centres only.
IV refers to currently or previously injecting. Data are collected on a census basis, and injection status is assessed at time of data collection. Presentation of results in this table may overestimate the proportion
of injectors, but using only ‘currently injecting’ would underestimate the injection behaviour to a much larger extent. (g) Data refer to specialised out-patient centres. (h) IV  = currently injecting any drug. 
(i) UK data correspond to the period 1 April 1997 to 30 September 1997. Data are for persons presenting for treatment, not persons treated.
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d.a. = data available, but not comparable with the other years;  n.a. = data not available
(a) Cases from the former West Germany. Former East Germany: 1996 (13 cases); 1997 (15 cases).
(b) Only cases related to opiates or cocaine, although from 1996 other psychoactive substances have been included. Cases for 1997 from Seville are estimated (36).
(c) Only overdoses are presented for greater comparability with other countries.
(d) Only overdoses are reported. In 1997, there may have been an under-notification of cases.
Notes: 1. Data from different countries are not directly comparable, as there are differences in the ways cases are defined (see Table 8 of the EMCDDA’s 1997 annual report).
2. In some countries, the case definitions used for this table have been modified from those described in Table 8 of the EMCDDA’s 1997 annual report. Finland: set of International Classification of
Diseases, ninth edition (ICD-9) codes (1988–95) and ICD-10 codes (1996) related to harmful use, dependence syndrome, substance-induced brain syndrome, poisoning and other drug-related syndromes.
Netherlands: cases whose underlying cause of death were ICD-9 codes 292, 304, 305.2–9, E850.0, E854.1 or E854.2 (1985–95) and cases whose underlying cause of death were ICD-10 codes F11–F19
(excluding F17) or X42 (from 1996). United Kingdom: cases whose underlying cause of death were ICD-9 codes 1304, 305.2–9, 965.0, 967, 968.5, 969 and 977.8–9.
3. The population at risk is different from the total population only when cases of death are recorded from a defined subgroup of the population (Ireland and Luxembourg — population aged 15 to 49; 
Spain — population of six major cities).
Number of acute drug-related deaths recorded in the EU (1985–97)Table 7
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 Population at
risk (million)
Belgium 12 20 17 37 49 96 90 75 80 46 48 n.a. n.a. 10.1
Denmark 150 109 140 135 123 115 188 208 210 271 274 266 275 5.2
Germany (a) 324 348 442 670 991 1 491 2 125 2 099 1 738 1 624 1 565 1 699 1 486 81.8
Greece 10 28 56 62 72 66 79 79 78 146 176 222 232 10.4
Spain (b) 143 163 234 337 455 455 579 556 442 388 394 415 347 14.5
France 172 185 228 236 318 350 411 499 454 564 465 393 228 58.2
Ireland 19 6 4 7 5 7 7 14 16 19 39 50 52 3.6
Italy 242 292 543 809 974 1 161 1 383 1 217 888 867 1 195 1 566 1 160 57.1
Luxembourg 1 3 5 4 8 9 17 17 14 29 20 16 9 0.23 
Netherlands 40 42 23 33 30 43 49 43 38 50 33 61 67 15.6
Austria (c) d.a. d.a. d.a. d.a. 20 36 70 121 130 140 160 179 132 7.9
Portugal (d) n.a. 18 22 33 52 82 121 156 115 143 145 169 135 9.8
Finland n.a. n.a. n.a. 11 23 41 34 27 26 35 51 45 n.a. 5.1
Sweden 150 138 141 125 113 143 147 175 181 205 194 250 n.a. 8.8
UK (England and Wales) 1 254 1 362 1 332 1 348 1 321 1 339 1 411 1 533 1 615 1 796 1 956 2 150 2 144 58
n.a.  = not available
(1) See list of sources.
(2) See list of sources.
(a) Information based on local data is given between parentheses.
(b) Trend in prevalence is not always based on same data source as prevalence, see list of sources. 
(c) Data based on self-reports may be unreliable.
(d) Data are based on all opiate users entering treatment and thus represent a lower limit of prevalence for IDUs.
Prevalence of HIV infection among injecting drug users in the EUTable 8
Year Data Number tested Percentage infected (a) Prevalence trend (a) (b)
Belgium (Flemish C.) (1) 1996–97 Treatment/street studies 225 2.2 Stable
Belgium (French C.) (2) 1997 First treatments, self-reports (c) 270 2.6 Stable
Denmark 1995 Estimate from HIV notification n.a. 4 Stable
Germany 1997 Drug users in treatment, self-reports (c)(d) 1 605 0.6–3.8 Stable
Greece 1997–98 Treatment reporting system, self-reports, screening (c) 1 119 0.5–3.2 Stable
Spain 1996 Survey of treatment centres, self-reports confirmed 2 025 32 n.a.
by medical records
France 1997 Survey of specialised treatment centres, notifications/ 8 511 15.5–18.3 Stable
self-reports of lifetime IDUs (c); data from GPs
Ireland 1995–97 Dublin: study in treatment 333 (0.9) (Decrease)
Italy 1997 Treatment in public services, screening (d) 76 096 15.7/1–28 Decrease
Luxembourg 1998 Treatment reporting systems, self-reports (c) 274 3 Stable
Netherlands 1995–97 Repeated treatment/street studies 1 333 2–26 Stable
Austria 1997–98 Opiate overdose deaths; Vienna: low-threshold treatment 232 1.5–(2) Stable
Portugal 1996 Survey of treatment centres, self-reports (c) 379 14 Stable
Finland 1998 Helsinki: syringe exchange, saliva tests 135 (3) (Increase)
Sweden 1997 Study of nine prisons 196 2.6 Stable
UK (England and Wales) 1997 Unlinked Anonymous 2 678 1 Stable
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n.a.  = data not available
(1) See list of sources.
(2) See list of sources.
(a) Hepatitis B data partly reflects vaccination levels. The proportion not positive is
still at risk for infection and indicates the vaccination potential.
(b) Information based on local data is given between parentheses.
(c) Self-reports of hepatitis infection may be unreliable.
Prevalence of antibodies against hepatitis B and C among injecting drug users in the EUTable 10
Hepatitis B Hepatitis C
Year Data (a) % infected (b) Year Data % infected (b)
Belgium (Flemish C.) n.a. n.a. n.a. n.a. n.a. n.a.
Belgium (French C.) 1997 Treatment demands, self-reports (c) 22 1997 Treatment demands, self-reports (c) 47
Denmark 1995 Estimate 21 1995 Estimate 50
Germany 1996–97 Dortmund: treatment; (48–80) 1996–97 Dortmund: treatment; (63–95)
Frankfurt: emergencies Frankfurt: emergencies
Greece 1998 Methadone treatment 65 1996–98 Methadone treatment 50–80
Spain 1996 Survey of treatment centres 59 1996 Survey of treatment centres 83
France 1996 (1) Survey of specialised treatment centres 15–30 1997 (2) Survey of treatment centres, notifications/ 62–70
self-reports (c)
Ireland n.a. n.a. n.a. 1997 Dublin: study in treatment (62)
Italy 1997 Treatment 40 1997 Treatment 67
Luxembourg 1998 Treatment, self-reports (c) 23 1998 Treatment, self-reports (c) 18
Netherlands 1994–96 Rotterdam/Heerlen/Maastricht: treatment (59–63) 1994–96 Rotterdam/Heerlen/Maastricht: treatment (74–84)
Austria 1996 Vienna/Vorarlberg: hospital, low-threshold (50–56) 1996 Vienna/Vorarlberg: hospital, low-threshold (72–79)
treatment treatment
Portugal n.a. n.a. n.a. 1996 Treatment, self-reports (c) 74
Finland 1997 Helsinki: needle exchange, self-reports (c) (34) 1997 Helsinki: needle exchange, self-reports (c), (63–85)
treated addicts
Sweden 1997 (1) Study in nine prisons, saliva 55 1994 (2) Stockholm: study in prison/treatment (92)
UK 1997 (1) Unlinked Anonymous, England and Wales 19 1998 (2) Community and treatment agencies,  38
England, saliva tests
Notes: 1. Figures for the years 1996–98 are adjusted for reporting delays.
2. In some countries, there may be small differences between incidence rates
provided by the European Centre for the Epidemiological Monitoring of AIDS
and national figures due to reporting delays.
Incidence of AIDS cases related to injecting drug use in the EU (by 31 December 1998)Table 9
Annual incidence rates per million population % of AIDS cases 
related  to 
injecting drug use
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1985–98
Belgium 0.0 0.1 0.5 0.7 1.0 1.1 2.2 2.3 2.1 2.0 1.3 1.0 0.6 1.3 6.5 
Denmark 0.0 0.2 0.6 1.2 1.6 3.1 3.1 3.5 4.1 4.6 5.4 3.3 1.7 0.6 7.9 
Germany 0.2 0.6 1.6 2.2 2.9 2.9 2.9 3.4 3.4 3.7 3.1 2.6 1.5 1.1 14.2 
Greece 0.0 0.1 0.1 0.2 0.5 0.6 1.2 0.6 0.8 0.5 0.4 0.9 1.0 0.5 3.9 
Spain 2.4 7.1 17.1 38.8 52.1 64.7 73.4 79.2 86.0 120.5 111.2 102.1 71.9 52.7 65.1 
France 0.8 2.7 6.0 11.1 15.7 18.5 20.8 22.8 25.2 23.1 22.0 15.9 7.0 5.5 23.6 
Ireland 0.6 0.3 2.8 3.1 6.8 8.3 9.4 10.3 10.8 7.1 5.9 7.1 2.8 0.7 42.5 
Italy 1.7 4.8 12.0 21.3 29.0 36.1 43.3 48.3 52.7 58.7 58.3 50.0 30.8 18.8 61.7 
Luxembourg 0.0 2.7 0.0 2.7 8.0 0.0 2.6 7.7 12.7 5.0 0.0 4.9 5.0 7.5 16.9 
Netherlands 0.1 0.4 1.1 2.3 2.3 2.7 2.9 3.7 3.9 4.0 5.0 3.1 2.8 1.1 10.9 
Austria 0.8 0.4 3.6 4.3 5.7 5.8 7.0 7.2 7.4 5.2 4.6 3.0 2.5 2.9 25.4 
Portugal 0.1 0.3 0.7 1.0 3.0 4.3 7.3 13.5 23.7 33.1 39.3 46.5 50.1 50.1 45.7 
Finland 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.6 0.2 0.2 0.2 0.4 0.4 0.0 3.8 
Sweden 0.0 0.0 0.1 0.6 0.5 1.3 2.3 2.5 3.8 3.0 2.7 2.5 1.0 0.8 11.5 
UK 0.0 0.1 0.3 0.5 1.1 1.4 1.5 1.4 2.6 2.3 2.5 2.0 1.4 0.7 6.5 
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n.a.  = data not available
Notes: These data are derived from qualitative descriptions in national reports provided by the Focal Points and were validated by the Focal Points and other experts. However,
the data provide little or no information on coverage of the measures, quality or utilization. In many instances these may still be on average very low.
Harm reduction measures for IDUs in the EUTable 11
Syringe- Unrestricted Availability/ HIV HIV Hepatitis B Hepatitis C Substitution Measures
exchange access to distribution of counselling treatment vaccination action therapy available to 
programmes syringes in condoms and testing prisoners
pharmacies 
Belgium Some Yes Yes Via NGOs Yes Yes Some Since 1990 HIV testing
measures
Denmark Yes Yes Yes Yes n.a. n.a. Testing Yes Information
Germany In most cities, Yes, cheap Yes, Yes n.a. n.a. n.a. Increase Methadone
via low- including in since 1992
threshold and prostitution
outreach projects
services
Greece Yes, and via Yes Yes Yes Yes Yes Testing Since 1996 Information 
low-threshold plus testing
and outreach
services
Spain Yes, via low- Yes Yes Yes Yes In prisons Testing Yes Information 
threshold and testing,
services vaccinations, 
methadone
France 86 Yes Yes Yes Since 1996 Experimental Testing Since 1993 Testing, 
programmes in prisons vaccinations
Ireland Yes No Yes Yes Yes Yes Information Yes Information
and screening
Italy All regions,  Yes Yes Yes Yes, free Yes (5–6 % Screening Yes Information plus
mostly from vaccinated) (60 % tested) testing, 
machines methadone, bleach
for cleaning
needles 
Luxembourg Yes, via low- Yes, but Yes, via Yes, via Yes n.a. n.a. Yes Information
threshold expensive outreach outreach plus
services services services methadone 
Netherlands Yes Yes Yes Yes Yes Pilot Experimental Yes Information
treatment
Austria Many, via low- Yes, sold Via low- Via low- Yes Yes Information Yes Information  
threshold nationally threshold threshold and testing and condoms
services services and other
services
Portugal 1 mobile unit, Yes, but Yes Yes Yes, but very Yes n.a. Yes, but very Information 
rest via some limited limited and testing, 
pharmacies problems condoms, 
methadone, 
vaccination
Finland Few, Helsinki Recently Rare Rare n.a. Experimental Information Limited HIV testing
restricted
Sweden 2 programmes No Yes Yes Yes Yes n.a. Yes Information  
and HIV testing
UK Yes > 300 Yes > 2 000 Yes Yes Yes Information Information Yes n.a.
programmes pharmacies and testing for pregnant 
women
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(P)  = person; (O)  = offence; (C)  = charge; (A) =arrest;
n.a.  = data not available
(a) For precise definitions of ‘arrests’ for drug offences, see Figure 13.
(b) Figure from Eurostat.
(c) Provisional figure.
Number of ‘arrests’ (a) for drug offences in the EU (1997 and 1998)Table 12
Population as at 1 January 1997 (b) Number of ‘arrests’ for drug Number of ‘arrests’ for drug 
(1 000) offences, 1997 offences, 1998
Belgium (P) 10 170.2 n.a. 23 184
Denmark (P) 5 275.1 8 234 8 900
Germany (O) 82 012.2 205 099 n.a.
Greece (P) 10 486.6 6 040 n.a.
Spain (P) 39 298.6 78 847 81 644
France (A) 58 491.6 89 285 91 048
Ireland (C) 3 652.2 4 156 n.a.
Italy (P) 57 461.0 22 705 33 179
Luxembourg (P) 418.3 154 143
Netherlands (O) 15 567.1 10 300 (c) n.a.
Austria (O) 8 067.8 17 868 16 624
Portugal (O) 9 934.1 9 333 11 333
Finland (P) 5 132.3 7 015 8 173
Sweden (P) 8 844.5 10 625 n.a.
UK (P) 58 901.8 113 154 n.a.
Total EU 373 713.4 628 582 n.a.
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Note: The note numbers in the table reflect those given in the list of sources.
Drug users among prisoners in the EUTable 13
Definition Percentage of drug Year Methodological comments
users among 
prison population
Belgium People reporting having used illicit drugs (1) 42 1993 Survey in one prison (n  = 1 627)
Denmark Drug abusers: those having used euphoriants regularly 36 1997 Nationwide survey
in the six months prior to imprisonment (2)
Heavy drug abusers: those who habitually use substances 19 1997 Nationwide survey
other than cannabis (2)
Germany Drug users in prison (based on positive urine samples) (3) 5–26 1995 Survey in one German Länd (n  = 5 771)
Drug users in prison (based on information given by  60 1996 Survey in one prison based on 
key persons) (4) reports of pre-selected prisoners
(n  = 16), doctor, pastor(s)
Hard drug users (based on information given by 10 1996 Survey in one prison based on 
key persons) (4) reports of pre-selected key 
prisoners (n  = 16), doctor, 
pastor(s)
Soft drug users (based on information given by  50 1996 Survey in one prison based on 
key persons) (4) reports of pre-selected key 
prisoners (n  = 16), doctor, 
pastor(s)
Greece Injecting drug users (5) 31 1995 Survey in one prison (n  = 1 183)
Spain Women reporting lifetime drug use (alcohol included) (6) 70 1998 Survey in 18 prisons (n  = 356)
Women reporting having used drugs several times a day 35 1998 Survey in 18 prisons (n  = 356)
(alcohol included) (7)
People reporting to be drug users (8) 56 1998 Survey in 62 prisons (n  = 1 011)
People whose frequency of heroin and/or cocaine  54 1994 Nationwide survey in 25 % of all prisons
use in the past two years is at least once a week for   among people entering prison (n  = 1 541)
a minimum of one month (9)
France People reporting regular use of all illicit drugs in the 33 1997 Nationwide survey among 86 % of 
12 months prior to imprisonment (10) (Cannabis: 25; those entering prison (n  = 8 728)
Heroin: 14)
People reporting illicit drug use within the 12 months prior 43 1997 Survey in four prisons (n  = 1 212)
to imprisonment (11)
People reporting lifetime intravenous drug use (11) 23 1996 Survey in one prison (n  = 574)
Ireland Regular heroin users (12) 35 1997 Estimated in one prison
People with a history of heroin abuse (12) 70 1997 Estimated in one prison
People reporting heroin use while in prison (13) 42 1996 Survey in one male prison (n  = 108)
People reporting ever having used heroin or cannabis (13) Heroin: 66; 1996 Survey in one male prison (n  = 108)
Cannabis: 86
Netherlands People judged by a clinical psychologist to have drug- 29 1997 Survey in one prison (n  = 528)
addiction problems (14)
People reporting drug abuse or drug dependence within 14 1997 Survey in one prison (n  = 135)
the last month (14)
People judged to be drug addicts according to two 44 1997 Survey in one prison (n  = 319)
criteria (at least two months of regular use within the   
past two years; and a severity score of over three in
the EuropASI drug section) (15)
Austria Intravenous drug users (16) 15 1996 Estimated by experts
People reporting having used illicit drugs (17) 72 1994 Survey in one prison focusing on 
those convicted under the Narcotic 
Drug Act (n  = 307)
Finland People reporting having used drugs (18) 31 1995 Survey in four prisons
Sweden People having used drugs intravenously or on a 44 1997 Nationwide survey (n  = 3 616)
daily (or almost daily) basis within the 12 months prior  
to imprisonment (19)
UK Prisoners testing positive for drugs during random 19 1998 Nationwide survey among 10 % of
mandatory drug testing (20) prisoners (n  = 10 340)
England People reporting use of drugs in the 12 months prior to 68 1994 Nationwide survey (n  = 1 000)
and Wales imprisonment (21)
Men entering prison reporting a history of injecting drug use (22) 29 1996 Survey in one prison
Men entering prison reporting a history of injecting drug use (23) 15 1995 Survey in three prisons
Scotland Men reporting a history of injecting drug use (24) 32 1991–96 Survey in six male prisons (n  = 2 256)
Women reporting a history of injecting drug use (24) 43 1991–96 Survey in one female prison (n  = 127)
Young offenders reporting a history of injecting drug use (24) 18 1991–96 Survey in two young offenders’ 
institutions (n  = 556)
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n.a.  = data not available
(a) The number of ecstasy seizures also includes amphetamines.
(b) Provisional figures; the number of ecstasy seizures also includes other synthetic drugs.
Number of drug seizures in the EU (1997 and 1998)Table 14
Country Cannabis Cocaine Heroin Amphetamines Ecstasy LSD
1997 1998 1997 1998 1997 1998 1997 1998 1997 1998 1997 1998
Belgium (a) n.a. 13 020 n.a. 799 n.a. 1 112 n.a. n.a. n.a. 2 675 n.a. 75
Denmark 4 886 5 904 723 885 2 509 2 199 1 324 1 609 110 143 15 24
Germany 29 826 31 241 5 482 5 532 9 509 8 387 3 571 4 079 2 368 1 986 727 561
Greece n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Spain 44 227 48 363 12 276 13 567 15 399 13 393 5 040 4 083 1 999 1 358 475 289
France 34 266 40 115 1 471 1 688 3 924 31 113 163 158 628 608 171 154
Ireland 4 102 n.a. 157 n.a. 599 n.a. 475 n.a. 347 n.a. 48 n.a.
Italy 11 423 12 406 3 163 3 867 6 851 6 360 53 41 847 729 173 120
Luxembourg 190 237 54 22 237 189 3 5 12 22 3 0
Netherlands (b) n.a. 2 681 n.a. 1 168 n.a. 797 n.a. n.a. n.a. 583 n.a. 15
Austria 4 957 4 683 651 531 861 654 221 n.a. 253 135 113 61
Portugal 1 604 2 003 1 234 1 373 3 476 3 696 n.a. n.a. 34 33 n.a. n.a.
Finland 1 686 1 997 16 24 153 210 1 339 1 641 74 57 14 n.a.
Sweden 4 545 5 061 116 172 833 1 285 4 639 4 859 203 104 86 61
UK 106 753 n.a. 4 093 n.a. 12 474 n.a. 18 575 n.a. 5 087 n.a. 851 n.a.
Total EU 248 465 n.a. 29 436 n.a. 56 825 n.a. 35 403 n.a. 138 173 n.a. 2 676 n.a.
n.a.  = data not available
(a) Cannabis leaves plus resin plus plants.
(b) Ecstasy plus amphetamines.
(c) Cannabis leaves plus resin plus concentrate; 67 065 additional plants in 1997 and 81 097 in 1998.
(d) Small number of items also seized.
(e) 1 479 821 additional ‘nederwiet plants’.
Note: For the Netherlands: 1998 figures are provisional. The quantities of ecstasy seized also include other
synthetic drugs. The 1997 ecstasy figure is also provisional.
Quantities of drugs seized in the EU (1997 and 1998)Table 15
Cannabis (kg) Cocaine (kg) Heroin (kg) Amphetamines (kg) Ecstasy (pill) LSD (dose)
1997 1998 1997 1998 1997 1998 1997 1998 1997 1998 1997 1998
Belgium 48 705 (a) n.a. 3 329 2 028 55 76 n.a. n.a. 126 211 (b) 271 080 621 2 050
Denmark 467 1 572 58 44 38 55 119 25 5 803 27 038 381 105
Germany 11 498 (c) 21 007 (c) 1 721 1 133 722 686 234 310 694 281 419 329 78 430 32 250
Greece 19 237 48 321 17 283 146 185 0.05 0.003 (d) 179 101 166 44
Spain 315 328 428 234 18 419 11 687 479 444 120 202 184 950 194 493 25 357 9 063
France 55 122 55 698 844 1 051 415 344 194 165 198 941 1 142 226 5 983 18 681
Ireland 1 347 n.a. 11 n.a. 8 n.a. 102.9 n.a. 17 516 n.a. 1 851 n.a.
Italy 60 613 54 199 1 650 2 144 537 307 0.4 0.5 161 631 129 773 7 973 9 752
Luxembourg 35 (a) 7 (a) 9 6 3 4 0.01 0.07 367 145 4 0
Netherlands 31 513 (e) 118 122 6 744 11 437 194 2 043 n.a. n.a. 1 054 218 1 673 592 137 218 35 964
Austria 912 1 336 87 99 102 118 8 n.a. 23 522 114 677 5 243 2 494
Portugal 9 693 5 550 3 163 621 57 97 0 0 525 1 127 84 261
Finland 210 161 0.1 2 2 2 22 25 3 062 3 320 323 301
Sweden 660 496 34 19 12 71 186 135 20 254 21 273 1 397 2 704
UK 149 969 n.a. 2 350 n.a. 2 235 n.a. 3 296 n.a. 1 925 500 n.a. 164 000 n.a.
Total EU 705 309 n.a. 38 436 n.a. 5 005 n.a. 4 282 n.a. 4 416 960 n.a. 429 031 n.a.
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Table 1
All sources are presented as submitted by
the Reitox national focal points.
Belgium (Flemish C.): Quataert, P. and
Van Oyen, H., Gegeveninzamzeling in
verband met middelengebruik door
middel van CATI, IHE/Episeries No 6,
CCOV (Brussels: IHE, 1995).
Denmark:(1) ‘Health and morbidity in
Denmark 1994’, DIKE, 1994 
(unpublished report).
Denmark:(2) Laursen, L., ‘Nordic alcohol
and drug use survey’, Centre of Alcohol
and Drug Research, 1996.
Germany:(1) Herbst, K., Kraus, L. and
Scherer, K., Representative survey on the
consumption of psychoactive substances
in the German adult population 1995,
Bonn: Bundesministerium für
Gesundheit, 1996.
Germany:(2) Kraus, L. and Bauernfeind,
R., Representative survey on the
consumption of psychoactive substances
in the German adult population 1997,
Bonn: Bundesministerium für
Gesundheit, 1998.
Greece: Kokkevi, A., Loukadakis, M.,
Plagianakou, S., Politikou, K. and
Stefanis, C., Outburst of illicit drug use in
Greece: Trends from a general population
survey on illicit drug use (Athens:
University Mental Health Research
Institute, in press).
Spain:(1) ‘Household Survey on Drugs
1995’, National Plan on Drugs 
(unpublished report).
Spain:(2) ‘Household Survey on Drugs
1997’, National Plan on Drugs 
(unpublished report).
France: Baudier, F. and Arenes, J.,
Barométre Santé adultes 1995 (CFES,
1997).
Netherlands: Abraham, M., Cohen, P.
and De Winter, M., Licit and illicit drug
use in the Netherlands, UvA/CBS
(Amsterdam: CEDRO, 1999).
Finland: (1) Kontula, O., Drugs in Finland
in the 1990s (Helsinki: Ministry of Social
Affairs and Health, 1997) Monisteita 27.
Finland: (2) Partanen, J. and Metso, L.,
‘The second drug wave in Finland’,
Yhteiskuntapolitiikka-lenti, 2, 1999.
Sweden: (1) Drogutvecklingen i Sverige.
Rapport 99 (Stockholm: National Institute
of Public Health and Swedish Council for
Information on Alcohol and Other Drugs,
1999).
UK (England and Wales): (1) Ramsay, M.
and Percy, A., ‘Drug Misuse Declared:
Results of the 1994 British Crime Survey’,
Research Study 151 (London: Home
Office, 1996).
UK (England and Wales): (2) Ramsay, M.
and Percy, A., ‘Drug Misuse Declared:
Results of the 1996 British Crime Survey’,
Research Study 172 (London: Home
Office, 1997).
Table 2
Sources as for Table 1.
Table 3
All sources are presented as submitted by
the Reitox national focal points.
Belgium (Flemish C.): (1) Maes, L. and
Vereecken, C., ‘Jongeren en gezondheid
1996’ database, Department of Public
Health, University of Ghent, 1999.
Belgium (Flemish C.): (2) Maes, L. and
Vereecken, C., ‘Jongeren en gezondheid
1998’ database, Department of Public
Health, University of Ghent, 1999.
Denmark: Sabroe, S. and Fonager, K.,
‘Young people, alcohol and drugs’,
ESPAD study 1995 (Arhus: FADL, 1996).
Germany: Christiansen, G. and Töppich, J.,
Die Drogenaffinittät Jugendlicher in der
Bundesrepublik Deutschland.
Wiederholungsbefragung 1997
Bundeszentrale für gesundheitliche
Aufklärung (Köln, 1998).
Greece: (1) Kokkevi, A. and Stefanis, C.,
Licit and Illicit Drug Use in Greece:
Trends in the General and in the School
Population (Athens: University Mental
Health Research Institute, 1994).
Greece: (2) Kokkevi, A., Terzidou, M.,
Politikou, K. and Stefanis, C., Substance
Use among High School Students in
Greece: Outburst of Illicit Drug Use in a
Society Under Change (Athens:
University Mental Health Research
Institute, in press).
Spain: (1) ‘School Survey on Drugs
1994’, Plan Nacional Sobre Drogas
(unpublished report).
Spain: (2) ‘School Survey on Drugs
1996’, Plan Nacional Sobre Drogas
(unpublished report).
France: (1) Choquet, M. and Ledoux, S.,
Enquête santé des adolescents 1993
(Paris: Inserm, 1994).
France: (2) Ballion, R., Enquête sur les
conduites déviantes des lycéens 1997,
Rapport OFDT (Paris: CADIS–OFDT,
1998).
Ireland: Hibell, B. et al., ‘Alcohol and
other drug use among students in 26
European countries’, ESPAD study 1995
(Stockhom: Swedish Council for
Information on Alcohol and Other Drugs,
1997).
Italy: Mariani, F., di Fiandra, T.,
Schiallero, L. and Rico, G., ESPAD study
1995.
Luxembourg: Les drogues de type ecstasy
au Grand-Duché de Luxembourg
(Luxembourg: Centre de Prévention des
Toxicomanies, 1998).
Netherlands: De Zwart, W. et al., Key
data: smoking, drinking, drug use and
gambling among pupils aged 10 years
and older (Utrecht: Trimbos Institute,
1997). 
Austria: Springer, A., Uhl, A. and
Widensky, K., ‘Schüler und Drogen in
Österreich: Wissen, Erfahrungen,
Einstellungen’, Wiener Zeitschrift für
Suchtforschung, 1–2, 1996, pp. 3–21.
Portugal: Machado Rodrigues, L. et al.,
Estudos em Meio Escolar – 3° ciclo
(Lisbon: GPCCD, 1996).
Finland: Salrue, A. et al., ESPAD study
1995 (Finland Social Research Institute of
Alcohol Studies, 1996).
Sweden: (1) Andersson, B. et al.,
Skolelevers drogvanor 1997, Report 53
(Stockholm: Swedish Council for
Information on Alcohol and Other Drugs,
1998).
Sweden: (2) ‘School Survey 1998’
(Stockholm: Swedish Council for
Information on Alcohol and Other Drugs)
(unpublished report).
UK: (1) Miller, P. and Plant, M.,
‘Drinking, smoking and illicit drug use
among 15 and 16-year-olds in the United
Kingdom’, British Medical Journal, 313,
1996, pp. 394–397.
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Ireland: Moran, R., O’Brian, M. and Duff,
P., Treated Drug Misuse in Ireland
(Dublin: Health Research Board, 1997).
Italy: SER.T Monitoring System Annual
Report (Rome: Health Ministry).
Luxembourg: Origer, A., RELIS/LINDDA
Annual Report 1998 (Luxembourg:
Service d’action socio–therapeutique,
Ministère de la Santé, 1999).
Netherlands: LADIS Reporting System.
IVV, 1997.
Portugal: Félix da Costa, N.,
‘Toxicodependentes em tratamento:
estudo sagital de 1997’,
Toxicodepêndencias, 5(1), pp. 35–48,
1999.
Finland: National Hospital Patient
Discharge Register Stakes.
Sweden: National Hospital Discharge
Registry, National Board of Health and
Welfare.
UK (England, Scotland and Wales): ‘Drug
misuse statistics for the six months ending
30 September 1997’, Statistical Bulletin
1998/29, Department of Health, London,
1998.
Table 7
Reitox national focal points, based on the
following information sources:
Belgium: Service général d’appui
policier.
Denmark: National Commissioner of
Police.
Germany: Federal Criminal Police Office
(BKA).
Greece: Forensic Department for Autopsy
and Toxicology, and the police central
office for registration and publication.
Spain: SEIT, based on information of 
institutes of pathology and the National
Institute of Toxicology.
France: OCRTIS, National File of
Perpetrators of Narcotic-related
Legislative Infractions.
Ireland: Office of the Registrar General
and Central Statistics Office.
Italy: Central Office of Anti-drug Services
(DCSA).
Luxembourg: Drug Unit of the Criminal
Investigation Department.
Netherlands: Central Bureau of Statistics
(CBS) in its Cause of death statistics.
Austria: Federal Ministry of Health and
Consumer Protection.
Portugal: Institutes of legal medicine in
Lisbon, Oporto and Coimbra.
Finland: Stakes.
Sweden: Cases are recorded by Statistics
Sweden and reported and published by
the National Board of Health and
Welfare.
UK: Office of Population Censuses and
Surveys (OPCS).
Table 8
All sources are presented as submitted by
the Reitox national focal points.
Belgium (Flemish C.): (1) Todts, S.,
‘Risicogedrag bij injecterende drugge-
bruikers in Vlaanderen’, GIG project,
VAD and Free Clinic, 1997.
Belgium (French C.): (2) Belgium French
Community Sub-Focal Point, CCAD,
1998 (prevalence trend based on last
three years: 3 %, 1.4 %, 2.6 %).
Denmark: Smith, E., ‘Status of the
HIV/AIDS epidemic in Denmark by the
end of 1995’, Ugeskr Læger 159, pp.
585–590, 1997 (prevalence trend based
on notifications of HIV among IDUs).
Germany: German National Focal Point,
1999.
Greece: Greek National Focal Point 1999
(screening drug-free treatment: n  = 409,
0.48 %; Athens methadone treatment
reporting system n  = 710, confirmed
tests 3.2 %.Trend in prevalence from
treatment reporting system: 1996 1.6%,
1997 2.0%, 1998 3.2%; trend non- 
significant).
Spain: Encuesta sobre Consumidores de
Heroína en Tratamiento — ECHT—
1996, reported in DGPNSD,
Observatorio Español sobre Drogas,
Informe no 1 (Madrid: Ministerio de
Justicia e Interior, 1998).
UK: (2) Balding, J., ‘Young people in
1997: The health-related behaviour
questionnaire results for 37 538 pupils (9
to 16)’, Schools Health Education Unit,
University of Exeter, 1998.
Table 4
‘Study to obtain comparable national
estimates of problem drug use prevalence
for all EU Member States’, EMCDDA,
1999.
Austria: (1) National Focal Point.
Table 5
‘Study to obtain comparable national
estimates of problem drug use prevalence
for all EU Member States’, EMCDDA,
1999.
Table 6
All sources are presented as submitted by
the Reitox national focal points.
Belgium (Brussels): Vanderveken, M.,
Rapport epidemiologique 1997 (Brussels:
CTB–ODB, 1998).
Belgium (Flemish C.): Van Baelen, L. and
Wydoodt, J. P., Vlaamse Registratie
Middelengebruik (VRM), Jaarrapport
1996 (VAD, 1998).
Belgium (French C.): Preumont, C. and
Bills, L., Fiche commune, ‘1ere deman-
des et demandes de traitement,
Communauté Francaise’, CCAD, 1997.
Denmark: Register of Drug Abusers in
Treatment. New Figures from the
National Board of Health No 6, National
Board of Health, 1998.
Germany: Simon, R. et al., ‘Erweiterte
Jahresstatististik 1998 de ambulanten
Beratungs und B. fur S.’ in der
Bundesrepublik D (Tabellenband)
(Berichtszeitraum 1,1,98–31,12,98
1999).
Greece: Greek Reitox Focal Point 1999.
Spain: Delegacion del Gbobierno para el
Plan Nacional sobre Drogas, ‘Sistema
Estatal de Informacion sobre
Toxicomanias (SEIT)’ (unpublished
report, 1998).
France: Tellier, S., Unpublished results
from the ‘Enquete sur les toxicomanies
suivis dans les structures sanitaires et
sociales en novembre 1997’, Direction
de la recherche, des études, de l’évalua-
tion et de la statistique (DREES).
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France: Gadel, G. and Nunes, C. ‘Les
toxicomanes suivis dans les structures
sanitaires et sociales en novembre 1996’,
Études et résultats No 1 (Paris: Direction
de la recherche, des études, de l’évalua-
tion et de la statistique (DREES), 1998.)
(The range is not geographical; the upper
limit gives the seropositives among all
known test results while the lower limit
assumes that those who do not know
their test result are seronegative.)
Ireland: Smyth, B. P., Keenan, E. and
O’Connor, J. J., ‘Bloodborne viral infec-
tion in Irish injecting drug users’,
Addiction 93, pp.1649–1656, 1998.
Italy: ‘Prevalence of HIV antibodies in
SER.T users by region 1990–97’, Ministry
of Health (national average and range of
seroprevalence by region).
Luxembourg: RELIS–LINDDA, 1998 (2 %
assumes that all with unknown test
results are seronegative; 3 % is preva-
lence in all those with known test result;
4 % if also corrected for 79 % IDUs and
assuming all seropositives are IDUs).
Netherlands: ‘National surveillance of
HIV in IDUs’, Report series (Bilthoven:
RIVM, 1998) (1995: Arnhem 2 %; 1996:
Amsterdam 26 %, Utrecht 5 %; 1997:
Heerlen 16 %, Maastricht 3 %,
Rotterdam 9 %).
Austria: Data on overdose deaths
provided by the Ministry of Labour,
Health and Social Affairs; treatment data
from Jahresbericht 1998 des
Ambulatoriums Ganslwirt, Vienna.
Portugal: Portuguese National Focal Point
1998.
Finland: Finnish National Focal Point
1999.
Sweden: Käll, K. and Thorstensson, R.,
12th World AIDS Conference, Geneva,
28 June to 3 July 1998 (abstract 23552)
(trend in prevalence based on notifica-
tions of IDUs).
UK: Unlinked Anonymous Surveys
Steering Group (1998), ‘Prevalence of
HIV in England and Wales in 1997’,
Department of Health, Public Health
Laboratory Service, Institute of Child
Health, London.
Table 9
European Centre for the Epidemiological
Monitoring of AIDS.
Table 10
All sources are presented as submitted by
the Reitox national focal points.
Belgium: Belgium French Community
Sub-Focal Point, CCAD 1999.
Denmark: Estimates from HIV notifica-
tion and study on national prevalence of
drug use, Stalens Serums Institute.
Germany: Bätz, B. and Reymann, G.,
Sucht 1997; 43, pp. 264–266.
Jugendberatung und Jugendhilfe e.V.,
Frankfurt, 1998.
Greece: Greek National Focal Point 1999
(previously only % HbsAg+ was reported.
Anti-HCV —  Athens 68 %, Thessaloniki
80.47 %, other 49.6 %).
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(approx. n  = 1 000 heroin users who ever
injected).
France: (1) Six, C., Hamers, F. and
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infections à VIH, VHC et VHB chez les
résidents des centres de soins spécialisés
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Rapport global sur les 10 semestres
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CESES, 1999.
France: (2) Gadel, G. and Nunes, C., ‘Les
toxicomanes suivis dans les structures
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Études et résultats No 1 (Paris: Direction
de la recherche, des études, de l’évalua-
tion et de la statistique (DREES), 1998).
Ireland: Smyth, B. P., Keenan, E. and
O’Connor, J. J., ‘Bloodborne viral infec-
tion in Irish injecting drug users’,
Addiction 1998, 93, pp. 1649–1656
(prevalence of hepatitis B antibodies n.a.
as vaccination is being offered. In 1997 
(n  = 116 tested).
Italy: Ministerio della Sanità – Sistema
Informativo Sanitario — Dipartimento
della Prevenzione — Ufficio Dipendenze
da Farmaci e Sostanze d’abuso e AIDS 
(n  = 66 623 tested).
Luxembourg: RELIS–LINDDA, 1998.
Netherlands: ‘National surveillance of
HIV in IDUs’, Report series (Bilthoven:
RIVM, 1998).
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Ambulatoriums Ganslwirt; HIOB.
Portugal: Portuguese National Focal Point
1998.
Finland: Ovaska, A., Holopainen, A. and
Annala, T., Information Service Vinkki:
Final report on activities in the health
information service experiment on 4
April–31 December 1997 (Turkia, Mika
1998); ‘Private practitioner and heroin
addicts: a case study on the impact of
medical outpatient care on criminal
activities’, Aiheita 51/1998.
Sweden: (1) Kall, K. and Thorstensson, R.,
12th World AIDS Conference, Geneva,
28 June to 3 July 1998 (abstract 23552).
Sweden: (2) Krook, A., Albert, J. and
Andersson, S. et al. in Journal of Acquired
Immune Deficiency Syndrome Human
Retrovirol 1997;15, pp. 381–386.
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Steering Group (1998), ‘Prevalence of
HIV in England and Wales in 1997’,
Department of Health, Public Health
Laboratory Service, Institute of Child
Health, London.
UK: (2) CRDHB and PHLS CDSC, unpub-
lished data (prevalence of 30.4 %
(895/2943) corrected for test sensitivity of
80 %).
Table 11
Reitox national focal points.
Table 12
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Drug prevention is high on the EU agenda. In the second
half of 1998, during the Austrian Presidency of the
Council of the European Union, the issue was given a
boost with the launch of the third European Drug
Prevention Week (EDPW) from 16 to 22 November. The
event highlighted a variety of initiatives and projects
throughout the EU, as well as in participating non-
member countries, such as Norway.
The main objective of the EDPW is to reinforce coopera-
tion at European level on health aspects of the drugs
phenomenon, highlight long-term prevention activities in
the Member States and raise public awareness at EU level.
Since the first EDPW in 1992, the Week has helped 
to strengthen cooperation between professionals involved
in drug-prevention work, particularly those in the health,
education and social services, youth work and 
law-enforcement agencies within and among the 
Member States.
Building on experience gained from the previous weeks
(held in 1992 and 1994), the Commission opted to retain
a similar organisational structure for the 1998 event. In
addition to providing financial support to EU initiatives
and national programmes, this included setting up a
coordination group of highly qualified representatives
from the Member States and 15 ad hoc national coordi-
nation agencies.
Although conducted on the same basis as previously, the
1998 EDPW was the first to be organised and held in the
context of the EU’s action programme for the prevention
of drug dependency (1996–2000). For the first time, the
new Member States, Austria, Finland and Sweden, partici-
pated, along with Norway.
Young people and youth workers, families, professionals
in the field, politicians and representatives of the media
were all targeted by activities developed during the
EDPW. Some Member States also identified other groups,
such as ethnic minorities, drug-users and very young
children.
The Week’s theme was multidisciplinary — to raise
awareness in society and to increase working partner-
ships — and in this context an EU-wide campaign,
‘Talking is the first step’, was launched. The Week also
promoted the evaluation of drug-prevention activities
using EMCDDA tools such as its guidelines for the evalua-
tion of drug-prevention activities. The exchange on drug
demand reduction action (EDDRA) questionnaire was
used to report back on the Week’s activities. The results
are being examined by the Commission and a report on
the EDPW is expected by the end of 1999.
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‘Drug prevention and drug policy’,
opening event of the Week
As the EDPW was held during the Austrian Presidency of
the Council of the European Union, the event opened in
Vienna. A conference entitled ‘Drug prevention and drug
policy’ was held on 5 and 6 November involving 300
experts and politicians from all 15 Member States as well
as representatives from Liechtenstein, Norway and central
and eastern Europe. The conference, conceived as a
forum for exchanging information and good practice,
discussed pragmatic ways of cooperating and coordinat-
ing drug-prevention strategies at local, national and
European level, and examined health and social policy,
education and youth issues, security policies, regional
and local politics, and public relations.
Delegates concluded that more work was needed to
improve the quality and comparability of data on the drug
phenomenon in the EU. Such information would help
substantially in drawing up current and new strategies.
During the conference, an exhibition was held to highlight
all projects supported by the EU’s action programme for
the prevention of drug dependency (1996–2000).
The event was organised by representatives of the City of
Vienna, the European Commission, the EMCDDA, the
Pompidou Group of the Council of Europe, the World
Health Organisation and the United Nations International
Drug Control Programme.
Talking is the first step
During the first two EDPWs, the Commission supported
pan-European radio campaigns created and implemented
by the European Foundation of Drug Helplines. The aims
were to inform European citizens about helpline services,
strengthen links between preventive structures and media
targeted at young people and to publicise the Week itself.
The 1994 campaign covered 19 helplines in 11 Member
States and involved 400 radio stations. The helplines
involved dealt with over 51 000 calls during the
campaign — for some, this represented an increase of 
300 % in their normal workload over the same time
period.
The 1998 communication campaign concentrated on a
common slogan, ‘Talking is the first step’, highlighting the
importance of dialogue in drug prevention. The campaign
itself was directed mainly at adults in permanent contact
with young people, including parents, teachers, youth
workers, instructors and sports trainers. Despite differ-
ences in prevention approaches, constructive dialogue is
seen as the common denominator in the field of preven-
tion at all levels.
The media campaign, carried out by a professional
public-relations agency, consisted of: a television
commercial in 18 languages; a radio commercial in six
languages; a poster produced in 19 language versions; a
leaflet in 13 languages; a press advertisement in 12
languages; and a press release in 18 languages. To reach
Lessons from the European Drug Prevention Week
• Although the European Commission’s final evaluation
of European Drug Prevention Week events throughout the
participating countries is still to be finalised, some obser-
vations can already be made about the 1998 event.
Information from the national reports of the Reitox
national focal points has helped to highlight some of the
Week’s key elements.
• The European Drug Prevention Weeks are efficient 
tools for promoting both EU and national prevention
activities. The events help to encourage and promote 
the exchange of information on best practice in 
prevention at European level.
• The organisation of the 1998 Week itself highlighted 
the benefits of coordination at EU level, as well as
helping national agencies to collaborate in a wider
European context.
• The European media campaign did have an impact, 
but would have benefited from addressing a specific and
common drug prevention message — similar to the
Europe Against Cancer Weeks.
• Taking into account the difficulties encountered 
by some project leaders to develop the European 
component of their initiatives, support at an early stage
should be envisaged for the next EDPW to facilitate the
development of projects with a Europe-wide dimension
that focus on a common European-defined theme.
• The use of EMCDDA reporting tools will allow for 
a standardised presentation of the Weeks’ activities.
Nevertheless, the evaluation procedure was not begun
early enough and it will therefore take some time until
reporting is completed.
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as wide an audience as possible, the European
Commission produced material not only in the 11 official
EU languages, but also in Luxembourgish and others.
At a meeting of national coordinators, the Commission
outlined the preliminary results of the campaign. It
revealed that 28 television channels in 10 Member States
used the commercial, 23 radio stations in seven Member
States broadcast the radio commercial and 76 magazines
and newspapers in 10 Member States published 93
inserts on the EDPW. This coverage represented free
publicity worth over EUR 1.6 million, excluding the free
media space obtained directly by the national coordina-
tors. In addition, over 1 300 articles published in all EU
Member States and Norway mentioned the event.
The 1994 campaign reached an estimated 100 million,
far more than in 1992, with 90 % contacted through
television, press and radio. The 1998 event reached an
even wider audience.
Member State overview
The adoption of the 1994 structure —16 national coordi-
nators from all 15 EU Member States plus Norway and ad
hoc national agencies co-financed by the Commission —
resulted in over 1 000 initiatives launched at national,
regional and local level during the Week (see
http://europa.eu.int/comm/dg05/phealth/index_ph.htm).
The Commission contributed about EUR 950 000 to
activities implemented in the Member States that
included a transnational component. These activities are
still being evaluated in the Member States. An EU evalua-
tion report based on contributions from the Association of
Schools of Public Health in the European Region
(Aspher), which evaluates the Commission’s public health
programmes, is expected to be published by the end of
1999. From information already available from the
Commission and the Reitox national focal points, some
preliminary elements can be identified.
Drug-prevention strategies
Generally, the Member States incorporated the EDPW
into their national annual drug-prevention strategies and
used it to draw public attention to long-term projects. In
some States, the Week coincided with debates on existing
national prevention strategies and new approaches 
to prevention.
In Austria, in addition to the opening conference, the
overall programme was tailored to inform the public
about national prevention policies and activities devel-
oped over recent years.
Drug policy was also one of the themes of a symposium
in Tyrol organised by the Tyrolean drug coordinators in
cooperation with the Faculty of Law of the University of
Innsbruck. Austria also initiated a broad debate on the
theoretical and organisational basis for preventive
measures. For example, one project, ‘Theoretical basis
and structure of primary prevention — analysis and
development’, organised by the nine Austrian drug units
in cooperation with a research institute, aimed at
contributing to the further development of drug preven-
tion in Austria. Cooperation with experts from Germany,
Luxembourg, the Netherlands, Spain and Switzerland
allowed the project to contribute to a wider, European
discussion of models of addiction prevention.
As a major aspect of the Dutch EDPW programme, the
Trimbos Institute organised a national working confer-
ence in Arnhem which targeted professionals and policy-
makers working in the field of drug prevention. The
conference consisted of presentations on community
approaches, the efficiency of drug prevention, new trends
in Dutch drug-prevention policy and financing of preven-
tion work. Workshops allowed for an exchange of infor-
mation and experiences. Five EDPW projects were
presented during five workshops, while in five others
participants discussed major issues of prevention in the
Netherlands, including effectiveness of measures, preven-
tion aimed at migrants and prevention in small communi-
ties, at parties and in schools. Representatives from
Denmark, Germany and Sweden presented their experi-
ences of drug prevention in schools and in the party
scene.
In Sweden, 10 press seminars were held to support and
educate the media in writing on new synthetic drugs, as
well as on other drug-related topics.
The UK programme reflected the objectives set out in its
drugs strategy, ‘Tackling drugs to build a better Britain’. It
used the EDPW to help local professionals and planners
in the field increase the profile of drug prevention and
education on the local agenda and to ensure that both
national and European level activities during the Week
actually helped local drug prevention and education
initiatives.
Young people
All the Member States targeted young people and those in
close contact with them during the EDPW.
Activities dealing with childhood intervention played an
important role in Austria’s EDPW projects. During
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‘Summer Talks ’98’, Austrian, German and Hungarian
experts discussed a variety of drug-prevention options
and strategies for children aged three to six. A conference
on drug prevention in kindergartens was organised by the
Vienna Information Centre on Addiction Prevention.
In Finland, activities were mainly directed at young people
and their parents. An international meeting for nurses
specialised in treating drug addiction also took place.
In France, out of 46 projects, 39 targeted the young reach-
ing 18 000 people — 70 % aged 15 to 25 and 13 % aged
less than 15 years.
In Greece, the drug and alcohol dependency unit of the
Psychiatric Hospital of Thessaloniki, in cooperation with
Centro Italiano di Solidarietà, organised prevention activ-
ities for students from minority populations such as
Roma, and those from the former Soviet republics. The
main aims were to promote the cultural identity of minor-
ity groups and the concept of prevention through the
active involvement of students in planning and imple-
menting preventive activities.
In Sweden, the Week’s programme included 15 local
projects in cooperation with other Member States targeting
young women’s groups, refugees, peer-support schemes in
schools, community programmes, prevention in the dance
scene and parental empowerment in rural areas.
Dialogue, creativity and arts
In addition to traditional activities such as conferences,
seminars and training courses, all Member States organ-
ised activities that encouraged a dialogue with young
people, raised awareness of the issue and reinforced self-
esteem. ‘Establishing self-esteem and pleasure’ was the
underlying theme of projects in France.
A large number of artistic and cultural activities were held
throughout the EU during the Week. In Austria, a project
on theatre and addiction prevention was organised by the
addiction prevention coordinating body of the provincial
government of Carinthia. This idea was based on the
concepts of creativity, pleasure and sensation and
addressed young people aged 15 to 17 using drama as a
means of motivating them to deal with addiction.
The German Week’s programme focused on enhancing
self-respect in children and young people using artistic
means of expression such as music, theatre, dance,
drawing, plastic arts, games, photography, films and
video. Activities were also designed to promote intercul-
tural understanding.
Ireland launched its EDPW with a ‘fun day’ for families
offering a variety of activities including music groups,
magicians, face painting, games and treasure hunts.
The municipal health service of Groningen in the
Netherlands, in cooperation with a drug-prevention
agency in the UK, organised interactive theatre perform-
ances with a prevention message aimed at young people
aged 14 to 20 who experimented with party drugs. The
performances, on stages in schools and community
centres, provided the youngsters with information 
and education.
Peer-to-peer approaches
Peer-to-peer approaches were highlighted during the
EDPW in most Member States. For example, Belgium’s
EDPW programme included a ‘Prevention through peers’
project. Denmark’s National Board of Health, YAP-
Denmark and the county of Funen organised an interna-
tional seminar on peer-group communication focusing on
young people, alcohol, drugs and quality of life.
Participants included young people as well as drug-
prevention professionals from all over Europe and ended
with an anti-drug party.
In the Netherlands, CAD Limburg in Maastricht ran a
project involving drug users as peer workers in the
Limburg, Liège and Aachen area, on the border between
Belgium, Germany and the Netherlands. This scheme
produced and disseminated information on party and soft
drugs using bilingual leaflets distributed to drug users,
drug-prevention professionals and drug sales points such
as coffee shops. The leaflets contained information about
drugs, safer drug use, Dutch drug laws, nuisance-reduc-
tion measures and national behavioural codes.
New technologies
Jellinek Prevention of Amsterdam launched the ‘Tune in,
tune on’ scheme using new media such as CD-ROMs, the
Internet, chat-boxes and video performances. This project
provided young people in the party circuit with harm
reduction messages on party drugs. Activities were imple-
mented in two clubs — one in Amsterdam and one in
Liverpool. Prevention workers, generally peer workers,
were present to provide support to visitors to the clubs,
mainly young people aged 16 to 25.
The Irish National Television and Radio Broadcasting
Agency RTE broadcast a series of programmes focusing
on drug problems during the EDPW.
In Portugal, the Internet was used to undertake a national
investigation in schools of pupils’ and teachers’ knowl-
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edge and attitudes to drugs.  In Spain, the ‘Play preven-
tion’ project included computer games designed to
prevent drug dependence. The project also included the
use of various games (role-playing and table) as well as a
video forum to provide adolescents from 60 schools with
prevention information.
Partnership and interdisciplinary
approaches
The reinforcement of partnership and interdisciplinary
approaches also characterised a number of activities of
EDPW. Each Member State responded to the challenge of
the Week in a different way. Some Member States, such as
the Netherlands, created a national steering committee
made up of representatives from government and non-
governmental organisations (NGOs) responsible for drug
prevention. This group produced and implemented national
programmes following the Commission’s guidelines.
In Denmark, a prevention initiative, ‘Know your coopera-
tion partner’, was launched by the National Health
Board. The aim was to make contact with key agents
working in and around the drugs field and to encourage
them to establish multidisciplinary cooperation at local
level. The initiative targeted adults who work indirectly
with youngsters with abuse problems, such as teachers,
policemen, social workers, sports trainers and staff in fast-
food restaurants. The project began in early 1998 and
peaked in November during the EDPW with a series of
meetings for the target group.
In Greece, the national drug coordinating body, OKANA,
in collaboration with local television channels produced
a television commercial presenting the goals and activ-
ities of local prevention centres. This initiative aimed to
enhance the visibility of these centres at local level and to
promote their cooperation with local communities.
The EDPW programme in Luxembourg concentrated on
cooperation between different structures active in drug
prevention.
In Norway, families, schools, businesses and public insti-
tutions participated in a debate, ‘Time out’, that examined
ways and means of countering the drug problem.
In the UK, 106 drug-action team coordinators in England
and their equivalents in Scotland, Wales and Northern
Ireland, were involved in the Week’s activities.
Follow-up
The European Commission is currently evaluating the
EDPW, as well as the other activities implemented as part
of the EU action programme for the prevention of drug
dependence (1996–2000). This global evaluation of the
action programme is carried out with the support of the
Association of Schools of Public Health in the European
Region (Aspher).
Concerning the evaluation methodology, in an attempt to
ensure standardised information from Member States on
the Week, the Commission provided all national coordi-
nators with a reporting questionnaire produced by the
EMCDDA as part of its exchange on drug demand reduc-
tion action (EDDRA) information system. At the time of
writing, the completed questionnaires were not yet avail-
able, but should provide a more complete picture of the
Week in the different Member States.
The EMCDDA also provided the Commission and the
national coordinators with its ‘Guidelines for the evalua-
tion of drug prevention’ for distribution to project leaders
of the Week. The main purpose of this tool was to
promote the evaluation of preventive
activities and to provide guidance to
project leaders when conceiving
new activities and related evalua-
tion.
A selection of the initiatives devel-
oped in the context of the 1998
EDPW will be included in the
EDDRA information system.
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Cannabis is the most common illicit drug in Europe, as it
is in the rest of the world. During the 1990s, the extent
and patterns of cannabis use and availability have been
changing, health and social issues related to cannabis
and appropriate responses are being re-examined, and
debates have intensified over the legal status and pos-
sible medical uses of cannabis.
Historical context
The cannabis plant has been used for around 6 000 years,
partly because the fibres from the plant’s stem, called
hemp, were used for making clothes, ropes, nets, paper
and other items. Around 4 000 years ago, the Chinese
used cannabis for medical purposes, in treating malaria,
rheumatism, cramps and lack of appetite.
In modern Europe, cannabis made its primary entrance as
a recreational drug in the 1950s via the jazz scene. In the
1960s and early 1970s, the use of cannabis as a euphoric
substance boomed with the rise of the hippie culture. Use
then stabilised and in some countries declined until a
fresh resurgence in the late 1980s which resulted in the
spread of cannabis use across a broad social and
geographic spectrum. Cannabis and its consumption are
now more widespread than ever before in Europe.
Legal status
Cannabis extracts — marijuana, hashish and oil — are
classified as narcotic drugs under Schedule I of the 1961
United Nations Single Convention on Narcotic Drugs,
Cannabis: trends and responses
which provides for strong control measures. The
Convention prohibits the production, trade, possession or
use of narcotic drugs, except for amounts necessary for
medical or scientific research (see Table 1).
The Single Convention obliges each party to adopt
measures ensuring that a wide range of activities, includ-
ing the cultivation, manufacture, possession and distribu-
tion of narcotic drugs, are punishable. However, ‘when
abusers of drugs have committed such offences’, the
Convention permits recourse to therapeutic measures
‘either as an alternative to conviction or punishment, or
in addition to conviction or punishment’.
The general obligations under the Single Convention to
limit the use and possession of these drugs exclusively to
medical and scientific purposes are reinforced by the
1988 UN Convention against Illicit Traffic in Narcotic
Drugs and Psychotropic Substances, which invites each
party, according to their respective constitutions and
basic legal concepts, to establish as a criminal offence the
possession, purchase or cultivation of narcotic drugs –
including cannabis — for personal consumption.
The EU Member States have transposed the UN precepts
concerning the penal or administrative control of
cannabis, and have applied them according to their own
local or regional circumstances. This has resulted in an
heterogeneous ‘legal map’ regarding cannabis offences:
some countries or regions tolerate certain forms of
possession and consumption; other countries apply
administrative sanctions or fines; while still others apply
penal sanctions.
Classification of cannabis in the 1961 UN Single Convention on Narcotic Drugs (as amended by the 1972 protocol)
Schedule I
Opiates and derivatives, coca and derivates, cannabis
and derivatives and many other substances
• High-risk abuse
• Dangerous drugs
• Low therapeutic value
• Strict control
Schedule III
Preparations of cocaine, codeine morphine, opium 
and several others
• Low-risk abuse
• Medium dangerous drugs
• High therapeutic value
• Low control
Schedule II
Codeine, propriram and others
• High-risk abuse
• Dangerous drugs
• High therapeutic value
• Medium control
Schedule IV
Heroin, cannabis and its resin and others
• High-risk abuse
• Dangerous drugs
• No therapeutic value
• Maximum control
Table 1
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(1) Law No 73 of 26 March 1996 establishes the following daily average doses: marijuana: 2.5 g; hashish: 0.5 g.
Legal status of cannabis in the EU Member States
Legislation Prosecution level Notes
Belgium Drug-related offences (including cannabis) are punishable Possession and cultivation for personal use  
by imprisonment for between three months and five years are less likely to be punished according to the  
and/or a fine. directive of 17 April 1998.
Denmark Cannabis-related offences (possession) are punishable For possession of small quantities of cannabis, 
by a fine or imprisonment for up two years. the Chief Public Prosecutor recommends that   
the police should settle cases by dismissing  
the offender with a caution.
Germany Drug-related offences (including cannabis) are The Constitutional Court stated that even if Possession of a small quantity of all drugs 
punishable by up to five years’ imprisonment or a fine; penal  provisions for the possession of is a criminal offence, but is not prosecuted/
punishment can be remitted in case of ‘insignificant cannabis are in line with the Constitution, the punished when:
quantities’ for personal use. Länder should waive prosecution in minor
cases when possession of cannabis is for • there is no harm to third persons;
personal use. The Länder have determined • minors are not involved;
the following amounts as ‘insignificant • it is for personal use;
quantities’ of cannabis: up to three consumer • it involves an ‘insignificant quantity’.
units or up to 6 g (four Länder), up to 10 g 
(three Länder), up to 15 g (two Länder), up to 
30 g (two Länder), up to the ‘size of a 
matchbox’ (one Land).
Greece Drug-related offences (including cannabis) are 
punishable by up to five years’ imprisonment, which 
the offender can exchange for compulsory treatment. 
Spain Drug-related offences, such as possession and use in 
public places, are punished by administrative sanctions. 
France Cannabis-related offences, such as use, are punishable Warnings are given for first cannabis use, if 
by a fine or imprisonment for up to one year. use is occasional and the circumstances  
justify not prosecuting.
Ireland Cannabis-related offences (possession for personal use) are  
punishable by a fine on the first or second conviction. From the
third offence onwards, the offender incurs  prison sentences of
up to one year (summary) or up to three years (on indictment).
Italy Cannabis-related offences (such as possession for personal
use) are punishable by administrative sanctions (such as 
suspension of driving licence) from the second offence 
onwards. Only a warning is given for first offences for 
possession of cannabis for personal use.
Luxembourg Drug-related offences (including cannabis) are punishable First offences of simple consumption usually The distinction between  lower-risk and 
by imprisonment for between three months and three years incur only a warning. higher-risk drugs is proposed as a 
and/or a fine. modification of the drug law.
Netherlands Sale, production and possession of up to 30 g of cannabis Investigation and prosecution of possession of AHOJ-G guidelines specify the terms
are punishable by one month’s imprisonment and/or a fine cannabis for personal use (up to 5 g) carry the and conditions for sale of cannabis in coffee
(NLG 5 000); for possession of more than 30 g of cannabis, lowest priority; the sale of cannabis in coffee shops. AHOJ-G criteria  = ‘A’ stands for 
the maximum penalties are four years’ imprisonment for shops of up to 5 g per transaction is generally no advertising of any drug; ’H’ for no hard 
import or export, and two years for manufacture including not investigated. drug sale; ’J’ for not selling cannabis to 
cultivation of hemp for non-agricultural purposes, young persons (under 18); ’O’ for no public 
transportation, sale or possession/storage. nuisance; ’G’ for no large quantities (more 
than 5 g of cannabis) per transaction. The 
maximum stock allowed at any one time is 
500 g per coffee shop.
Austria Drug-related offences (including cannabis) are punishable by
up to six months’ imprisonment. If the defined conditions are
fulfilled, reports have to be withdrawn in cases involving small
quantities. The conditions for withdrawal of reports in connec-
tion with ‘first consumers’ of cannabis are easier to fulfil.
Portugal Cannabis-related offences, such as use, incur up to Offences involving very small quantities are The new strategy proposes to distinguish
three months’ imprisonment or a fine if the quantity does usually exempt from punishment. penalties and administrative sanctions
not exceed three daily doses, and up to one year’s taking into account the varying risks of
imprisonment if the quantity exceeds this limit (1). illicit substances.
Finland Cannabis-related offences, such as use, possession, Finnish law recognises the concept of
and cultivation, are punishable by a fine or up to two a ‘very dangerous drug’, which refers 
years’ imprisonment. to a narcotic drug that may cause death 
by overdose or serious damage to 
health. This definition is not normally 
applied to cannabis.
Sweden Drug-related offences, such as use of cannabis, if Users are usually fined, which may be 
judged minor, are punished with imprisonment for up exchanged on a voluntary basis for counselling.
to six months or a fine.
UK Cannabis-related offences, such as possession, are Where only small amounts are involved for 
punishable by up to five years’ imprisonment; police may personal use,  the offence is often met by a fine.
caution instead of prosecuting; courts may apply fines,
probation or community service. 
Table 2
through specific studies that analyse data from police
forces and prosecutors in more detail.
Extent and patterns of use
Prevalence
As stated in Chapter 1, a tentative, conservative extrapola-
tion from recent surveys suggests that over 40 million
people in the EU (about 16 % of the population aged 15 to
64) have used cannabis and at least 12 million (about 5 %
of those aged 15 to 64) have used it in the last 12 months.
Levels of use are higher among young people, with on
average about one in five adolescents aged 15 to 16, and
at least one in four adults aged 15 to 34, admitting to
having used cannabis.
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However, despite the different legal approaches towards
cannabis, a common trend can be seen across the
Member States in the development of alternative thera-
peutic measures to criminal prosecution for cases of use
and possession of small quantities of cannabis for
personal use without aggravating circumstances. Fines,
cautions, probation, exemption from punishment and
counselling are favoured by most European justice
systems. However, as noted in Chapter 2, police arrests
for drug offences, mainly for cannabis and mostly for use-
related offences, are increasing in several countries.
Imprisonment seems to play a major role above all when
cannabis is linked to trafficking. However, a more
accurate understanding of how drug policy is applied in
practice in relation to cannabis can only be achieved
Cannabis, marijuana and hashish
In 1753, Carl von Linnaeus first named the cannabis
plant ‘cannabis sativa’. This plant is found widely
throughout the world and contains the psychoactive
substance delta9-tetrahydro cannabinol (THC), the
principal active ingredient of the drug cannabis.
‘Marijuana’ is another name for the same plant and is
used most often to refer to its dried leaves and flowering
tops. The resin extracted from the buds and flower heads
of the cannabis plant is known as hashish, and hash oil
can be extracted from the resin.
Today, the terms ‘cannabis’, ‘marijuana’ and ‘hashish’ are
all commonly used, sometimes without any differentia-
tion. The word ‘cannabis’ comes from the Greek word
‘kannabas’, while ‘marijuana’ has more uncertain and
indistinct origins. It is most likely derived from the
Mexican-Spanish word ‘Mariguana’ (meaning ‘Mary’s
leaf’) or from the names Maria and Juan — or from a
combination of both. Americans often use this term
instead of cannabis, but spell it ‘marihuana’. The name
‘hashish’ is alleged to have derived from a tribe of Arabs
known as the ‘ashishin’ who supposedly consumed the
substance (in the 12th century) before ambushing or
raiding opponents, although there is little historical
evidence for this. A fourth term, ‘Indica’, is a variety of
cannabis characterised by its appearance, odour and high
THC content.
Lifetime prevalence of cannabis use among all adults and young adults in some EU countries 
(measured by population surveys) 
Figure 1
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Note: For more detailed information on each survey, see Chapter 2, Table 1.
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Considerable differences remain between countries in the
extent of cannabis use (see Chapter 2), but there are
indications of a convergence in prevalence levels. In
higher-prevalence countries, the trend appears to be
stable or decreasing following increases in the 1990s. In
lower-prevalence countries, however, use is increasing.
The stabilisation or decrease in cannabis use in some
higher-prevalence countries should be examined more
closely. For example, surveys in the UK show a fall in
drug use (mainly cannabis) among some young people.
Balding suggests that this may be due to the fact that the
young people surveyed in 1997 were younger, on
average, than those surveyed in 1996. Another explana-
tion is that drug use is decreasing because alcohol use is
rising, a ‘fashionable renaissance’ encouraged by market-
ing efforts by the industry to reclaim the lucrative youth
market. Furthermore, it has been suggested in the UK that
a crossover between problematic drug and alcohol use
has been better observed by alcohol agencies than by
drug agencies (Druglink, May–June 1998). Some other
countries also note indications of increased alcohol use
among young people.
Patterns of use
In much of the EU, cannabis use is not associated with
any specific social or recreational context or group. In
much of the EU, there appears to be a trend towards
perceiving cannabis use as normal or mundane rather
than as deviant. However, cannabis users cannot be
considered as a homogeneous group and different
patterns of use are reported.
For example, in the Netherlands, Cohen and Sas (1997)
re-analysed data from the Amsterdam population surveys
on use of drugs among residents of 12 years or over
(1987, 1990, 1994). They first tested the hypothesis that
cannabis consumption leads to regular use of other 
drugs. In general, cannabis use indeed preceded experi-
ence with other drugs. However, the large majority of
persons who had ever used cannabis had never experi-
mented with other drugs. About 22 % had used cocaine,
about 10 % ecstasy and only 4 % heroin. In the previous
month, non-use of other drugs was almost universal
among people taking cannabis. Some eight other variants
of the so-called ‘stepping stone’ hypothesis were tested,
but none of these was confirmed under the criterion that
at least 75 % of the cannabis consumers behaved in
accordance with the hypothesis. Some support was 
found only in the small group of people using cannabis
heavily (20 times or more in the last month). In this
sample, about half had taken cocaine, 28 % ecstasy 
and 17 % heroin. However, only very few became
current or regular users of hard drugs. This group, with
heavy recreational poly-drug histories, may now be
represented among those seeking help for cannabis
problems.
Similarly in Germany, cannabis users frequently live
inconspicuously and without great problems, although in
the last few years there has been a marked increase in the
number of clients starting treatment for cannabis
problems in out-patient centres. Most are young people,
some of them with multiple drug use patterns whose
primary drug may be reported as cannabis, but who are
frequently also using ecstasy and other drugs. This group
is partly associated with the ‘rave’ scene, where other
drugs are also found. In particular there is evidence of an
increase in LSD and cocaine.
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Evolution of lifetime prevalence of cannabis use in some EU countries during the 1990s
 (measured by population surveys)
Figure 2 
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Survey 2
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Netherlands are often reported as transit countries for
cannabis imported into the EU.
Herbal marijuana seized in the EU largely comes from
Colombia, Nigeria, South Africa and Thailand. Cannabis
is also grown domestically in almost every Member State,
although there is little evidence of large-scale trafficking.
The potency of cannabis on the 
European market
In some countries, a variety of ‘pedigree’ cannabis seeds
(‘indica’) are bred specifically for indoor cultivation,
giving bushy plants and high-quality flowering tops.
Many of the newer strains appear to have been developed
from Himalayan plants, whereas domestically produced
cannabis had previously used seeds that give taller plants
from Africa, the Caribbean and the Far East.
Some countries report an increase in the potency of
cannabis, in particular of herbal cannabis (marijuana),
over recent years, and concern over this has been
expressed by law-enforcement agencies amongst others.
The limited data available give the content of delta9-
tetrahydro cannabinol or THC (the main active ingredient
of cannabis) as predominantly 5 to 11 % in Germany
(German national report, 1998), 6 to 9 % in the
Netherlands (Dutch national report, 1997) and 2 to 14 %
in the UK (UK national report, 1998), although in a few
cases higher potency is reported. However, it is not
always specified if this is for hashish, marijuana or oil.
Others suggest that marijuana contains 0.5 to 5.0 % THC,
hashish 2 to 20 % and hash oil 15 to 50 %.
The available evidence in the EU is rather haphazard and
difficult to interpret. Neither the typical content of differ-
ent forms of cannabis on the market nor to what extent
the potency has actually increased is clear. Furthermore,
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Chait and Perry’s 1994 UK study shows that the combina-
tion of alcohol and cannabis produces a greater level of
impairment than either drug alone.
Cannabis market in the EU
Seizures and sources
The quantities of cannabis seized each year in the EU
have remained stable since 1994, although the number of
seizures is steadily increasing (see Figure 3). Availability
remains high across most of the Union and the market for
cannabis appears entrenched with relatively stable prices.
The cannabis seized in the EU comes mainly from
Morocco, which is the first producer of hashish for the
European market, although smaller seizures originate in
Afghanistan, Lebanon and Pakistan. Spain and the
Notes:  Numbers of seizures are not available for Greece and the Netherlands.       
             Numbers of seizures are underestimated in 1996 and 1997 as data for Belgium are missing.
             For more information, see Chapter 2, Tables 14 and 15.       
Cannabis quantities seized and number of 
seizures in the EU (1985–97)         
Figure 3 
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Drugs, cannabis and driving
A review of the scientific literature on drugs and driving
commissioned by the EMCDDA found that evidence as to
whether cannabis impairs driving and increases the risk
of road accidents was inconclusive.
Experimental studies are not entirely consistent, with
some finding no significant effects on perception, and
others pointing to some impairment of attention and
short-term memory, although these effects are typically
observed at higher doses.
In some field studies which tested the bodily fluids of
drivers involved in accidents, cannabis has been found to
be quite prevalent, but since these tests may give positive
results up to one month after the cannabis has been used,
they may not be a reliable measure in this case.
Interpretation of the causal contribution of cannabis to
road accidents is further complicated by the concurrent
presence of other drugs, especially alcohol. Some studies
suggest that cannabis does not appear to pose a high risk
for drivers since it was found that drivers under the influ-
ence of cannabis actually drive more carefully.
Established responses to drug misuse in the EU
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consumer behaviours and preferences are not known; for
example, is higher-potency cannabis preferred or not,
and if so are smaller quantities used to take account of
this? Detailed, systematic studies would help to establish
a more informed basis for discussion.
Treatment of cannabis-related
problems
Trends and patterns of treatment demand
Cannabis is considered the main drug in only a minority
of clients starting treatment, typically around 10 % or less
(see Figure 2), but is more commonly reported as a
secondary drug for those entering treatment for other
substances. Some increase is noted in several countries,
and the proportion is higher in new clients entering treat-
ment for the first time (see Figure 1). Most treatment
demands for cannabis involve clients who are much
younger than those whose main drug is heroin or other
drugs. This difference is also found in similar data from
the United States. More detailed information is needed to
ascertain if cannabis clients differ in other ways too.
The data come from treatment-monitoring systems that
mostly cover specialised treatment centres and often
exclude other services such as youth advisory services or
general practitioners (GPs) who may see cases involving
cannabis. This makes it difficult to be certain about the
extent and characteristics of cannabis-related problems
and the exact demand for treatment.
What the demand for treatment for cannabis and the
observed increase mean in terms of needs and possible
responses depends on a better understanding of the types
of problems linked to cannabis.
• Are these problems primarily caused by cannabis or are
other drugs, including alcohol, involved?
• Is cannabis a convenient label for a wider cluster of
problems? For example, in some countries, mental-health
problems in general, including suicides, are increasing
amongst adolescents and young people.
• How far does the increase in treatment demand reflect
increased prevalence, frequency of use or changes in the
potency of cannabis?
• Have there been changes in treatment services, for
example new services oriented towards young users or
non-opiate users?
• Has the use of therapeutic or administrative alternatives
by prosecutors and courts increased?
All these issues need more detailed investigation in order
to identify appropriate responses.
Treatment responses
There are very few services targeted specifically at
cannabis users, so clients seeking treatment for cannabis-
related problems usually do so in settings where most
clients seek treatment for other substances, for example
heroin and/or cocaine. Since clients with cannabis-related
Commercial use of hemp
‘Hemp’ is the name given to the fibres produced in the
stem of the cannabis plant and to the variety of cannabis
which is cultivated for the commercial production of its
fibres and seeds which are valued for the oil they contain.
Two varieties of cannabis are recognised: the drug type in
which THC predominates and the fibre type in which
another cannabinoid, cannabidiol (CBD), predominates.
The second does not posses the euphoriant properties of
THC, but tends instead to be a depressant. The EU
provides subsidies for the cultivation of hemp with a THC
content of less than 0.3 % by weight under Article 1 of
Council Regulation (EEC) No 2059/84. Hemp is used in
industry for various products
Notes: 1. For more detailed information on the characteristics of clients admitted to drug treatment, 
            see Chapter 2, Table 6, which presents information on 'all clients' but not on 'new clients'.
            2. For Denmark it is 'new clients' versus 'old clients'.
 Proportion of clients admitted to treatment 
for cannabis use in some EU countries
Figure 4 
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problems constitute only a minority of those in treatment
throughout Europe, and since they present a different
profile compared with other treated drug users, it is difficult
to know if the treatment on offer is appropriate, and what
kind of alternative approaches might be most helpful.
Examples of some of the few treatment initiatives targeted
specifically at cannabis problems are reported from
Denmark, Germany, the Netherlands and Sweden. The
municipality of Århus in Denmark began out-patient
treatment of cannabis users in 1993, offering them access
to a psychologist on a more or less regular basis. The
initiative is still running, although it has undergone some
organisational change. It reserves 15 to 20 treatment
slots, depending on the frequency of consultations, for
cannabis users.
Germany has a special unit in Berlin specifically working
on the treatment of cannabis users. An outcome evalua-
tion is planned.
In the Netherlands, the Jellinek Centre in Amsterdam has
for some years helped cannabis users to learn self-control
and self-regulation. Relatives, family or social workers
may be invited to take part in the treatment which aims at
total abstinence or regulated use.
In Sweden, two specialised out-patient programmes for
heavy cannabis smokers are run in Lund and Uppsala.
The treatment focuses on cognitive impairment and on
the need for personal support during the first three
months of abstinence from cannabis. The Lund
programme is scientifically evaluated while the Uppsala
programme is evaluated on an ongoing, small-scale basis.
Much more information is needed on the nature of the
problems associated with cannabis. Since people who
experience difficulties with cannabis may also be using
other substances or may have a range of psychosocial
problems, it is important to clarify the extent to which
cannabis-specific services are needed and how far
improved assistance might be provided within the frame-
work of other interventions.
Prevention
Most prevention initiatives try to talk people out of taking
cannabis. Few of the reported campaigns aim at prevent-
ing excessive cannabis use in particular, with most aiming
at total abstinence. As with treatment, few prevention
initiatives solely target cannabis. Telephone helplines in
all Member States are open to cannabis users, but none
are devoted purely to cannabis. All Member States distrib-
ute information on drugs which includes cannabis, and
some have produced material specially on cannabis.
Some initiatives are meant to provide general information
about cannabis and the effects of THC, while other
measures are aimed at parents.
Belgium’s Flemish Community established a self-help
group for cannabis users in 1997. If this initiative is seen
to work, it may be taken up by the French and German-
speaking Communities in Belgium.
Also in 1997, Denmark produced material about
cannabis for school pupils aged 13 to 16. The material
includes information leaflets, books and video tapes for
those who are curious about the drug or who have a
0
5
10
15
20
25
30
UK
 (S
co
tla
nd
)
UK
 (E
ng
la
nd
)
Sw
ed
en
Fi
nl
an
d
Po
rtu
ga
l
N
et
he
rla
nd
s
Lu
xe
m
bo
ur
g
Ita
ly
Ire
la
nd
Fr
an
ce
Sp
ai
n
Gr
ee
ce
Ge
rm
an
y
De
nm
ar
k
Be
lg
iu
m
 
(F
re
nc
h 
C.
)
Be
lg
iu
m
 
(F
le
m
is
h 
C.
)
Be
lg
iu
m
 
(B
ru
ss
el
s)
All clients
Note:  For more detailed information on characteristics of clients admitted to treatment for drug use, see Chapter 2, Table 6.
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growing problem with it. One leaflet is aimed at parents
who want to know more about cannabis.
Luxembourg has organised a series of training activities,
including an information seminar on cannabis for social
workers and other actors in the drug field. There are plans
to evaluate the initiative to see whether the training
session should be repeated in 1999.
In the Netherlands, prevention activities are directed at
specific risk groups with some initiatives specifically about
cannabis. Two mass-media campaigns were launched in
1996 and 1997, one directed at parents and the other at
young people. The central message of the parental
campaign was ‘inform yourself’, and was disseminated via
a variety of media. Evaluation showed it was generally
successful, although the information tended to reach those
who were already well informed rather than the less
informed. The campaign was restructured for youngsters in
1997, connecting activities to a regional and local level.
Evaluation showed that its reach was considerably greater
than the previous year’s campaign.
Spain has launched prevention programmes in schools
targeting 12- to 16-year-olds, involving non-governmen-
tal organisations (NGOs) and accompanied by nation-
wide campaigns using leaflets, television commercials
and posters. Training programmes were offered to teach-
ers, NGO volunteers and other professional groups for
work on cannabis use.
Prevention of cannabis use among young people in
Greece is thought to be more effective if it is approached
through a holistic strategy (such as school health-educa-
tion programmes) whereby, according to the particular
needs of the target group, emphasis is given to preventing
the use of a specific substance.
For many years, Sweden published The hashish book
which was distributed to the parents of teenagers. In
1998, it was replaced with The book on drugs, which
covers all drugs including alcohol and tobacco.
Medical uses of cannabis or
derivatives
In recent years, debate in Europe has intensified around
whether cannabis can or should be used for medical
purposes. In most countries, the debate is informal, but in
Denmark, Germany, Spain, the Netherlands, Austria and
the UK the debate has moved into more formal settings.
The EU situation
In Austria in May 1999, the Viennese drug plan was
presented. This stated that the medical use of cannabis
should be scientifically investigated and that research
projects should be carried out after clarifying the legal
and organisational framework.
The Bispebjerg Hospital in Copenhagen recently initiated
a survey into the medicinal potential of cannabis, but it
will be some time before the results are made public.
Germany is the only country that has taken steps to allow
cannabis derivatives for medical purposes. From February
1998, a change in the narcotic drug law has allowed THC
to be used for medical purposes. Three German import
companies may import the US artificially produced
cannabis derivative Marinol. The product comes in the
shape of a pill and is meant to be taken for pain relief by
Treatment initiatives Prevention initiatives Prevention initiatives aimed Evaluation of cannabis
specifically for aimed mainly at the mainly at the intermediate demand reduction
cannabis abuse final target group (a) target group (b) measures
Belgium No Yes Yes Yes
Denmark Yes Yes Yes Yes
Germany Yes No No Yes
Greece No Yes No No
Spain No Yes Yes No
Luxembourg No Yes No No
Netherlands Yes Yes Yes Yes
Sweden Yes Yes Yes No
Cannabis demand reduction measuresTable 3
(a) Final target group = abusers or potential abusers.
(b) Intermediate target group = those related to the final target group, whether parents, relatives or teachers. 
Note: France, Ireland, Italy, Austria, Portugal, Finland and the UK have no reported demand reduction measures specifically for cannabis.
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cancer patients receiving chemotherapy, as an appetite
stimulator for AIDS patients, for asthma patients and to
combat insomnia.
The Netherlands carried out a review in 1997 on the
potential medical uses of cannabis and concluded that
the evidence was insufficient to justify such use. Patients
have called for more research into the possible medical
uses of marijuana and clinical studies are planned. The
government is considering establishing an official agency
to approve and control the cultivation and processing of
hemp for scientific purposes.
In 1998, Spain organised an international seminar,
‘Scientific advances on cannabis derivatives’, with the
participation of Spanish and foreign experts. The seminar
stressed that future research into cannabis for medical
purposes should consider how it could be used without
leading to problems of dependency.
In the UK, a House of Lords subcommittee launched an
investigation in 1997 into the use of cannabis for medical
and recreational purposes. The subcommittee’s report in
November 1998 concluded that there was sufficient clini-
cal and anecdotal evidence to indicate the medical value
of cannabis and recommended that doctors should be
allowed to prescribe it to relieve pain, and for symptoms
of multiple sclerosis. They did not recommend lifting the
ban on cannabis for recreational use. The government
rejected the subcommittee’s recommendations on the
grounds that there had been insufficient clinical trials. A
new clinical study will begin in 1999 and the results are
expected in 2004–05 when most informed observers
believe a new form of cannabis will be patented and
licensed as a prescription medicine.
The global context
In other regions of the world, debate on the therapeutic
value of marijuana have led to political discussions,
mainly focusing on initiatives to reform ‘prohibitive laws’
to allow medical doctors to prescribe marijuana.
Australia, Canada and the United States are among the
most active in this domain.
Established responses to drug misuse in the EU
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Political and public concern about synthetic drugs
escalated during the 1990s in response to increasing and
apparently widespread use of ecstasy by a broad
spectrum of mainstream youth. Concerns were also
raised because control of these drugs, which are easily
manufactured at low cost within the EU using readily
available materials, was becoming increasingly difficult.
With the introduction of the single market and increased
freedom of movement, particularly within the Schengen
area, Europe’s doors were opened to entrepreneurial
activity. Drug traffickers were quick to take advantage of
the looser controls. Trade in the precursors used to
manufacture these drugs, as well as trade in the end
products themselves, increased dramatically.
In the context of the widespread availability of synthetic
drugs and the evolution of a vigorous youth/music/dance
culture, new patterns of drug consumption established
themselves rapidly across the EU. This phenomenon 
was described in the EMCDDA’s 1997 annual report 
and in more detail in the first volume in the Centre’s
Insights series.
Defining synthetic drugs
The term ‘synthetic drug’ strictly refers to psychoactive
substances that are manufactured in a laboratory rather
than derived from natural sources, such as plants. In this
sense, tranquillisers and methadone are synthetic drugs
as well as amphetamines, ecstasy and lysergic acid
diethylamide (LSD).
In recent years, however, ‘synthetic drug’ has come to be
applied more loosely to drugs like MDMA (ecstasy) that are
commonly used in party and dance settings. The term ‘new
synthetic drug’ is also used to refer to new substances
found on the ecstasy market that fall outside existing legal
controls (and indeed may be manufactured in order to
avoid such control). This use of the term ‘synthetic drug’
thus indicates a preoccupation with the particular
problems of controlling the production and distribution of
these substances, rather than reflecting the actual patterns
of drug use observed amongst young people.
In many recreational settings, young people are likely to
use not only ecstasy, but also amphetamines, LSD and
benzodiazepines — which are ‘old’ synthetic drugs —as
well as substances that are not synthetic, such as alcohol,
cannabis, cocaine, magic mushrooms and, sometimes,
heroin.
The present report uses the term ‘synthetic’ to describe
drugs that include:
• amphetamines, first synthesised in 1887 and identified
with music trends and dance settings since the 1960s;
• ring-substituted amphetamines such as MDMA, which
were first synthesised in 1912 and used in the 1970s for
psychotherapy before being used socially by young
people in the 1980s as ecstasy;
• Lysergic acid diethylamide (LSD) which was acciden-
tally discovered in 1943 by a Swiss chemist; and
• other newly synthesised drugs about which, by defini-
tion, little is known.
What is ecstasy?
Most users assume that pills called ‘ecstasy’ contain
MDMA. However, MDMA is only one of a family 
of phenethylamines, which includes MDA, MDEA 
and MBDB. What is bought and used as ecstasy may,
therefore, in fact be another ecstasy-like synthetic drug.
Synthetic drugs: developments and responses
Entactogenic effect
Dr David Nichols, Professor of Medicinal Chemistry and
Pharmacology at Purdue University in the United States
coined the term ‘entactogen’ for drugs such as MDMA
(ecstasy). The entactogenic effect of a drug is the way it
acts as an emotional ‘brace’, facilitating the retrieval of
inner material and enhancing introspective states. In
Nichols’ words, an entactogenic effect ‘means essentially
to produce a touching within’. In the words of an MDMA
user, it provides a sense that the world is ‘an okay place 
to be’.
Other ecstasy users comment that they feel no need for
affirmation, recognition or judgment, as in the following
statement: ‘I felt I could handle the entire world and at the
same time I felt no need at all to do so. I had conversa-
tions without feeling restricted, obliged or having the urge
to compete with the other person.’
Box 1
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These drugs are usually taken orally as a pill (what is
contained in these pills is discussed in more detail later in
the chapter). The effects of ecstasy are generally experi-
enced as energising, euphoric and entactogenic.
In general, 30 to 60 minutes after taking ecstasy the effects
begin to be experienced before peaking and falling away
to a plateau which is maintained for another three hours.
The effects are influenced not only by the pharmacologi-
cal properties of the pill, but also by the individual and the
setting. Different patterns are advocated and adopted to
prolong the effects; for example, taking cannabis simulta-
neously, or taking further doses at intervals.
Compared with other stimulants, ecstasy does not tend to
produce the extreme mood swings (high energy followed
by feelings of deep depression) characteristic of ampheta-
mines and, compared with cocaine, the positive effects of
ecstasy last much longer. Some users do report feelings of
depression and difficulty in concentrating in the days
immediately following ecstasy use, although these effects
could also result from sleep deprivation as well as from
the concurrent use of other drugs such as amphetamines.
The rise of ecstasy
In the early 1990s, ecstasy rapidly gained popularity
among middle-class students and other socially
integrated young people who believed MDMA to be safe
and non-addictive in comparison with hard drugs such as
heroin which were associated with marginalisation and
social deprivation. This new trend in drug use developed
within a mass recreation and music culture known as
‘rave’, ‘acid house’ or ‘techno’.
One of the most significant features of this trend was the
way it transcended traditional social networks and
national borders. Rapid communication gave young
people access to new trends through the music industry,
television (terrestrial, satellite and cable), fashion, the
media (magazines and other publications) and the
Internet.
In Belgium, Germany, Spain, Italy, the Netherlands and
the UK, and possibly other Member States, young people
travelled considerable distances to attend large, adver-
tised, commercial parties where they could meet, make
friends and exchange information. This facilitated the
spread of knowledge about the different drugs as well as
access to them.
The major predictor of a person’s willingness to try
ecstasy seems to be knowing, liking or admiring a person
Understanding dance culture
‘You can’t have any understanding of dance culture
without understanding ecstasy. It’s like trying to under-
stand pub culture without understanding beer … DJs and
record producers who say they have nothing to do with
drugs are hypocrites. They owe their whole career to
drugs. In the old days, people used to dance for ages to
get themselves worked up. Now, you’re taking the lift,
rather than the stairs.’
Irvine Welsh (widely acclaimed author of Trainspotting
and Ecstasy). Interview in Ministry Magazine, April 1999.
Health risks of ecstasy
Heavy or frequent ecstasy use reduces, or eliminates, the
entactogenic effect, although the energising effect
remains. Consequently, ecstasy has been largely confined
to weekend use which acts as a safety valve against
problems developing as a result of daily or heavy use.
Acute risks
Conservative estimates of ecstasy use in the UK in the
mid-1990s put consumption at over a million doses taken
in dance clubs every weekend. This led to calculations 
of the risk of death from ecstasy consumption as approxi-
mately one dose in 6.8 million. Acute health risks
increase with diversification to more intense consump-
tion and when ecstasy is used in combination with 
drugs with sedative effects, such as alcohol, heroin and
benzodiazepines.
Chronic risks
Research into the chronic effects of ecstasy use has been
limited by bias and lack of data. Accumulating scientific
evidence points towards some degree of neurotoxicity
associated with heavy ecstasy use. Recent results of
experiments with monkeys show that four days of
exposure to MDMA caused some damage to areas of 
the brain that persisted for six to seven years, although 
the consequences of this damage are not yet clearly
understood. Human studies have shown damage to 
the serotonin-producing neurones and the memory
impairment related to the toxic effect of MDMA on those 
brain cells.
Box 2
Box 3
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who takes the drug. In the large party settings that
became a prominent feature of youth culture during the
1990s, the effects of pills and powders were easy to
observe and convenient to try. They were available and
could be shared with friends at affordable prices. These
extended networks also allowed information to be
diffused about the negative as well as positive effects of
different drugs or certain pills.
The combination of the stimulating and entactogenic
effects of ecstasy gave it a key role in music and dance
events. In the early phase, these events developed along-
side a rejection of the alcohol-associated physical aggres-
sion and sexual harassment prevalent in many
mainstream night clubs and licensed venues. Ecstasy, in
turn, contributed to the success of commercial
party/dance events by facilitating an inclusive, bonding
atmosphere and the drive to dance.
What’s in an ecstasy pill?
In the manufacture of pills aimed at the ecstasy market,
producers consistently use brand names and logos as
marketing tools and to distinguish their product from that
of competitors. Among the more popular logos are the
Mitsubishi symbol, a dove, a butterfly and a four-leaf
clover which, in themselves, are no guarantee of the pill’s
contents.
In the absence of more reliable means for users to assess
the contents of the pills they purchase or are given,
Contents of pills analysed in the laboratory, the Netherlands, (1998)    
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(1) Contain amphetamine or methamphetamine, alone or together with other substances.
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conclusions are usually based on experience and judged
in terms of the pills’ strength and length of effect. If a new
pill appears on the market or at an event, caution is gener-
ally exercised by consulting friends and taking limited
doses such as a half or a quarter of a pill. After a chosen
time interval, based on perceived effects and previous
experience or information, another dose may be taken.
The difficulty of assessing pill contents is a key feature of
the ecstasy market and laboratory analyses have proved
experienced ecstasy users to be wrong in their personal
assessment of pill contents. This feature of the consumer
market is different from the heroin or cocaine markets
where experienced users have the colour, structure and
taste of powders on which to base and make more
accurate personal judgments about contents.
Recent studies in a few Member States which analysed
ecstasy pills have found that their contents vary consider-
ably, from those containing pure MDMA, to ones with
high levels of amphetamines, to a mixture of lactose and
caffeine alone. In the Netherlands, ecstasy users are able
to take their pills to street agencies where staff identify
pills on the spot using a simple colour-change test
(Marquis Reagent) and an identification checklist of
known pills. If the pill cannot be identified in these ways,
it is sent for laboratory analysis. In this way, low-threshold
agencies ensure regular contact with drug users and,
when laboratory analyses identify a drug which carries a
health risk, warnings can be issued rapidly if necessary.
Pill testing is discussed in more detail later in the chapter.
A particularly high proportion of pills sold as ecstasy
were identified by the Drugs Information Monitoring
System (DIMS) in the Netherlands between August 1997
and January 1998 as actually containing amphetamines.
The ‘Checkit’ project in Vienna, which operates a drug-
monitoring system with similar aims, also identified
unusually high levels of amphetamine in spring 1998.
Concerns about the amphetamine content of ecstasy pills
have also been expressed in Germany, Spain, France and
the UK. The reasons for the increase in amphetamine
content during particular time periods are not clear, but it
may indicate that producers are facing a shortage of the
precursors needed to manufacture MDMA or its
analogues.
Organised crime appears to be involved in the manufac-
ture and distribution of ecstasy-like drugs in a number of
countries. Synthetic drugs are reported to be produced
mainly in clandestine laboratories in the Netherlands,
Poland, Spain and the UK, and new manufacturers are
said to be trying to enter the market. Some young drug
users involved in the distribution of ecstasy-type pills
have been threatened by more organised distributors.
Prevalence of synthetic drug use
What is known about the current level of synthetic drug
use in the EU? The data presented here relate to preva-
lence figures currently available from national sources
and are limited to what users have believed to be ecstasy,
amphetamines and LSD.
School pupils
Among the countries that have conducted school surveys,
the proportion of 15- to 16-year-olds who admit having
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tried amphetamines is typically between 2 and 4 %, but
ranges from under 1 % in Finland to nearly 8 % in the
Netherlands and 13 % in the UK. There is also a wide
variation in ecstasy use among this age group, from under
1 % in Finland to 5 to 6 % in Belgium and Spain, and 8 to
9 % in Ireland, the Netherlands and the UK. The lifetime
prevalence figures for LSD among schoolchildren is
around 13 to 14 % in Ireland and the UK, 5 to 6 % in
Spain and Italy and 2 % or less in the other Member
States. The marked differences in lifetime prevalence of
LSD among schoolchildren are difficult to interpret and
may be partially explained by some definitions which
include hallucinogenic mushrooms.
Young adults
The proportion of young adults who have used ampheta-
mines and ecstasy typically falls in the range of 2 to 5 %,
although the rates are higher for those aged 18 to 25 (for
exact age ranges, see Chapter 2). In terms of recent use in
the past year, the rates are mostly in the 1 to 2 % range,
although higher for the UK. This suggests that after experi-
menting with amphetamines at school, young people in
the UK continue to take amphetamines in early adult-
hood in greater numbers than in other countries.
Recent trends: diversification,
amphetamines and alcohol
Ecstasy
Recent reports from several Member States suggest a
stabilisation or decline in the level of ecstasy use and
some disenchantment with what is being sold as ecstasy.
It is not, however, clear to what extent this disenchant-
ment is the result of negative effects, adverse publicity
about health risks, the loss of novelty value, or a combi-
nation of all these factors. Data on seizures of ecstasy
show an overall decrease in both incidence and quantity
of pills seized.
Recent articles in youth/music/style magazines reflect the
‘passé’ feelings surrounding some earlier rave-related
behaviour such as hugging, ‘gurning’ (facial distortions)
and other visible signs of stimulant consumption. Music
media articles complain about the loss of exclusivity on the
dance floors of the ecstasy market and expressly criticise
the physical manifestations of amphetamine-type drug use
in terms of ‘lolling tongues, red faces and grimaces’.
This does not mean that ecstasy is disappearing. In many
parts of the EU, it continues to be widely available and
used within recreational dance and party settings as well
as in more private situations, although there are consider-
able differences between countries (see Figures 1 and 2
and also Chapter 2). It does mean, however, that along-
side the continuing use of ecstasy, there is a diversifica-
tion in the patterns of use.
Amphetamines
The dominant trend, confirming the EMCDDA’s 1998
annual report, is a long-term, and continuing, rise in the
availability and use of amphetamines. Within the broad,
recreational youth culture, amphetamines are mostly taken
as powder by sniffing or orally as pills or added to drinks.
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As with ecstasy, increases in amphetamine use are barely
reflected in indicators such as treatment demand. This
may mean that the sharp increase in use is not creating
health problems. It is also possible that such problems
have not been recorded or that drug services are not
adequately responding to this trend. Amphetamines may
play a significant role in some of the problems that are
being observed by low-threshold agencies and attributed
to ecstasy or cannabis.
In some northern countries, amphetamines have long
been, and continue to be, used in other settings. They are
often injected by chronic, problematic drug users in more
socially marginalised situations usually not linked to the
mainstream youth drug scene.
Alcohol
In recent years, both dance drugs and dance music —
originally associated with unofficial large, out-of-town,
commercial parties — have been found in downtown
night clubs. There is also evidence of a parallel shift back
to alcohol consumption. The lucrative nature of the
music/dance market appears to have propelled the
alcohol industry into sponsoring, advertising and promot-
ing alcohol aimed specifically at the dance drug or
ecstasy market and using drug imagery with the intention
of reclaiming this market.
Although much attention in recent years has been
focused on synthetic drugs such as ecstasy, the use of
alcohol, including for the purpose of intoxication, may be
(re)-emerging as an important component of the drug-use
patterns found within the broader arena of youth leisure
activities and youth markets.
Divergent patterns, divergent drugs
More specific patterns of diversification in the use of
synthetic drugs are difficult to define. Various reports
point to increased use of alcohol and an interest in stimu-
lant-type drugs such as amphetamines and/or cocaine in
some situations, and in hallucinogens such as LSD or
mushrooms in others. Some low-threshold drug agencies
have reported an increase in requests for help from young
people who have developed some degree of psychologi-
cal dependence on heavy drug consumption in party and
dance settings. In a minority of these cases, heroin has
also been involved. Other developments include reports
of Viagra being sold as a recreational drug in the dance
scene, as well as various steroids used to develop
physique for non-sporting purposes.
The major source of information about synthetic drug use
has been young people in dance and party settings.
However, synthetic drug use also takes place in other
contexts. For example, they may also be used in more
private circumstances for their relaxing and libido-
enhancing effects, for developing physical or mental
capacities, or to self-treat insomnia, stress or drug-
induced problems. Evidence of these other uses of
synthetic drugs can be found on the Internet in specific
websites and discussion groups and in other forms of
mass and micro media.
Demand reduction activities
The main demand reduction strategies in the EU can be
classified in terms of how they intend to reach the non-
homogeneous target group of synthetic drug users. It is
not possible to draw an overall picture of European strate-
gies because sufficient information is available from only
a few countries, but some examples may give an impres-
sion of the main activities.
In the cultural context of synthetic drugs described above,
a special variety of peer-group education is used involv-
ing ‘ravers’, prevention staff and party organisers in a
bottom-up strategy for prevention work. The underlying
concept of these approaches is illustrated by the Dutch
strategy which is a variation on the familiar ‘just say no’. It
has been changed to ‘just say know’, focusing on individ-
ualised counselling without encouraging drug use.
As increasing numbers of users integrate drug use into
their daily life or leisure activities — like ecstasy at parties
— preventing health damage means providing informa-
tion about the risks of excessive use and of adulterated
pills. In this context, prevention should mean that the
consumer knows what he or she is doing.
Demand reduction activities can be seen as a consumer
service delivered from experienced users to others. For
example, a border zone cooperation project between
Belgium, Germany and the Netherlands employs drug
users as peer workers together with prevention workers to
produce and disseminate information about party drugs
(see the discussion of the peer-to-peer approach in the
EDPW section above).
The approach is often highly targeted in order to protect
non-drug users in recreational dance settings from
exposure to information that might be thought to encour-
age drug use and to ensure that they are supported in
maintaining abstinence. One approach is aimed at the
experienced user who wants to use drugs in a responsible
Established responses to drug misuse in the EU
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and controlled way. Flyers or ‘ravers’ guides’ have been
compiled for this group, which evaluation has shown to
be useful. For teachers and parents who want factual
information, videos and brochures are available.
The police can also be involved in these activities. For
example, the Belgian Gendarmerie organises training for
those responsible for mega-dances.
Guidelines for safe dancing developed by local 
authorities, NGOs and ‘rave’ organisers have a tradition
in the UK and are also being adopted in Denmark and
Germany. In these countries, the organisers of ‘rave’
parties help to produce and distribute information on
designer drugs, ecstasy and other substances commonly
used at ‘raves’.
Typically, such requests have come from the organisers
themselves who want to provide factual information on
drugs and their effects. At the same time, associated drug-
counselling centres are running campaigns addressing
different target groups with a variety of ‘safer use’ or
‘clean use’ messages. Members of specific youth environ-
ments are commonly motivated to ask for support in
providing information and undertaking preventive 
activities on their own territory.
Some programmes use or organise parties in order to
promote prevention. One example is a Franco-German
youth organisation which organised a seminar on
‘techno’ culture and prevention. This was linked to a
‘techno’ parade and a street ‘rave’ attended by well-
known ‘rave’ personalities. In Belgium, a mega-disco
involving 1 500 to 2 000 young people was organised
and included an exhibition and workshops.
Aside from ‘rave’ parties, wider community approaches
in specific localities and youth centres aim to involve
‘techno’ clubs in preventive efforts by establishing peer
networks which can be used as prevention agents among
‘ravers’. This has been successfully achieved in France.
Specific drug-related community activities may include
events under a drug-free banner — like anti-drugs discos
or ‘rave’ parties with a ‘no-drugs’ slogan, as in Germany
and Portugal.
Pill testing
On-the-spot toxicological pill tests, mostly at ‘raves’, offer
buyers a chance to have the purity and contents of tablets
tested before use while also allowing demand reduction
professionals to contact users directly. Such testing is a
controversial practice in Europe and is carried out in only
a few countries. Reporting of such tests is therefore
sketchy (see also the discussion of ecstasy pill contents
above). In Austria, pill testing is used for research and
prevention purposes. Vienna’s ‘Check-it’ project, focusing
on ‘ravers’ and ecstasy users, interviews users during
testing. This approach offers the possibility of intensified
preventive activities aimed at specific groups.
Some countries find anonymous, cost-free testing of
tablets sold as ecstasy at major ‘rave’ events, together
with information and on-the-spot counselling, a good
prevention approach. This approach mainly targets
teenagers, since it is clear from various pilot studies that
many young users do not distinguish between different
pills. They see themselves as consumers of ecstasy, even if
toxicological tests show the tablets are primarily made of
some other substance.
Since 1992, the DIMS in the Netherlands has tried to limit
health damage from overdoses or toxicity. Drug samples
are sent or collected from fieldwork organisations and
drug users before being tested at affiliated offices or in
specialised hospital laboratories. Preparations containing
especially dangerous ingredients are then the subject of 
a warning campaign aimed at potential users. Written
information on the overall danger of drugs is also deliv-
ered to users.
Due to the semi-legal status of ‘techno’ parties in France,
preventive and research access to this setting is difficult.
The ‘rave’ mission operated by Médecins du monde
Information materials
Distribution of information materials is still the most
frequently reported strategy in the Member States’ fight
against drugs. The materials may be linked to peer
approaches, to mass-media campaigns or to stand-alone
projects.
In Denmark, materials consisting of a video programme,
a magazine for young people, a computer programme, a
poster and guidelines for teachers were distributed in all
schools.
Another possible approach is to use cultural events —
like EXPO ’98 in Lisbon — to distribute information
material to young adults attending ‘house’ and ‘techno’
parties together with personalised information using
trained volunteers and professionals.
Almost all 17 of Spain’s autonomous regions
(comunidades autónomas) publish their own posters,
brochures and leaflets with information concerning
synthetic drugs.
1999 Extended annual report on the state of the drugs problem in the European Union
88
(http://www.medecinsdumonde.org/) tests pills during
raves. It also gathers information on synthetic drug
consumption and on users and tries to engage partici-
pants in discussions about drug use.
Mass-media campaigns
The mass media are used in many countries as a means of
raising awareness among young people. A Spanish
campaign publicised the risk of alcohol, hashish and
synthetic drug use. These campaigns adopt specific
slogans such as ‘Enjoy yourself with sport. Avoid drugs’.
In many cases, local organisations are responsible for
awareness campaigns.
The substance most frequently targeted in mass-media
campaigns is alcohol, but in some cases synthetic drugs
take centre stage. Others address narrow target groups.
For example, an Irish television campaign to alert, remind
and warn people of the dangers of drug use was targeted
at 15- to 25-year-olds who experiment with drugs and at
parents of young people. A radio campaign was also
aimed specifically at parents, urging them to seek advice
if they thought their children were involved with drugs.
Specific information about ecstasy and heroin was given
in a radio spot and a permanent telephone information
line was advertised.
Internet activities
The Internet is one of the newest media for finding 
out about drugs, and to be used in drug-demand reduc-
tion activities. An Internet site called Drugsmart
(http://www.drugsmart.com), run by the Swedish Ministry
of Health and Social Affairs, covers both new synthetic
drugs and ‘smart’ drugs (licit products containing
psychoactive substances such as magic mushrooms,
amanita mushrooms or belladonna). The site is targeted at
younger age groups, but includes information for teachers
as well. The aim is to strengthen the resistance of
teenagers who have not so far taken drugs or who have
stopped experimenting with drugs. Aside from detailed
information on various drugs, the site provides answers to
e-mailed questions and a chat service for those who wish
to discuss drug-related topics
Other Internet sites are also springing up in Europe. The
Prevnet website (http://www.a-klinikka.fi/prevnet/euro/
index.html), originally a Finnish initiative, has been
expanded into the European network for prevention via
the Internet. The site, however, is not dedicated exclu-
sively to synthetic drugs.
Evaluation
Evaluations of interventions on synthetic drugs are rare.
One exception is the 1997–98 ‘SafeRave’ campaign in
Denmark which targeted middle-class youth. The evalua-
tion concluded that over time the campaign had lost 
its originally strong roots in the ‘techno’ environment, 
but that the clear attitude against ecstasy was well
received and succeeded in motivating a limited section 
of the target group. The evaluation also highlighted an
interest within the techno environment to take a stand
against drugs, which could be influential in further
prevention work.
Evaluation of peer-group approaches in the Netherlands
concluded that small informal groups were easier to
organise if ecstasy users were contacted at discotheques
and at a so-called ‘rave shuttle’, a mobile intervention
unit used at ‘raves’. The project contributed to a more
realistic and non-moralistic approach to drug prevention.
During the evaluation of ‘Safer dancing’ in London,
around 300 ‘clubbers’ were interviewed before, during
and after the campaign. The programme targeted individ-
ual behaviour, the physical environment of the club and
in-club outreach work through trained staff. Almost 90 %
of clubbers said that they intended to keep the informa-
tion booklet provided — an important result given the
transient nature of the club environment. Thirty-three per
cent said the campaign might change their attitude to
drug use in future. Overall, understanding about the
effects of ecstasy, cannabis and amphetamines increased.
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Term Definition
Council of Europe Set up in 1949, the Council of Europe, based in Strasbourg, is an intergovern-
mental political organisation of some 40 European pluralist democracies.
Although often confused with the European Union, the Council is a distinct
organisation primarily concerned with strengthening political, social, legal
and cultural cooperation and promoting human values throughout Europe
Demand reduction Activities aimed at preventing drug use, assisting and treating drug users,
reducing the harmful consequences of such use and promoting positive health
Depenalisation Administrative sanctions (such as suspension of driving licence, confiscation
of passport) or fines are applied in response to an offence instead of the crimi-
nal code
Domestically produced drugs Home-made illicit drugs (frequently produced by consumers). ‘Domestic’ in
law-enforcement and street terminology, particularly in the United States,
means produced within the Member State rather than imported
Entactogenic effect The entactogenic effect of a drug is the way it acts as an emotional ‘brace’,
facilitating the retrieval of inner material and enhancing introspective states. In
the words of an MDMA user, it provides a sense that the world is ‘an okay
place to be’
ESPAD European school survey project on alcohol and other drugs
Eurostat Statistical Office of the European Communities
Fifth framework programme An overall EU framework programme which defines priorities for EU research,
development and technological programmes for a five-year period
(1998–2002)
High-threshold services Services with high entry barriers requiring a high level of commitment on the
part of the client
LAAM Levo-alpha-acetyl-methadole, a longer-acting alternative to methadone
Legalisation Legal measure aimed at controlling a substance and its related market. With
legalisation, the production process belongs to the authority, the State, that
through laws and regulations may control production, cultivation, sale and
consumption
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Liberalisation This term is used to indicate the political approach of a drug policy or strategy;
when it refers to a substance (e.g. liberalisation of soft drugs), this means that
the drug will be available on the market and regulated by the economic law of
supply and demand (often the term is improperly used, meaning legalisation
or depenalisation)
Low-threshold services Treatment facilities with easy access and reduced time delays (frequently part  
or agencies of harm reduction strategies)
LSD Lysergic acid diethylamide
National focal points (NFPs) National expert monitoring centres forming the EMCDDA’s Reitox network
NGOs Non-governmental organisations
Poly-drug use Concurrent or consecutive use of more than one illicit substance, alcohol
and/or non-medical use of pharmaceuticals
Pompidou Group An intergovernmental structure within the Council of Europe which aims to
‘promote and support the establishment of national policies and programmes
and the strengthening of international cooperation allowing a multidiscipli-
nary approach to the problem of drug abuse and illicit trafficking in a pan-
European context’
Precursors Substances used in the manufacture or preparation of illicit drugs
Reitox European information network on drugs and drug addiction (réseau européen
d’information sur les drogues et les toxicomanies)
Supply reduction Reducing the availability of illicit drugs by targeting producers, importers and
traffickers
Synthetic drugs Psychoactive substances that are manufactured in a laboratory rather than
derived from natural sources, such as plants. Tranquillisers and methadone are
synthetic drugs, as well as amphetamines, ecstasy and lysergic acid diethy-
lamide (LSD)
Trafficking Transportation and bulk trading in illicit drugs, usually at international level,
for the purpose of distribution or sale
WHO World Health Organisation (based in Geneva)
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